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Summary 
 
Prions diseases are a group of fatal neurodegenerative disorders called the 
transmissible spongiform encephalopathies (TSEs), which include bovine 
spongiform encephalopathy in cattle, scrapie in sheep and Creutzfeldt-Jakob 
disease (CJD) in humans. TSEs are associated with the conversion of normal 
cellular form of the prion protein (PrP
C
) to an altered pathological form (PrP
Sc
). 
An important phenomenon known as the species barrier affects prion 
transmission, resulting in longer incubation time and lower incidence of disease 
upon transfer between species. Another feature of prion diseases is disease-
modulating polymorphisms in PrP sequence which can alter individual‟s 
susceptibility to infection.  
This thesis investigates two properties of PrP that may elucidate the mechanisms 
underlying both species barrier and disease resistance; (i) effect of disease-
modulating mutations on folding kinetics of PrP and (ii) impact of disease-
modulating mutations on formation of PrP fibrils. 
Equilibrium and kinetic folding studies demonstrate that the folding pathway of 
PrP is affected by mutation Q167R which confers disease resistance, and 
mutations S170N, N174T and S170N/N174T characteristic for Chronic Wasting 
Disease in cervids, which are known to increase disease susceptibility. 
The destabilising effect of Q167R mutation previously observed via equilibrium 
folding studies was confirmed through direct kinetic observations. Subsequent 
fibrilisation experiments suggested a possible link between the stability of mouse 
prion protein and its propensity to form fibrils, elucidating a potential mechanism 
of increased disease resistance conferred by Q167R mutation. 
Equilibrium folding studies of S170N, N174T and S170N/N174T revealed a 
surprising correlation between the structural effects of these mutations and 
fibrilisation propensity.  
Based on these findings, a disease resistance mechanism centred on decreased 
formation of neurotoxic particles in the organism as well as diminished ability of 
infectious oligomers from both inside and outside to propagate oligomerisation of 
PrP has been proposed.  
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Chapter 1: Introduction 
 
 
1.1 Prions 
 
 
1.1.1 Transmissible spongiform encephelopathies 
 
Prion diseases, also known as transmissible spongiform encephalopathies 
(TSEs), are a group of fatal neurodegenerative disorders affecting numerous species, 
including cattle (bovine spongiform encephalopathy, BSE), sheep (scrapie), cervids 
(chronic wasting disease, CWD), humans (Creutzfeldt-Jakob disease, Gerstmann-
Straussler-Scheinker disease, and fatal familial insomnia), exotic ungulates (exotic 
ungulates encephalopathy) and cats (feline spongiform encephalopathy, FSE). 
All of the transmissible spongiform encephalopathies are characterised by spongiform 
degradation, neuronal loss, brain vacuolation, astrogliosis and formation of large 
amyloid plaques composed of the prion protein in the brain (Collinge, 2005; 
Unterberger et al., 2005). 
 
 
1.1.1.1 Scrapie – first identified prion disease 
 
First indications of recognition of scrapie as an infectious disease can be traced 
as far back as early 18
th
 century. In 1772, scrapie was reported to be known for 
approximately 40 years in England, indicating that the earliest mentions of the disease 
originated around 1730. By 1750, a clear description of the disease was available in 
literature, presenting characteristics such as symptoms as well as possibility of 
horizontal transmission (Schneider et al. 2008).  
Despite such early recognition of scrapie, it was not until 1936 that conclusive 
experimental evidence of natural transmission proved the infectious nature of the 
disease, supported by an accidental iatrogenic transfer through vaccination for looping-
ill (Schneider et al. 2008). By 1960s, it was determined that scrapie can be successfully 
transferred to mice, which were recognised as a potential experimental model for 
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studies of disease transmission and progression (Chandler 1961). It was not until 1982 
that famous experiments of Stanley Pruisner finally allowed scrapie to be categorised as 
prion disease. 
 
 
1.1.1.2 Creutzfeldt-Jakob disease and Kuru 
 
The earliest description of the human form of prion disease originates from 
1920's when two German neuropathologists discovered an unknown neurodegenerative 
disorder. In 1957 the fatal neurological disease Kuru was discovered amongst the stone-
age Fore people in New Guinea (Gajdusek and Ziggas, 1957). Studies of brain samples 
from individuals who had died of Kuru provided a link between pathogenesis of scrapie 
and CJD which were until then considered unrelated. This similarity was first described 
by Hadlow, who proposed that both diseases could be caused by the same agent, based 
on their pathology and epidemiology. 
Subsequent transmission experiments demonstrated that both CJD and Kuru can 
be transferred to chimpanzees through intracerebral inoculation of infected brain 
material (Gajdusek et al., 1966). Moreover, amyloid plaques resembling those found in 
brains of victims of Kuru were also found in CJD infected brains, providing further 
connection between the two conditions (Chou and Martin 1971).  
The discovery that CJD, Kuru and scrapie all share common pathogenic traits such as 
degeneration of neurones, presence of amyloid plaques in the brain, lack of an 
inflammatory response and transmissibility to primates led to their common 
classification as transmissible spongiform encephalopathies (Adams, Beck et al. 1974). 
Chronic wasting disease affecting cervids and mink encephalopathy were later added to 
the group (Williams and Young 1980). 
 
 
1.1.1.3 Bovine spongiform encephalopathy  
 
Bovine spongiform encephalopathy, or “mad cow disease” is best known from 
the sudden outbreak in early 1990s. The disease itself, however, emerged as a new 
cattle disease in the United Kingdom almost a decade earlier, in the 1980s. 
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The symptoms of the disease resembled those of scrapie, which led to investigation of 
pathology and transmissibility. Scrapie-like fibrils were found in the brains of infected 
cows, which together with confirmed transmissibility to other laboratory animals 
allowed the disease to be grouped together with CJD and scrapie as transmissible 
spongiform encephalopathies (Hope et al. 1988; Fraser et al. 1988). Following the 
classification, a number of cases of BSE started to be monitored. While less than 2000 
cases were observed in 1988, their number increased sharply in the following years, 
untill 37,011 cases of BSE were confirmed in UK in 1993, which is generally 
considered a peak of BSE epidemic. High economic impact of the disease including 
worldwide ban on British beef export introduced by European Union resulted in 
increased interest in BSE epidemics and transmission. While the exact origins of the 
disease are unknown, feeding cows with BSE-contaminated cattle meat and bone meal 
is a widely accepted cause (Weissmann and Aguzzi 1997). Introducing a ban on 
ruminant offal usage as a protein supplement for cattle allowed for curtailing the 
epidemic, leading to a gradual decline in cases since 1993 (Figure 1.1) (figures from the 
DEFRA website, www.defra.gov.uk). 
 
 
1.1.1.4 Variant Creutzfeldt-Jakob disease (vCJD) 
 
In 1996, the first case of new variant Creutzfeldt-Jakob disease (vCJD) was first 
reported in the UK (Will et al., 1996) as a result of a widespread monitoring action 
initiated by the fear that individuals who consumed contaminated beef during the 
outbreak of BSE could contract the human form of prion disease. The disease exhibited 
novel neuropathological features that distinguished it from sporadic CJD, as well as a 
much lower age of onset compared to its classical, sporadic form. Although origin of 
the disease was unknown at the time, the fact that all known cases were reported in the 
UK suggested that it could be linked to BSE. Transmission experiments provided 
conclusive evidence for the origin of vCJD demonstrating that the BSE could be 
transferred from cows to macaques and that upon transmission it induced similar 
pathological changes in the brain (Lasmezas et al. 1996).  
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Figure 1.1 Cases of BSE, and vCJD in the UK from 1988 to 2007. The epizootic of 
bovine spongiform encephalopathy is represented by blue bars, the epidemic of variant 
Creutzfeldt-Jakobs disease in humans is shown by brown bars and three cases of 
transmission of vCJD between humans by blood transfusion are indicated with yellow 
bars. 
 
Figure adapted from (Norrby, 2011). 
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1.1.1.5 Chronic wasting disease 
 
Chronic wasting disease (CWD) is a prion disease of free-ranging wildlife, 
affecting a number of cervid species such as deer, elk and moose. It is the only prion 
disease identified so far which affects wild animals, which coupled with its high 
transmission rate and the fact that the exact prevalence remains currently unknown is of 
major concern in terms of epidemiology.  
CWD was first reported in 1967 in a US research facility, but it was more than a decade 
later when pathologists recognized the brain lesions characteristic for a transmissible 
spongiform encephalopathy. The disease was subsequently demonstrated as a prion 
disease by neuronal changes, accumulation of aggregated prion protein (Spraker et al., 
2002) as well as prion infectivity in the brain (Browning et al., 2004). 
While originally thought to be limited to a small area in central United States, it proved 
to be spreading quickly. Only in the last decade it was identified in several more states 
of USA, as well as in southern Canada and even in South Korea, raising possibility of a 
widespread occurrence akin to that of bovine spongiform encephalopathy (BSE).   
Since CWD affects wild animals, controlling its spread has proved to be particularly 
difficult. Moreover, it is likely that disease-associated prions are progressively 
accumulating in the environment due to the fact that PrP
Sc
 binds to soil and can retain 
its infectivity for a long period of time (Miller and Williams, 2004; Sigurdson and 
Aguzzi, 2007). 
Since millions of North Americans hunt deer and elk, it is very likely that a large 
number of humans have been exposed to CWD-infected meat, either by contact or 
consumption (Sigurdson, 2008). While the possibility of transmission of CWD to other 
species remains unknown, only a handful of occurrences in human population could 
result in a new disease, much like transmission of bovine prions to humans resulted in 
an emergence of a variant of Creutzfeld-Jakobs disease. No clinical evidence linking 
humans exposed to CWD and patients suffering from CJD has been found, however, 
the autopsies on suspect human TSE cases were not performed until recently, 
hampering the diagnosis of new TSE strains (Sigurdson, 2008). 
In transmission experiments, inoculation of squirrel monkeys with CWD prions induced 
the disease, yet transgenic mice expressing human PrP remained unaffected, indicating 
that the species barrier effect between humans and cervids is stronger than between 
cattle and humans (Kong et al., 2005; Sandberg et al., 2010).  
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1.1.1.6 Inherited prion disease 
 
Familial diseases such as Gerstmann-Sträussler syndrome (GSS) or familial 
CJD account for approximately 10-15 % of human TSE cases. Mutations in PRNP gene 
encoding prion protein which result in amino acid substitutions or additional insertions 
of the octapeptide repeat in unstructured N-terminus of PrP have been linked with the 
familial form prion disease.  
First such mutation identified was a proline to leucine substitution at codon 102 (Hsiao 
et al. 1989) linked to GSS. Subsequently it was found that an additional range of amino 
substitutions, including a stop mutation at position 145 resulting in a truncated form of 
PrP could cause the disease (Kitamoto et al. 1993, Brown 2002).  
Familial CJD-inducing mutations were first tracked to a point mutation resulting in 
substitution of Glu at position 200 for Lys (Goldfarb et al. 1990, Gabizon et al. 1993) 
and to date additional disease-associated mutations resulting in amino acid substitutions 
have been identified (Brown 2002). 
While the link between PrP mutations and familial prion diseases provides 
strong support for the protein-only model, the mechanism by which these mutations 
facilitate the pathogenic process remains unclear. It has been postulated that these 
mutations may facilitate the pathogenic process by reducing the stability of the prion 
protein (PrP). 
Interestingly, introduction of several point mutations such as P102L corresponding to 
Gerstmann-Straussler-Scheinker syndrome, E200K linked with Creutzfeld-Jakob 
disease and M129/D178N inducing fatal familial insomnia into the recombinant 
variants of human PrP(90–231) resulted in virtually no alterations in neither secondary 
structure nor thermodynamic stability. While E200K substitution induced a very small 
destabilization of the protein, it was deemed extremely unlikely that such a slight 
destabilizing effect alone could account for the pathogenicity associated with the 
mutation. These experiments, together with the predictive analysis of other familial 
mutations, indicate that the pathogenic mutations do not exert a uniform effect on the 
thermodynamic stability of the human prion protein, and consequently, not all 
hereditary forms of the disease may be rationalized through a common mechanism 
based on the mutation-induced decrease in global stability of PrP
C
.  
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Especially intriguing in this context are GSS-associated mutations at residues 102, 105, 
and 117 which lie within the unstructured region of PrP, as their effect cannot be 
rationalized by a model based on an increase in the population of partially folded 
intermediates, as proposed for mutations within the C-terminal domain (14).  
Another proposed pathogenic mechanism associated with these mutations postulates an 
increased amyloidogenic propensity of the unstructured N-terminal region (14) 
conferred by P102L and P105L mutations which replace a_β-sheet incompatible Pro 
residue as well as A117V and other mutations which introduce a branched hydrophobic 
side chains which are believed to increase the capability of amyloid formation (33–35).  
However, as demonstrated by experimental evidence (paper reference) the kinetics of 
amyloid fibril formation of several GSS-linked mutants are very similar to those of 
wild-type protein. Moreover, fibrils formed by GSS variants of prion protein are 
indistinguishable in conformation and seeding properties, indicating that these 
mutations do not affect the amyloidogenic properties of PrP.  
Consequently, other factors, such as alterations in PrPC interactions with a complex 
cellular environment (36–38) or metabolic effects related to PrP trafficking (39–41) 
should be considered to explain how these familial mutations facilitate PrP conversion 
in vivo. 
 
 
1.1.2 Chronology of prion discovery 
 
Since the very first demonstration of transmissibility of scrapie a lot of interest 
in the disease has been generated due to the unique properties of the elusive infectious 
agent. The first attempts to investigate the nature of the causative agent date back to 
1938, when spinal cord homogenate obtained from scrapie-affected sheep was shown to 
induce disease in unaffected animal, prompting speculations that the infectious agent 
was a “filterable virus” (Cuille and Chelle, 1938). 
Irradiation experiments of brains from infected mice performed in 1966 revealed that 
very large doses of ultraviolet radiation of 253.7 nm wavelength, which was known to 
be specifically absorbed by DNA, do not inactivate the scrapie agent (Alper et al. 1966) 
Since only ionizing radiation at unusually high doses resulted in inactivation, it was 
concluded that the infectious agent is either a very short nucleic acid in the range of 800 
bases, or other particle “of an unusual nature”.  
8 
 
Speculations on the nature of the scrapie agent involved replicating polysaccharides 
(Alper et al., 1967), replicating membrane fragments (Gibbons and Hunter, 1967), 
DNA-polysaccharide complex (Adams and Caspary, 1968), viroids (Diener, 1972) and 
even lipids (Alper et al., 1978). 
 
 
1.1.2.1 Protein only hypothesis – introduction and supporting evidence 
 
In 1967 a series of extraction and electrodialysis experiments with scrapie agent 
led to the conclusion that “the transmissible agent may be, or may be associated with, a 
small basic protein” (Pattison and Jones, 1967). In the very same year the 
mathematician J. S. Griffith presented a “protein only” theory which encompassed three 
ideas of modes of transmission, all of which required the prion protein to be host 
encoded. One of the theories, which is nearly identical to what is today believed to be 
the mode of transmission, suggested that upon introduction of a seed of modified prion 
protein, the native cellular prion protein molecules are prompted to attach to this seed 
which eventually splits into two new seeds, thereby giving rise to its exponential 
propagation (Griffith 1967).  
Subsequent experiments demonstrated that inactivation of scrapie infectious 
agent can be achieved if it is subjected to compounds or environments that modify 
proteins or disrupt their structure, such as protease treatment or exposure to chaotropic 
agents (Prusiner, McKinley et al. 1981). This suggested that it is the protein itself that is 
an essential component of the infectious agent, supporting the protein-only hypothesis.  
Consequently, in 1982, based on the unusual resistance of the pathogen and 
experimental evidence indicating that it consists primarily of protein, Stanley Pruisner 
introduced the term “prion” which denotes proteinaceous infectious particle (Prusiner 
1982). Due to lack of certainty at the time, two possibilities for the nature of prions 
were considered: a small nucleic acid surrounded by a tightly packed protein coat or a 
protein devoid of nucleic acid which is itself infectious. It should be noted that while at 
the time Pruisner himself admitted that the second idea is “clearly heretical”, prions 
today are clearly defined as “proteinaceous infectious particles lacking a nucleic acid” 
(Prusiner 1998). 
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1.1.2.2 Purification and isolation of infectious material 
 
Since Griffith proposed the “protein only” hypothesis to explain the unique 
features of scrapie infectious agent, numerous attempts have been made to identify the 
elusive particle. Analysis of protein associated with prion material allowed to determine 
its molecular weight, which was estimated to be 27–30 kDa (Bolton et al., 1982).  
The presence of rod-like structures in the brain referred to as “scrapie associated fibrils” 
was discovered during attempts to purify the scrapie agent from affected neural tissue 
(Merz et al. 1981). Eventually, prions were successfully isolated from brain tissue of 
infected hamsters following extensive purification by detergent extraction, proteinase K 
treatment, and sucrose density gradient (Prusiner et al., 1983). Subsequent structural 
characterisation confirmed that they are composed of polypeptides, with no covalently 
bound nucleic acids. Moreover, isolation of a short N-terminal fragment of the protein 
allowed for sequencing and subsequent production of molecular probes, which were 
used to identify mRNA coding for the prion protein. It was quickly discovered that the 
prion protein was encoded by a cellular gene present in non-diseased brain tissue as 
well as other body tissues (Chesebro et al., 1985; Oesch et al., 1985). 
Sequencing of the prion gene revealed that the cellular form of the prion protein called 
PrP
C 
had a molecular weight of approximately 33–35 kDa, which was later confirmed 
by determining the molecular weight of prion protein isolated from brain tissue without 
the use of proteinase K.  
Analysis of scrapie associated fibrils determined that they were composed of the same 
host-encoded protein, which led to the conclusion that prion protein exists as a normal 
cellular form, which can be converted to a disease associated conformation names 
scrapie-isoform (PrP
Sc
). This misfolded PrP could then be recruited into formation of 
fibrillar structures found in brain tissue of animals suffering from TSEs. 
The PrP
C
-PrP
Sc
 model was consistent with the protein-only hypothesis presented twenty 
years earlier by Griffith, which proposed that seed of modified prion protein (PrP
Sc
) can 
induce autocatalytic conversion of the native cellular protein molecules (PrP
C
) and 
subsequent formation of fibrils.  
Further investigation confirmed that both PrP
C
 and PrP
Sc
 are encoded by the same 
single gene, indicating that the differences between isoforms are not caused by different 
primary structures, but a post-translational modification or change in conformation 
(Basler et al., 1986). The idea of autocatalytic conversion of PrP
C
 by PrP
Sc
 was 
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supported by subsequent findings that knock-out mice mutants which do not express 
prion protein were completely resistant to scrapie (Bueler, Aguzzi et al. 1993), 
indicating that expression of the protein within the host is essential for disease 
progression. 
 
 
1.1.2.3 Yeast prions – in support of proteinaceous nature of prions 
 
The protein-only hypothesis is supported by observation of prion-like behaviour 
of proteins in the yeast Saccharomyces cerevisiae. While these proteins have no relation 
to PrP, they exhibit similar templating mechanism of autocatalytic conversion, as well 
as transfer of genetic elements between cells without the presence of nucleic acids. 
Two proteins: a nitrogen regulator Ure2p, and translation termination factor Sup35p, 
were determined to have a soluble form and an amyloid form ([URE3] and [PSI+], 
respectively). Moreover, both of the amyloid isoforms can cause their soluble 
counterparts to convert to the prion-like state and form long -structured fibres, 
similarly to how PrP
Sc 
affects PrP
C
 (Caughey, 2000; Wickner et al., 2004).  
Other examples of prion-like behaviour in yeast involve Rnq1p soluble protein with its 
amyloid form [PIN+] (Patel and Liebman 2007), Swi1 subunit of SWI/SNF chromatin 
remodelling complex and its prion form [SWI+] (Du, Park et al. 2008), as well as 
global transcription repressor Cyc8, isoform of which (called [OCT+]) was also 
demonstrated to have prion activity upon overexpression (Patel, Gavin-Smyth et al. 
2009).  
 
 
1.1.3 Characteristics of prion diseases 
 
Although, throughout many years of research, numerous aspects of prion 
diseases have been investigated and characterised, there still remain several 
characteristics lacking definitive proof or explanation. One such feature is the 
transmissibility of prion diseases and the fact that it has so far been impossible to isolate 
single neurotoxic agent responsible for neurodegeneration of infected neural tissue. 
Still, a growing body of evidence indicates that small, soluble oligomers are primary 
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cytotoxic mechanism as opposed to fibril formation and deposition on cellular 
membranes (Chisea et al., 2001; Novitskaya et al., 2005). Moreover, formation of 
fibrils and their aggregation as well as subsequent formation of plaques is considered a 
protective mechanism evolved to avoid high toxicity of soluble oligomers (Buccianti et 
al., 2002; Kirkitadze et al., 2002; Caughey et al., 2003). 
Another interesting aspect of prion diseases is the fact that infectious material, 
composed only of PrP, can induce a disease with widely different incubation time, 
pathology, and other phenotypic aspects (Prusiner et al., 1998), suggesting the existence 
of different “strains” of prions. 
 
 
1.1.3.1 Prion strains 
 
One of the most interesting features of prions is the existence of “strains” which 
induce different disease phenotypes differing in incubation time, brain pathology and 
other features and which can be transferred between hosts with surprisingly high 
fidelity (Safar et al., 1998). Some of these aspects of strain phenotype do not depend on 
the host, leading to the conclusion that they must be encoded by the infectious agent 
(Bruce et al., 1991). In such a case, the autocatalytic template mechanism through 
which 
PrP
Sc
 propagates would allow it to impose its conformation onto the host expressed 
PrP
C
, consequently dictating the strain phenotype of the disease (Telling et al., 1996). 
 
 
1.1.3.2 Species barrier 
 
An interesting phenomenon associated with prion transmission is the apparent 
inability of infectious prions to induce a disease in certain species, while retaining full 
infectivity upon transferring to others. The species barrier, as it is known, results in a 
longer incubation time and lower incidence of disease upon transfer of the infection 
between individuals from different species (Bruce 1993).  Through compelling 
experimental evidence, it has been demonstrated that the mechanism of the species 
barrier is directly controlled by the primary sequence of prion proteins. Transgenic mice 
expressing hamster PrP exhibited high susceptibility to hamster prion infection, a 
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feature absent in wildtype animals (Scott et al., 1989; Moore et al., 2005). Interestingly, 
mice expressing human prion protein demonstrated high resistance to bovine prion 
infection, while showing high susceptibility to vCJD (Bishop, Hart et al. 2006). This 
suggests an existence of a strong species barrier between humans and cattle which is 
likely to be a primary reason of very low vCJD incidence after the BSE outbreak in 
1990s, compared to number of cases in cattle. 
Since the structure of PrP is highly conserved, it is unlikely that structural differences 
between PrP from different species are directly responsible; however, the very fact that 
both primary sequence and structure are conserved does not mean that the folding 
mechanism itself is conserved (Robinson and Pinheiro, 2009). 
 
 
1.1.3.3 Disease-associated mutations in humans – inheritance and increased 
susceptibility 
 
Prion diseases in general can be classified as sporadic, inherited or acquired 
through transmission, although the most common reasons of occurrence vary greatly 
between the species. In humans, sporadic CJD accounts for 85% of all cases of disease, 
with around 10–15% of cases associated with the familial cause and less than 5% 
acquired through transmission (Collinge, 2005). All the familial forms of the disease are 
caused by mutations in the PRNP gene which encodes prion protein. Gene alterations 
which result in amino acid substitutions or insertions of additional octapeptide repeats 
in the N-terminus of PrP have been linked to familial CJD. 
One of the genetic forms of human prion disease is a Gerstmann-Sträussler syndrome 
(GSS) transmitted in an autosomal dominant fashion. Several mutations have been 
linked with GSS, including substitution of proline residue at position 102 with leucine 
(Hsiao, Baker et al. 1989) and a stop mutation at position 145 which produces a 
truncated form of prion protein (Kitamoto, Iizuka et al. 1993). 
Not all mutations in the PRNP gene result in spontaneous disease generation. Some of 
the alterations have been demonstrated to increase susceptibility to the disease acquired 
from external source. An example of such a mutation is a human polymorphism which 
results in presence of valine or methionine residue at position 129. It was discovered 
that 95% of patients suffering from a sporadic form of CJD are homozygous at codon 
129. In comparison, 51% of the population not affected by CJD were found to be 
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heterozygous, indicating that homozygous mutation greatly increases susceptibility to 
sporadic form of the disease (Palmer, Dryden et al. 1991). 
 
 
1.1.4 Diagnostics of prions and possible therapies 
 
Increased interest in prion diseases generated during the BSE and vCJD 
outbreaks, as well as due to increased prevalence of CWD in the cervid population and 
concerns of possible transfer to humans resulted in a widespread search for possible 
methods of TSE diagnostics. 
Although several in vitro methods have been reported, most have major limitations that 
would preclude their use in routine diagnostic or screening applications. Of particular 
interest are methods capable of detecting prions in blood or plasma, but these 
environments exhibit extremely low prion concentrations and contain inhibitors 
lowering the effectiveness of most sensitive prion tests (Orru et al., 2011).  
One of the methods capable of detecting prions of variant Creutzfeldt-Jakob disease 
(vCJD) in human plasma is a quaking-induced conversion (QuIC). It exhibits sensitivity 
similar to that of in vivo bioassays, yet is much more rapid and less expensive (Orru et 
al., 2011). Another potential assay for PrP is the detection of glycated PrP by 
monoclonal antibodies specific for carboxymethyl lysine/arginine-modified prion 
protein (Dvorakova et al., 2011).  
The discovery of the proteinaceous nature of PrP allowed for focussing of the attempts 
to develop effective treatment of prion diseases. Thousands of compounds have been 
screened for anti-prion effect, and while many show promising results in in vitro 
studies, very few are equally effective in vivo, especially if administered in the later 
stages of disease (Sim, 2012).  
The vast majority of potential therapeutic effects was limited to prolonged incubation 
periods, but required the treatment to begin near the time of infection, which is difficult 
to estimate particularly in sporadic or familial forms of human disease (Brown, 2009). 
However, development of new diagnostic techniques, together with experimental 
insight into the mechanism of prion pathogenesis, particularly the role of oligomers and 
fibrils in neuropathology, increases the chances of finding effective therapeutic 
strategies. Many of the proposed methods rely on redistribution, sequestering, or down-
regulation of PrP
C
 by polyanionic or polycyclic agents, thus preventing conversion of 
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cellular form of PrP to PrP
Sc
. Novel approaches include trapping the multimeric form of 
PrP
Sc
, increasing clearance of scrapie isoform, targeting accessory molecules playing a 
role in conversion, targeting pathways which lead to neurodegeneration and even stem 
cell therapy (Sim, 2012). 
 
 
1.1.4.1 Protein misfolding cyclic amplification 
 
One of the potential diagnostic methods theoretically capable of detecting single 
molecules of PrP
Sc
 is a protein misfolding cyclic amplification (PMCA). 
The method relies on autocatalytic conversion of PrP
C
 by small amounts of PrP
Sc
 
isolated from scrapie brain homogenate. Scrapie isoform is diluted to very low 
concentration and incubated with PrP
C
 while the reaction mixture is subjected to short 
bursts of sonication. The amount of PrP
Sc
 increases with every cycle as a result of 
autocatalytic conversion of PrP
C
, which is enhanced by sonication aimed to break up 
growing fibrils thus providing additional replication templates. The sensitivity of the 
assay is sufficient to detect several dozens of PrP
Sc
 monomers in the blood sample, 
which allows it to be used as effective diagnostic method (Castilla et al., 2005; Saa et 
al., 2006). 
 
 
1.1.5 Biosynthesis and metabolism of prion protein 
 
 
1.1.5.1 Expression and post-translational modification of PrP 
 
Prion proteins are encoded by PRNP gene in a form of 253 amino acid long 
polypeptide chain (Basler et al., 1986; Oesch et al., 1985). During translation by 
cytoplasmic ribosomes, a signal recognition peptide (SRP) binds to an N-terminal 
signal sequence of the growing polypeptide chain, targeting the ribosome-PrP complex 
to endoplasmic reticulum (ER), where the signal sequence is cleaved. Following 
translation, a C-terminal sequence of the polypeptide forms a transmembrane helix 
which anchors the protein to ER membrane. The C-terminal transmembrane segment is 
then cleaved by an enzyme which attaches the protein to a GPI anchor, allowing it to 
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remain connected to the membrane. Two high mannose oligosaccharides are 
subsequently attached to N-linked glycosylation sites at positions 181 and 197 in case 
of human PrP. Finally, a disulfide bond is formed between two cysteine residues at 
positions 179 and 214 (Lawson et al., 2005).  
High sequence identity of PrP genes between different species as well as experimental 
observaions indicate that these modifications are highly conserved (Wopfner et al., 
1999).  
Following the post-translational processing in the ER, the GPI-anchored PrP is directed 
to the Golgi body, where its glycosylations are processed to a range of variable 
glycosylations including un-glycosolyated, mono and di-glycosylated species (Lawson 
et al., 2005). PrP is then directed from the Golgi body to the outside face of the cell 
membrane. 
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Figure 1.2 Schematic representation of biosynthesis, processing, and conversion of 
prion protein. The initial polypeptide chain (A) is 253 amino acids in length, including 
the signal sequences at the N- and C- termini.  
A series of post-translational modifications yields cellular form of PrP
 
(B). During the 
maturation process the signal sequences are removed, residues 181 and 197 are 
glycosylated, disulfide bond formed between cysteine residues 179 and 214 and the 
glycosylfosphatidylinositol (GPI) anchor added.  
Upon conversion to PrP
Sc
 the primary structure remains unaffected, however extensive 
changes in secondary and tertiary structure result in formation of 142 amino acid-long 
proteinase-K resistant core (C). 
 
 
 
A 
B 
C 
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1.1.5.2 Trafficking to cell membrane and endocytosis 
 
 Following the variable glycosylation in the Golgi body, mature PrP is 
transported to the plasma membrane attached via GPI anchor to the luminal side of the 
membrane of secretory vesicles. Upon reaching the membrane, the protein is localised 
to the to the lipid rafts on the external surface of the lipid bilayer. This localisation is 
independent of the GPI anchor, due to the fact that unstructured N-terminal region of 
PrP contains targeting sequence which directs protein to the lipid rafts even in absence 
of GPI anchor (Walmsley, Zeng et al. 2003). PrP remains attached to the external 
surface of lipid bilayer for approximately 3 to 6 hours (Caughey, Race et al. 1989) 
before it is internalised and trafficked between the cell surface and endosomal 
compartments (Shyng, Huber et al. 1993). 
Like many other transmembrane proteins, PrP is internalised via clathrin coated pits. 
The unusual aspect of the process is the fact that prion protein lacks cytoplasmic 
domain, being GPI anchored (Shyng, Heuser et al. 1994), which should theoretically 
prevent its internalisation. N-terminal truncation provided some insight into the subject, 
demonstrating that partial removal of unstructured region reduces endocytosis, 
suggesting PrP interacts with a transmembrane protein that undergoes conventional 
endocytosis and is incorporated into clathrin coated pits along with it (Shyng et al., 
1994; Shyng et al., 1995). 
 
 
1.1.5.3 Physiological role of PrP 
 
Although prion protein was first identified almost 20 years ago and ever since 
has been the subject of continuous research interest, its physiological function has 
remained uncertain. 
Several lines of knockout mice not expressing PrP gene have been engineered to this 
date, displaying resistance to prion infection and no apparent anatomical abnormalities 
(Bueler et al., 1992). While some of these animals exhibited subtle behavioural and 
cellular alterations, the molecular basis of those defects remained unknown (Steele et 
al., 2007). 
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Compelling evidence for an involvement of PrP
C
 in cell adhesion has emerged recently 
from zebrafish research (Malaga-Trillo et al., 2009). Two genes expressing PrP-like 
protein were discovered, playing important role in embryogenesis (PrP1 gene) and 
development of nervous system (PrP2). Depletion of PrP1-encoded protein resulted in 
gastrulation arrest, which could be rescued by PrP-1 and PrP-2 proteins as well as 
mouse PrP (Malaga-Trillo et al., 2009), indicating very high conservation of biological 
activity. Subsequent research revealed that PrP-1 influences the delivery of E-cadherin 
to the plasma membrane, thus playing a role in cell adhesion modulation (Biasini et al., 
2012). 
Another possible function of PrP is the regulation of ion channels and synaptic 
development in general, a role supported by its localization at synaptic sites (Moya et 
al., 2000; Kanaani et al., 2005) and the fact that variety of electrophysiological 
abnormalities have been described in neurons of PrP-knockout mice (Biasini et al., 
2012). 
Extensive research into neuropathological effects of prion diseases revealed another, 
perhaps most surprising, possible function of PrP. Neuroprotective effects of PrP
C 
overexpression against several kinds of apoptotic stimuli have been demonstrated, 
together with its role in regulation of survival-mediating intracellular signaling cascades 
(Lo et al., 2007; Biasini et al., 2012). 
Moreover, recent findings indicate that prion protein may be linked to self-renewal of 
neural progenitor and stem cells (Santos et al., 2011) and regulation of neural precursor 
proliferation during mammalian neurogenesis (Steele et al., 2006). 
 
 
1.1.6 Structure of PrP 
 
The discovery and sequencing of PRNP gene demonstrated that both PrP
C
 and 
PrP
Sc
 are in fact the same protein (Basler et al., 1986; Stahl et al., 1993). Consequently, 
it became apparent that vastly different behaviour and properties of the two isoforms 
can only be attributed to structural differences. This was confirmed through initial 
spectroscopic characterisation of both isoforms, which revealed predominantly α-helical 
structure of the cellular form of PrP and β-sheet rich conformation of PrPSc extracted 
from neural tissue of animals suffering from TSEs (Pan et al., 1993). 
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High resolution studies of prion protein became possible upon successful cloning of 
PrP-encoding gene, which allowed for the induction of PrP expression in bacterial cells 
via PRNP-containing plasmids.  
To this date intact prion protein could not be successfully crystallised, excluding the 
application of X-ray crystallography and limiting high resolution studies of PrP to 
nuclear magnetic resonance (NMR) and related techniques. 
 
 
1.1.6.1 NMR structures of PrP
C 
 
The first high resolution structure of PrP
C
 was determined through NMR studies 
of truncated construct of murine PrP (Riek et al., 1996). The C-terminal fragment was 
found to contain three short α-helices designated helix A, helix B, and C, as well as a 
short antiparallel β-sheet composed of two short strands dubbed S1 and S2. A single 
disulfide bond was identified between first turn of the second helix (A2) and the last 
turn of the third helix (A3), in the hydrophobic core of the protein. Investigation of full 
length prion protein by fluorescence and circular dichroism revealed that the N-terminal 
region is composed solely of random coil and devoid of any structure (Hornemann, 
Korth et al. 1997), which was later confirmed through NMR studies (Donne et al., 
1997; Riek et al., 1997). 
NMR spectroscopy was also used to investigate the truncated construct of Syrian 
hamster PrP, the structure of which was found to be very similar to mouse prion protein 
(James et al., 1997; Liu et al.,1999). 
To this date, high resolution structures of cellular prion proteins from numerous 
mammalian species have been determined (Lysek et al., 2005), all showing remarkable 
structure similarities with primarily -helical C-terminal domain and a long 
unstructured N-terminus. Moreover, PrP structures from non-mammalian species 
sharing only 30% sequence homology with mammals were showed to be very similar, 
indicating high structure conservation (Calzolai et al., 2005). 
Recent studies of elk and bank vole PrP revealed a presence of highly rigid loop region 
between the -strand B2 and the -helix A2, not encountered in other species (Gorfe 
and Caflisch, 2007; Christen et al., 2008). NMR analysis of mouse-bank vole hybrids 
and molecular dynamics simultions of elk-mouse hybrids show that replacing the loop 
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of mouse PrP with that from bank voles or elk results in increased stability and rigidity 
of the loop (Christen et al., 2009; Scouras and Daggett, 2012). Experimental evidence 
demonstrates that increasing loop region stability induces spontaneous prion disease in 
mice (Sigurdson, Nilsson et al. 2009), indicating an important role of this region in 
disease susceptibility. 
 
 
1.1.6.2 Structural models of PrP
Sc 
 
While investigation of PrP
C
 structure from numerous species has been 
accomplished through a number of spectroscopic methods, the amount of information 
on structure of scrapie isoform PrP
Sc
 is much lower. Infectious species of prion protein 
are difficult to identify and extract due to multi-conformational nature of PrP
Sc
 deposits 
and the fact that isolation of scrapie isoform from brain tissue requires the use of 
detergents which may alter protein structure during purification. Moreover, amyloid 
fibrils are highly insoluble, preventing the use of X-ray crystallography and solution 
NMR. 
First information on PrP
Sc
 structure was obtained through FTIR studies, which 
suggested a -sheet rich conformation (Caughey et al., 1991). Subsequent X-ray 
diffraction studies confirmed the overall nature of PrP
Sc
, revealing cross -structure of 
the isoform (Nguyen et al., 1995). 
Co-purification of negatively stained crystals and prion rods and their subsequent 
analysis via electron crystallography provided further information about PrP
Sc
, allowing 
for extensive modelling of its structure. Currently available models suggest a -helix 
fold which can assemble into trimers, consequently forming repeating subunits of prion 
fibrils (Wille et al., 2002; Govaerts et al., 2004). 
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Figure 1.3 Ribbon representation of the structure of the C-terminal globular domain 
of mouse prion protein (residues 90-230) based on the NMR structure (Gossert et al. 
2005). Main structural features are highlighted in colour with key residues shown using 
stick representation. Three main α-helices are shown in orange, with short antiparallel 
β-sheet S highlighted in blue. Native tryptophan residues at positions 98 and 144 are 
highlighted in green and phenylalanine residue at position 197 is highlighted in red.   
 
The NMR structure was drawn from PDB file 1XYX using UCSF Chimera package 
from the Resource for Biocomputing, Visualization and Informatics at the University of 
Califormia, San Francisco (supported by NIH P41 RR-01081). 
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Figure 1.4 Modeling of β-helical conformation of residues 89-174 of PrPSc and its 
assembly into timeric subunits of prion fibrils. Panel A shows the β-helical model of the 
N-terminal part of PrP 27–30, panel B demonstrates the structure of PrPSc monomer, 
panel C depicts the trimeric model of PrP
Sc
 subunit present in fibrils. 
 
Figure adapted from (Govaerts et al., 2004). 
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1.1.7 Conversion of PrP
C
 to PrP
Sc 
 
Structural studies of prion protein revealed dramatic structural difference 
between the cellular form PrP
C
 and disease-associated PrP
Sc
. These findings, coupled 
with protein only hypothesis stating that the scrapie isoform can recruit and convert the 
cellular form of prion, sparked significant interest in the mechanism of such an 
extensive conversion.  
Several models of conversion mechanism were presented over the years, including 
template mechanism, equilibrium conversion and recruitment of intermediate. 
The template mechanism assumes that PrP
Sc
 binds directly to partially unfolded PrP
C
 
and acts as a replication template, inducing conformational change in a catalytic fashion 
(Prusiner et al., 1998). Second model implies existence of equilibrium between cellular 
and scrapie isoforms which can be shifted towards PrP
Sc
 upon formation of stable 
nucleus of the latter isoform (Jarret and Lansbury, 1993). Finally, PrP
Sc
 may be able to 
recruit an intermediate present in the folding pathway of PrP
C
 and force it down the 
alternative pathway leading to disease-associated conformation (Apetri et al., 2004; 
Liemann and Glockshuber, 1999). 
 
 
1.1.7.1 In vivo conversion 
 
It is widely accepted that destabilising environment contributes greatly to the 
misfolding of PrP. Consequently, endoplasmic reticulum, lysosomal pathway and the 
plasma membrane have all been suggested as possible locations of PrP
C
 to PrP
Sc
 
conversion, yet exact site of the process remains unknown (Campana et al., 2005).  
Recent quantitative analysis of PrP
C
 and PrP
Sc
 distribution coupled with estimation of 
PrP
Sc
 levels in different trafficking-impired neuronal cells allowed to exclude the early 
and late endosomes from possible sites of prion conversion. At the same time, 
endosomal recycling compartment where PrP is trafficked following internalization 
from the cell surface has been suggested as the most likely location of the process 
(Marijanovic et al., 2009). 
Involvement of host-specific factor was suggested as an important aspect of prion 
conversion. The yet-uncharacterised ligand dubbed “Protein-X” has been proposed to 
bind to the loop region encompassing residues 165-171, facilitating pathogenic 
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conversion of PrP (Telling et al., 1995, Kaneko et al.,1997). This hypothesis was based 
on the results of infectivity studies on transgenic mice expressing both murine and 
human prion protein, as well as mouse-human chimera based on mouse PrP with 
residues 90-167 of the human protein. Mice expressing human PrP and chimeric 
animals were found to be susceptible to human prions, while those expressing murine 
PrP were not, suggesting that a host-encoded protein with affinity for mouse PrP greater 
than that for human PrP binds in the loop region thus facilitating pathogenic conversion 
(Telling et al., 1995). 
 
 
1.1.7.2 In vitro conversion and fibrillization  
 
Since the discovery of two dramatically different conformations of prion 
protein, considerable efforts have been made to characterise the process of conversion, 
with many studies focussing on replicating the process in vitro. 
The conformational change from primarily α-helical form to a PrPSc-like structure rich 
in β-sheets was observed to occur under partially destabilising conditions such as 
presence of mild denaturant or low pH (Swietnicki et al., 2000; Baskakov et al., 2001). 
It was soon discovered that two distinct isoforms of PrP
Sc
 can be produced under 
slightly different experimental conditions: long, multimeric amyloid fibrils which were 
highly insoluble, as well as small oligomeric particles consisting of several (usually 8) 
monomers of PrP rich in -sheet structure (Baskakov et al., 2002; Bocharova et al., 
2005).  
Subsequent studies revealed that both oligomers and amyloid fibres can be produced 
from full-length PrP (Bocharova et al. 2005) and that pre-formed fibrillous material can 
act as seeds for fibrilization, effectively eliminating the nucleation phase and decreasing 
the lag time of fibril formation (Baskakov 2004). 
Interestingly, fibrilization pathways can be affected by minor structural features of PrP, 
as indicated by reports that even minor N-terminal truncations of full length PrP 
produces fibrils with distinctly different conformations (Ostapchenko et al., 2008). 
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Successful generation of infectious prions in vitro have been reported in several studies 
where the use of protein misfolding cyclic amplification allowed for conversion of PrP
C
 
to PrP
Sc
 (Castilla et al., 2005) and subsequent adaptation of the in vitro produced prions 
(Castilla et al., 2008). Hamster PrP
C
 misfolded by mouse PrP
Sc
 generated new prions 
infectious to wild type hamsters, with the inverse process yielding material infectious to 
mice. A detailed characterization of the species produced during the study indicated that 
their properties correspond to those of new prion strains (Castilla et al., 2008).   
Recent molecular dynamics simulations suggest that a compact loop encompassing 
residues 166-175 is necessary for aggregation and formation of the infectious particles 
in several species including bank vole, elk, sheep and mouse prion strains. Moreover, 
the stability of the loop region is decreased in a number of point mutations which are 
associated with increased disease resistance (Scouras and Daggett, 2012).  
According to the modelling studies of infectious protofibrils, the stabilised turn is 
buried between two PrP monomers, allowing for oligomerisation. In the absence of 
stabilising mutations, the loop region is destabilised, and the resulting flexible, 
expanded loop disrupts the packing of the adjacent monomers, consequently impairing 
their incorporation into the protofibril (Scouras and Daggett, 2012). Another potential 
disease-resistance mechanism is based on the possibility that if the PrP variants carrying 
loop-destabilising mutations become parts of the infectious seeds, the altered stability of 
their conformation prevents further oligomerisation (Ott et al., 2008). 
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Figure 1.5 Electron microscope images of mouse PrP fibrils formed in vitro (A and 
B) and prion rods purified from brain extracted material(C) which co-purify with 
infectivity. 
 
Images A and B were collected by the author following fibrilisation experiments (see 
Chapters 3 and 4), image C was reproduced from (Safar et al., 2006) 
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1.2 Protein folding  
 
 
1.2.1 Principles of protein folding 
 
Proteins are biological macromolecules essential in virtually every process 
occurring within living cells including catalysis of biochemical reactions, transport of 
molecules and metal ions or role in structural framework. 
They begin their life as long polypeptide chains which spontaneously adopt stable and 
active three-dimensional structure in order to perform their function within the cell 
(Jahn and Radford 2008). All of the structural information necessary for the polypeptide 
to adopt its native conformation is encoded in its amino acid sequence, also referred to 
as “primary structure” (Anfinsen, 1973). 
While protein folding is a spontaneous, self-assembly process, it cannot occur 
completely at random, as demonstrated by simple calculation showing that a 100 amino 
acid long polypeptide may adopt 3
198
 different conformations. If such a protein were to 
adopt its tertiary structure by random sampling all of the possible conformations with 
highest physically possible rate, the process would take longer than the present age of 
the universe (Levinthal 1968). Consequently, protein folding must be a directed process 
which occurs via clearly defined pathways (Zwanzig et al., 1992). 
 
 
1.2.1.1 Polar opposites – native state and unfolded state 
 
The final, fully functional structural conformation of the protein which is most 
thermodynamically stable is referred to as the native state. Physiological roles of 
proteins such as enzymatic catalysis or transport require structural flexibility, and due to 
this dynamic nature the native state often encompasses a population of near native 
structures rather than single rigid conformation (Jahn and Radford 2008).  
Proteins can spontaneously adopt correct three-dimensional structure due to the fact that 
self-assembly is a thermodynamically favoured process characterised by a negative 
change in free energy between the unfolded and native states.  
One of the major factors contributing to protein folding is the formation of 
thermodynamically favourable non-covalent interactions between side chains of amino 
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acids and the polypeptide chain backbone. Further stabilising effects are provided by 
formation of a complex network of hydrogen bonds as well as weaker electrostatic 
interactions between negatively and positively charged groups (Mathews et al., 2000). 
Another factor crucial for overall stability of the native conformation is the so-called 
hydrophobic effect, which results in majority of hydrophobic residues being buried in 
the protein core, where they are shielded from aqueous environment.  
The increase in entropy associated with the internalisation of hydrophobic regions 
induces a significant positive change in entropy of the system composed of the 
polypeptide chain and surrounding water molecules, contributing to the overall negative 
change in free energy and thus spontaneous nature of protein folding (Mathews et al., 
2000c). 
The unfolded state of the protein can be defined as the conformation where all the 
backbone NH groups of a polypeptide chain are solvent-exposed (Dill and Shortle 
1991), or alternatively as an ensemble of extended conformations, in which the protein 
chain is extensively hydrated and the individual residues do not interact with each other 
(Day, 1996). 
Interestingly, experimental evidence indicates partial retention of native interactions 
such as the hydrophobic clusters of aliphatic and aromatic side chains even in very high 
denaturant concentrations (Klein-Seetharaman, Oikawa et al. 2002), rising questions 
whether “true” unfolded state can be attained in experimental conditions. 
 
 
1.2.1.2 Intermediates and transition states 
 
Extensive study of the mechanism and kinetic properties of protein folding 
provided considerable insight into the process through which proteins attain their fully 
functional structural conformation. Due to its complexity, protein folding occurs in a 
series of steps, each encompassing small populations of distinct, metastable 
conformations referred to as intermediate states which are transiently populated during 
the progression of folding process (Brockwell and Radford 2007).  
A transition state, as opposed to an intermediate, is defined not as a metastable 
conformation but as a rate limiting step of the folding process corresponding to the 
highest point in the energy profile. 
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Intermediate states can be sampled by a variety of kinetic methods including techniques 
capable of following sudden shifts in the equilibrium of the system (Roder, Maki et al. 
2006) or rapid mixing techniques such as stopped-flow, continuous-flow or pressure-
jump capable of characterising protein folding on millisecond and microsecond 
timescale. 
Transition states are often studied using psi-value analysis, a powerful protein 
engineering technique which provides information about the role of individual side 
chains in the folding transition state, describing its structure in terms of the presence of 
native interactions (Matouschek et al., 1989; Oliveberg 2001). 
Populations of folding intermediates and transition states are often represented 
in a form of energy landscape (see Figure 1.6) which reflects the free energy of each 
conformation attainable by a polypeptide chain as a function of its degrees of freedom. 
Each point on the energy landscape represents a single conformation the polypeptide 
chain can adopt, with denatured states possessing high internal free energy and wide 
variety of conformational states found at the “edge” and upper region of the energy 
funnel and native state conformations with lower energy and smaller range of 
conformations close to or within the deepest “well” of the landscape (Radford, 2000; 
Jenkins, 2006). 
Representation of protein folding as an energy landscape is also useful in visualising 
both kinetic barriers and energy traps which can potentially slow, disrupt or even 
completely halt the process of spontaneous self-assembly of polypeptides due to the fact 
that molecule would have to revert to a higher energy state in order to proceed down the 
folding pathway, which is highly thermodynamically unfavourable.  
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Figure 1.6 Schematic representation of a “funnel” energy landscape of a protein 
illustrating all possible conformations populated between the unfolded state (U) and 
native state (N). Black lines indicate two parallel folding pathways, illustrating how a 
protein might fold without (A) and with an intermediate state (B). 
Reaction co-ordinates corresponding to pathways A and B illustrating the presence of 
unfolded state (U), transition state (T), intermediate (I) and native state (N) are 
presented below the energy landscape. 
Image depicting energy landscape adapted from (Dill and Chan,1997). 
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1.2.2 Experimental approaches for the study of protein folding 
 
Although numerous techniques have been employed to date to study the folding 
pathways of proteins, the in vitro studies can be divided into three general categories: 
kinetic studies, equilibrium studies and molecular dynamics simulations. 
 
 
1.2.2.1 Kinetic studies of protein folding 
 
Experimental techniques employed during kinetic studies of protein folding 
provide insight into the folding pathway in general, as well as specific events such as 
formation of intermediates and presence of transition states. A folding pathway devoid 
of any kinetic intermediates is referred two as two-state transition with conformational 
change occurring between unfolded and native states. Any deviations from a typical 
two-state model are typical for pathways which include the formation of one or more 
kinetic intermediates (Royer, 2006). 
Kinetic studies rely on detecting and following dynamic changes in protein 
conformation and related physical properties as the polypeptide proceeds down the 
folding or unfolding pathway. Both folding and unfolding of investigated protein are 
typically induced by rapid application or removal of destabilising conditions such as 
chemical denaturant (stop-flow and continuous-flow techniques), pressure (presser-
jump spectroscopy) or temperature (temperature-jump spectroscopy), or a combination 
of these factors. Changes in structural properties over the course of experiment can be 
monitored using a wide range of spectroscopic techniques such as fluorescence 
measurements, circular dichroism or NMR. 
Fluorescence spectroscopy involves detecting and monitoring changes in emission of 
fluorescent probes (such as tryptophan residues) within the protein which are sensitive 
to changes in local environment providing information regarding alterations in tertiary 
structure of the protein (Lakowicz, 1999; Royer, 2006). 
Far-UV circular dichroism is often employed to monitor changes in secondary structure 
of the polypeptide as it transits between native and unfolded states (Kelly and Price, 
1997), allowing for detection of structurally distinctive conformations on the folding 
pathway such as intermediates. 
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NMR studies can complement both fluorescence and CD techniques, providing detailed 
information on specific residues within the protein, often revealing subtle but crucial 
changes undetectable by other methods (Kumar and Yu, 2004). 
 
 
1.2.2.2 Equilibrium studies of protein folding 
 
In contrast to kinetic studies, equilibrium techniques utilise incremental changes 
in destabilising conditions such as presence of denaturant or change in pressure or 
temperature (Fersht, 1999), rather than rapid and often total destabilisation of the 
structure employed by kinetic methods. 
Structural alterations induced by changes in denaturating conditions result in gradual 
shift in conformation of the protein over the course of experiment, allowing for 
monitoring of the folding and unfolding process. 
While differing in principles, equilibrium studies often utilise spectroscopic techniques 
similar if not identical to those employed in kinetic studies, including fluorescence 
spectroscopy, circular dichroism or NMR. 
Structural data provided by these measurements allow for the construction of denaturant 
folding curves which illustrate conformational changes in relation to gradual shift in 
conditions. These curves can be analysed using a non-linear least-squares regression 
(Santoro and Bolen, 1988), allowing for calculation of a number of parameters such as 
the free energy of folding in the absence of denaturant. 
Moreover, equilibrium folding curve analysis often indicates whether the folding 
pathway of the protein is highly cooperative and two-state or whether multiple states 
are present, indicating the presence of stable, partially-folded intermediates (Kim and 
Baldwin, 1982). 
 
 
1.2.2.3 Models of protein folding 
 
Over the years, studies of protein folding yielded two general models attempting 
to describe the sequential steps of the process.  
These two classical models are the framework model and the hydrophobic collapse 
model, both detailed below. 
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The framework model first proposed in 1973 states that the formation of secondary 
structure is the initial step of protein folding, subsequently followed and stabilised by 
tertiary interactions which result in the formation of the native state (Ptitsyn, 1973)  
In contrast, the hydrophobic collapse model predicts that the clustering of hydrophobic 
residues is the first event in folding, significantly restricting the space available in 
which defined tertiary structure can form, thus directing the process of folding along 
specific pathways. 
In agreement with an old phrase that the “truth lies in between”, experimental evidence 
suggests that folding of majority of the proteins follows a mechanism which shares the 
features of both models. This process is described as nucleation condensation, where 
secondary structure forms simultaneously with the hydrophobic collapse (Daggett and 
Fersht 2003). 
All three models of protein folding can be represented as a folding funnel (see Figure 
1.6), which encompasses all of the populations of intermediates and transitions 
occurring between unfolded and folded states. 
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Figure 1.7 Schematic representation of three proposed mechanisms of protein 
folding. 
In the framework model the formation of secondary structure is the initial step of 
protein folding, followed by tertiary interactions which resulting in the formation of the 
native state. According to the hydrophobic collapse model, the clustering of 
hydrophobic residues is the first event in folding, followed by formation of secondary 
and tertiary structure. The nucleation condensation model is the combination of the two 
previous models, in which secondary structure forms concurrently with the hydrophobic 
collapse. 
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1.2.3 Protein folding in vivo 
 
In vitro folding studies of protein folding provided invaluable information about 
the mechanisms and pathways associated with the adoption of functional tertiary 
structures by a polypeptide chains. It must be remembered, however, that protein 
folding in vivo is very likely to differ from in vitro process due to discrepancy in 
environmental conditions. 
In vitro studies of protein folding have been compared to observing behaviour of a 
single person in the desert, whereas in vivo conditions native to cellular proteins 
resemble a trip through a multimillion city at rush hour. 
While protein folding studies usually employ aqueous environment which may or may 
not contain a range of co-factors such as salts, metal ions substrates etc., protein folding 
in the cell takes place in the environment occupied by 300-400 g l
-1
 of proteins and 
other macromolecules (Hartl and Hayer-Hartl, 2009). Such a crowded environment is 
certain to significantly restrict initial entropy of unfolded polypeptide chain which may 
translate to alterations of folding pathways (Ellis, 2001) such as accelerated folding 
kinetics (Tokuriki et al., 2004). 
Moreover, proteins begin to adopt their native conformation even before the 
polypeptide chain is fully synthesized on the ribosome (Netzer and Hartl, 1997), a 
property which cannot be reliably reproduced in vitro. 
Another factor influencing protein folding in vivo is the interaction of polypeptide chain 
with molecular chaperones, a group of proteins capable of modulating the folding 
process (Ellis and van der Vies, 1991). Numerous chaperones are present in the ER, 
where they interact with folding proteins and prevent any incorrect interactions within 
and between polypeptides, ensuring adoption of a functional tertiary structure. 
The action of chaperones is complimented by folding catalysts, a group of enzymes 
encompassing protein disulfide isomerases which catalyse the formation of disulfide 
bonds an rearrangement of the incorrect ones, as well as peptidyl-prolyl isomerases 
which catalyse the isomerisation of peptide bonds before proline residues (Wilkinson 
and Gilbert, 2004; Lu et al., 2007). 
Further chaperones await proteins outside the ER, providing further assistance in 
correct folding as well as “quality control” mechanism prior to transportation of the 
protein to its designated location. All of these interactions are virtually impossible to 
reproduce in a single experimental environment in vitro. 
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1.2.4 Protein misfolding and aggregation 
 
Misfolding and subsequent aggregation of proteins have been linked to a 
number of human diseases including TSEs, Parkinson‟s disease, Alzheimer‟s disease 
and Huntington‟s disease, all of which are associated with formation and deposition of 
insoluble fibrils that exhibit birefringence when stained with congo-red (Lansbury, 
1992; Howie and Brewer, 2009). 
Aggregation is a general feature of proteins which can be observed in a number of 
denaturing conditions including presence of chemical denaturants, incubation at high 
temperature, presence of high salt concentration, pH change close to the isoelectric 
point of the polypeptide or presence of polar organic solvent or heavy metals (Ohnishi 
and Takano, 2004). While some of these conditions can increase the propensity of 
amyloid formation, fibrilisation in general remains strongly associated with adoption of 
stable, non-native conformation often referred to as misfolded state (Ohnishi and 
Takano, 2004). 
 
 
1.2.4.1 Amyloid fibrils and models of fibrilisation mechanics 
 
Due to its association with a number of human diseases, amyloid fibril 
formation has drawn a significant interest. 
In vitro studies determined that formation of amyloid fibrils is a two-step reaction 
consisting of a slow nucleation phase also referred to as lag phase, followed by a much 
more rapid molecular assembly step (Jarrett and Lansbury, 1992; Lomakin et al., 1996). 
It was soon discovered that addition of pre-formed fibrils results in significant reduction 
of the nucleation phase, indicating that nucleation itself plays important role in 
fibrilisation kinetics (Han et al., 1995; Wood et al., 1999). 
Numerous studies highlighted the importance of partial unfolding of the protein for the 
formation of amyloid fibrils. While the mechanism of association of partially unfolded 
polypeptides into fibrils has in many cases not been fully described, several models 
have been proposed. 
One of the fibrilisation models proposed as explanation to the role of expanded 
glutamine repeats linked to several inherited neurodegenerative diseases is the “polar 
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zipper” model, in which β-sheets are stabilized with a network of hydrogen bonds 
involving polar residues such as glutamine and asparagine (Perutz et al., 1994). 
Another proposed mechanism of amyloid formation is the domain-swapping model in 
which two or more protein molecules form a dimer or oligomer by exchanging one or 
more of their structural domains (Liu and Eisenberg, 2002). 
Interestingly, several experiments demonstrated that even non-pathogenic proteins may 
form amyloid fibrils under destabilizing conditions, supporting a hypothesis that the 
potential to form amyloid fibrils may be a common feature of all proteins (Guijarro et 
al., 1998). 
More recent results indicate that polythreonine, polyglutamate and polylysine are 
capable of forming amyloid fibrils, leading to hypothesis that amyloid fibril formation 
is driven by interactions between backbones and that side-chain interactions in the 
native state may be a limiting factor in fibrilisation (Fandrich and Dobson, 2002). 
These findings are consistent with the fact that in vitro fibrilisation is often achieved 
under destabilizing conditions where side-chain interactions are weakened, and that 
amyloid fibrils have a similar cross β-structure regardless of amino acid sequence 
(Ohnishi and Takano, 2004). 
 
 
1.2.4.2 Fibrilisation of prion protein 
 
Two models of amyloid fibril formation by prion proteins have been proposed: 
the nucleation-polymerization model and template-assistance model (see Figure 1.7). 
The nucleation-polymerization model assumes the existence of dynamic equilibrium 
between the PrP
C
 and PrP
Sc
 isoforms of prion protein. In the presence of an aggregate 
large enough to act as a stable nucleus, this equilibrium is shifted towards the PrP
Sc 
form, driving conversion and polymerisation of PrP
C
. 
In the template-assistance model, the conversion of PrP
C
 or its intermediate to PrP
Sc
 is 
extremely slow in the absence of scrapie isoform, but the process is essentially 
irreversible. Consequently, PrP
Sc
 is able to propagate itself by catalysing the conversion 
of folding intermediates to PrP
Sc
 confirmation.  
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Figure 1.8 Schematic representation of two models describing conversion of 
cellular form of prion protein to disease-associated isoform: the nucleation-
polymerization model (top) and template-assistance model (bottom). 
Circles represent the cellular isoform of PrP, with scrapie isoform depicted with 
squares. In the nucleation-polymerisation model, multiple squares are used to represent 
stable nucleus capable of driving PrP
C
 conversion and polymerisation. 
In the template-assistance model, the folding intermediate of PrP
C
 which can be 
recruited by PrP
Sc
 is represented as pink hexagon. 
 
Figure adapted from (Norrby, 2011). 
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1.3 Aims of the thesis 
 
The experiments described in this thesis utilised both truncated and full length 
forms of mouse prion protein and truncated form of Syrian hamster prion protein. 
Truncated constructs include the structured C-terminus and a short region of the 
unstructured N-terminus. 
 
The aim of experiments detailed in Chapter 3 was to fully characterise folding 
kinetics of mouse and Syrian hamster PrP, as well as investigate whether the folding 
properties of mouse PrP are influenced by the Q167R mutation which is known to 
confer decreased disease susceptibility.This was achieved by comparing the unfolding 
and refolding kinetics of wild type mouse PrP and Q167R mutant under native and 
mildly denaturing conditions using pressure-jump spectroscopy. Moreover, possible 
kinetic mechanisms underlying the species barrier were investigated by comparing 
unfolding and refolding kinetics of both mouse constructs with those of Syrian hamster 
PrP in search of species variation. 
Another aim of the thesis was to correlate the presence of possible intermediates 
in folding pathways of mouse and Syrian hamster prions with fibrilisation propensity. 
This was achieved through  fibrilisation studies of truncated mouse PrP, Q167R mutant 
and Syrian hamster PrP detailed in Chapter 3, conducted at a range of denaturant 
concentrations and pHs known to induce PrP conversion into β-state intermediate, in an 
attempt to answer the question of species variation and disease-modulating mutations in 
the folding properties of the prion protein. 
The aim of experiments detailed in Chapter 4 was to study the folding pathway 
of CWD mutations in mouse construct in order to investigate the importance of stability 
of the compact loop encompassing residues 166-175 of PrP which has been suggested 
to play an important role in aggregation and formation of the infectious particles of 
prion protein.  
The impact of a number of point mutations known to affect the stability of the loop 
region was determined by equilibrium studies of a series of full length mouse PrP 
mutants carrying one or two loop-stabilising point mutations (S170N, N174T and 
double mutant S170N/N174T) and comparison of their folding properties with full 
length wild-type mouse PrP. 
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Another aim of the research detailed in this thesis was to characterise 
fibrilisation properties of CWD-related elk mutations in mouse constructs. To 
accomplish this goal, equilibrium studies were complemented by fibrilisation assays of 
the four full length constructs in an attempt to correlate the kinetic effects of loop-
stabilising mutations with propensity to from fibrils, which should yield to our 
understanding of both the misfolding and fibril formation mechanisms associated with 
the occurrence of the disease and the phenomenon of the species barrier and varied 
disease susceptibility.  
Final aim of the thesis as detailed in Chapter 5 was to develop and thoroughly 
evaluate a new continuous-flow instrument which could be used to study the earliest 
kinetic events of the prion folding pathway. 
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Chapter 2: Expression and purification of recombinant mouse prion 
protein (MoPrP) and Syrian hamster prion protein (SHaPrP). 
 
 
2.1 Introduction 
 
 Biochemical studies such as protein folding often rely on repeating experiments 
multiple times in order to generate reliable and statistically valid data. Consequently, 
sample consumption can be high, driving the need for efficient and reliable material 
supply method. 
Initial studies of prion proteins relied on material purified from hamster brain extracts – 
a method both time consuming and generating low yields. A suitable illustration of the 
issue is a fact that one of the most efficient protocols based on immobilised Cu
2+
 and 
cation exchange chromatography of detergent-extracted material provided yields in 
range of only 120 μg per 100 g of brain tissue (Pan et al., 1992). Thus, structural studies 
of PrP benefitted greatly from development of bacterial overexpression systems. These 
recombinant expression systems provided an effective method of generating large 
yields in a much simpler manner, consuming less materials and labour. 
Recombinant PrP from a number of species obtained from bacterial expression allowed 
for high resolution structural analysis of prions through NMR spectroscopy 
(Hornemann et al. 1996; Viles et al. 1997; Zahn et al. 2000). This, coupled with 
determination that the structure of native PrP purified from brain tissue is identical to 
recombinant one (Hornemann et al. 2004) allowed for recombinant prion protein to be 
widely used as a model of PrP
C
 behaviour. 
 Studies presented in this thesis focus on investigating folding pathways of prion 
proteins from different species via two primary methods: the study of early folding 
kinetics of mouse and Syrian hamster prion protein in order to investigate the influence 
of a disease preventing mutation Q167R on the folding pathway of PrP, and fibrilisation 
studies of hamster, mouse and elk PrP to determine the effects of disease-related 
mutations on formation of fibrils. 
The early folding pathway of prion proteins was investigated using a number of 
spectroscopic and kinetic techniques such as circular dichroism and tryptophan 
fluorescence. 
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Tryptophan fluorescence measurements are particularly useful for studying protein 
folding pathways in aqueous solutions, since tryptophan residues within investigated 
protein can be selectively excited and act as a highly sensitive fluorescent probes 
responding to changes in their local environment induced by folding or unfolding of 
polypeptide chains. Upon unfolding of the protein, the tryptophan residues buried in 
hydrophobic core of the structure become solvent-exposed which is reflected in their 
spectral properties. 
Application of tryptophan fluorescence to structural studies of PrP required carefully 
modified constructs to be used. The structure of prion proteins employed in 
fluorescence studies encompasses residues 90–231 of Syrian hamster and 91–230 of 
mouse proteins, representing the globular folded domain and short unstructured N-
terminus section of PrP
C
 as well as proteinase K-resistant core of PrP
Sc
. The remainder 
of the N-terminus containing residues 23–90 of MoPrP and 23–89 of SHaPrP is 
unstructured and thus unlikely to have any influence on the folding of globular domain. 
The two native tryptophan residues present in globular domain of PrP are solvent-
exposed even in the folded state and thus unsuitable for protein folding monitoring by 
fluorescence. Consequently, both of the residues had to be removed by introducing 
point-mutations which replaced them with phenylalanines. Similarly, six tryptophans 
present in the unstructured domain would have to be removed if the N-terminus part of 
the protein was to be retained, a process both time and resource consuming. Since that 
particular region was deemed to be unimportant for folding of globular domain and 
consequently removed, only the residues in the globular domain were replaced.  
Following the removal of any undesirable native residues, site-directed mutagenesis can 
be used to introduce tryptophan residues in strategically important positions, allowing 
them to act as fluorescent reporters of structural changes. Such a strategy has been 
successfully employed by members of author‟s research group in kinetic and 
equilibrium folding studies of prion proteins (Sanghera and Pinheiro 2002, Kazlauskaite 
et al. 2003, Jenkins et al. 2008, Robinson and Pinheiro 2009). 
 Fibril formation by mouse, Syrian hamster and elk PrP was investigated in a 
series of fibrilisation and oligomeristaion studies using ThT fluorescence (Gill et al. 
2009) involving both truncated and full length constructs. Positively charged ThT is 
known to bind to negatively charged nucleic acids as well as fibrils formed by α-
synucleins and prion proteins. Upon binding, ThT molecules which exhibit low 
fluorescence emission upon excitation at 450 nm in water, show several-fold 
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enhancement in fluorescence intensity. This increase in emission is characteristic only 
for bound ThT and therefore is often used as a marker of fibril formation. Since ThT 
fluorescence measurements utilize different excitation and emission wavelengths than 
tryptophan fluorescence, both native tryptophans and unstructured N-terminus domain 
of PrP could be retained to investigate any effects they may have on fibril formation. 
This chapter details the methods used for expression and purification of recombinant 
constructs of mouse, hamster and elk prions, as well as their biophysical 
characterisation in order to confirm their identity, purity and structure for subsequent 
use in research detailed in experimental chapters of the thesis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
44 
 
 
 
 
Figure 2.1 Ribbon representation (A) and space-filling model (B) of the structure of 
the C-terminal globular domain of mouse prion protein (residues 90–230) based on the 
NMR structure (Gossert et al. 2005). Main structural features are highlighted in colour 
with key residues shown using stick representation. Three main α-helices are shown in 
orange, with short antiparallel β-sheet S highlighted in blue. Native tryptophan residues 
at positions 98 and 144 are highlighted in green and phenylalanine residue at position 
197 is highlighted in red.   
The NMR structure was drawn from PDB file 1XYX using UCSF Chimera package 
from the Resource for Biocomputing, Visualization and Informatics at the University of 
Califormia, San Francisco (supported by NIH P41 RR-01081). 
A 
B 
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Figure 2.2 Ribbon representation (A) and space-filling model (B) of the structure of 
the C-terminal globular domain of Syrian hamster prion protein (residues 90–231) 
based on the NMR structure (James et al. 1997). Main structural features are 
highlighted in colour with key residues shown using stick representation. Three main α-
helices are shown in orange, with short antiparallel β-sheet S highlighted in blue. Native 
tryptophan residues at positions 99 and 145 are highlighted in green and phenylalanine 
residue at position 198 is highlighted in red.   
The NMR structure was drawn from PDB file 1B10 using UCSF Chimera package 
from the Resource for Biocomputing, Visualization and Informatics at the University of 
Califormia, San Francisco (supported by NIH P41 RR-01081). 
A 
B 
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2.2 Materials and methods 
 
 
2.2.1 Expression and purification of mouse and Syrian hamster prion proteins 
 
 
2.2.1.1 Materials 
 
Acrylamide/bis acrylamide was purchased from Geneflow (Stafforshire, UK). 
Guanidine hydrochloride (GdnHCl) was purchased from Alfa Aesar (Heysham, UK). 
2-mercaptoethanol, acetonitrile, ammonium persulfate, ammonium sulfate, EDTA, 
ethanol, glucose, glycerol, MgSO4, NaCl and potassium acetate were purchased from 
Fischer Scientific (Loughbotough, UK). 
2-(N-morpholino)ethanesulfonic acid (MES), ampicillin, chloramphenicol, 
dithiothreitol (DTT) and isopropyl β-D-thiogalactoside (IPTG) were all purchased from 
Melford (Ipswitch, UK). 
Peptone and yeast extract were purchased from Merck (Darmstadt, Germany). 
SnakeSkin dialysis tubing was purchased from Pierce (Rockford, IL). 
Triethanolamine was purchased from Lancaster (Morecombe, UK). 
Trifluoroactic acid (TFA) was purchased from Acros Organics (New Jersey, USA). 
All other materials and chemicals were purchased from Sigma-Aldrich (Poole, UK) 
unless stated otherwise. 
 
 
2.2.1.2 Growth media  
 
Lysogeny broth (LB) growth medium constituents: 10 g of peptone, 5 g of yeast extract 
and 10 g of NaCl, made up to 1 litre with distilled water and autoclaved prior to use. 
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AP5 growth medium constituents: 1.5 g glucose, 11 g casein acid hydrosylate, 0.6 g 
yeast extract, 0.19 g MgS04, 1.07 g NH4Cl, 3.73 g KCl, 1.2 g NaCl, 60 ml 2 M 
triethanolamine pH 7.4 made up to 1 litre with distilled water. 
 
Terrific Broth (TB) growth medium constituents: 12 g peptone, 24 g yeast extract, 4 ml 
glycerol, made up to 900 ml with distilled water and autoclaved. Following the 
autoclaving of the broth 100 ml of 0.17 M KH2PO4/ 0.72 M K2HPO4 was added. 
 
NZY+ Transformation Broth constituents: 10 g casein acid hydrosylate, 5 g yeast 
extract, 5 g NaCl made up to 1 litre with distilled water (pH 7.5). Following the 
autoclaving of the broth 12.5 ml of 1 M MgCl2, 12.5 ml of 1 M MgS04 and 10 ml of 2 
M glucose were added. All solutions were filter-sterilised prior to their addition to 
autoclaved broth. 
 
 
2.2.1.3 Competent cell buffers 
 
TFB1 buffer constituents: 30 mM potassium acetate, 10 mM CaCl2 , 50 mM MnCl2, 
100 mM RbCl, 15 % (v/v) glycerol, pH 5.8. 
 
TFB2 buffer constituents: 10 mM MOPS, 75 mM CaCl2, 10 mM RbCl, 15% (v/v) 
glycerol, pH 6.5. 
 
 
2.2.1.4 Purification solutions 
 
Buffer A constituents: 25 mM TrisHCl, pH 8, 5 mM EDTA. 
 
Buffer B constituents: 8 M Guanidine HCl, 25 mM Tris-HCl pH 8, 100 mM DTT. 
 
Buffer C constituents: 6 M Guanidine HCl, 50 mM Tris-HCl, pH 8. 
 
Solvent 1: 0.1 % TFA (v/v) in water. 
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Solvent 2: 0.09 % TFA (v/v) in acetonitrile. 
 
 
2.2.1.5 SDS-PAGE solutions 
 
Resolving Gel solution constituents: 375 mM Tris (pH 8.8), 15 % acrylamide, 0.1 % 
SDS, 0.1 % ammonium presulfate, 0.004 % TEMED. 
 
Stacking Gel solution constituents: 100 mM Tris (pH 6.8), 5 % acrylamide, 0.1 % SDS, 
0.1 % ammonium persulfate, 0.001 % TEMED. 
 
Running Buffer constituents: 25 mM Tris base, 192 mM glycine, 0.1 % SDS, pH 8.3. 
 
Sample Buffer constituents: 62.5 mM Tris-HCL pH 6.8, 10 % glycerol (v/v), 2 % SDS, 
5 % 2-mercaptoehtanol, 0.05 % bromophenol blue. 
 
Staining Solution constituents: 10 % ammonium sulphate, 0.1 % Coomassie G250, 
20 % ethanol, 3 % phosphoric acid.  
 
 
2.2.1.6 Expression plasmids 
 
The pET23a plasmid encoding mouse PrP Met(91-230) (Figure 2.3, panel A) 
was provided by Professor David Brown, University of Bath. The plasmid was 
modified by Dr. Phil Robinson, University of Warwick to encode single-tryptophan 
mutant. Site-directed mutagenesis was used to replace native tryptophans at positions 
98 and 144 with phenylalanines and introduce folding sensitive tryptophan at position 
197 in place of native phenylalanine. 
The pET23a plasmid requires bacteriophage T7 RNA polymerase for expression as it 
contains a T7 promoter (Studier and Moffatt 1986). Expression of T7 RNA polymerase 
in E. coli cells can be induced by addition of IPTG, consequently driving expression of 
the target gene encoded on the plasmid. It should be noted that the plasmid contains a 
“plain” T7 promoter with both lacI gene and lac operator absent. 
49 
 
The pIngPrP plasmid encoding SHaPrP(90-231) (Figure 2.3, panel B) was obtained 
from Professor Stanley Prusiner. This plasmid was a modified version of phGH1 
(Chang, Rey et al. 1987). Modified version of the pIngPrP plasmid encoding single-
tryptophan mutants was prepared by Dr. Ian Sylvester, Institute of Animal Health. 
Modified plasmids had their native tryptophans at positions 99 and 145 replaced with 
phenylalanines using site directed mutagenesis. Additional tryptophan was introduced 
at position 198 in place of native phenylalanine to act as fluorescent reporter of 
structural changes. 
Since in pIngPrP plasmid expression of the PrP gene is under control of Ppho promoter 
from E. coli alkaline phosophatase A, the protein is expressed in high levels under low 
phosphate conditions. Expressed protein contains a signal sequence STII from the E. 
coli heat-stable enterotoxin II, which targets PrP to the periplasmic space of the E. coli. 
There, the signal sequence is cleaved (Mehlhorn, Groth et al. 1996) and mature protein 
forms insoluble aggregates – a property exploited by purification protocol. 
 
Both pET23a and pIngPrP plasmids encode the ampicillin resistance gene (see Figure 
2.3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
50 
 
 
Figure 2.3 Expression plasmids pET23a (A) encoding Mouse PrP(Met91-230) and 
pIngPrP (B) encoding Syrian hamster PrP(90-231). The T7 promoter (PT7, plasmid A) 
and phosphatase A promoter (Ppho, plasmid B) are indicated by white and black arrows 
respectively. Restriction sites used for PrP gene insertion are shown as black lines 
perpendicular to the plasmid and the genes themselves are represented by dark grey 
arrows. Ampicillin resistance genes (Ap-R) on both plasmids are highlighted in light 
grey. 
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2.2.1.7 Preparation of competent cells 
 
 Two strains of competent cells have been used throughout the project: 
Escherichia coli (E.coli) 27C7 cells obtained from ATCC (55244) used for Syrian 
hamster PrP expression and E. coli, BL21 Star obtained from Invitrogen, (Paisley, UK) 
used for mouse PrP expression. Competent cells of a given strain were streaked onto 
LB agar plate and incubated overnight at 37C. The following day single colonies were 
selected and used to inoculate 2.5 ml cultures of LB medium which were subsequently 
incubated overnight at 37C with shaking (200 rpm). The following morning starter 2.5 
ml cultures were used to inoculate 250 ml of LB medium containing 20 mM MgSO4. 
The cells were then incubated at 37C with shaking until the absorbance of the culture 
at 600 nm wavelength (A600) reached values of 0.4–0.6. Upon reaching the optical 
density of 0.4–0.6, cells in the liquid culture were harvested through centrifugation at 
4,500 g for 5 minutes at 4C. Resulting pellet was re-suspended in 100 ml of ice-cold 
TFB1 and incubated for 5 minutes on ice. Following incubation, the cells were again 
centrifuged at 4,500 g for 5 minutes at 4C and the resulting pellet was re-suspended in 
10 ml of ice cold TFB2. Re-suspended cells were incubated on ice for 30 minutes, flash 
frozen in liquid nitrogen and alliquoted for storage at -80C.  
 
 
2.2.1.8 Transformation of competent cells 
 
 Transformation of competent cells and any subsequent procedures involved in 
expression of prion proteins up to and including solubilisation of PrP-containing 
inclusion bodies were carried out in class-3 bio-containment suite. 
50 l aliquot of the appropriate competent cells (E. coli 27C7 cells for SHaPrP(90-231) 
expression and E. coli BL21* Rosetta cells for MoPrPMet(91-230) expression) was 
thawed on ice and 10 ng of relevant plasmid was added. Transformation mixture was 
gently mixed for approximately 1 minute and incubated on ice for 30 minutes. 
Following a 45 second heat shock at 37C the transformation mixture was added to 0.5 
ml of NZY+ medium and incubated for 45 minutes at 37C with shaking. Transformed 
cells were selected by spreading a 100 l aliquot of the transformation mix onto LB 
agar plate containing 100 g/ml ampicillin and 35 g/ml chloramphenicol for 
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MoPrPMet(91–230) or 100 g/ml ampicillin and 25 g/ml kanamycin for SHaPrP(90–
231) and incubating the plate overnight at 37C. 
 
 
2.2.1.9 Expression of PrP  
 
Single colonies of transformed cells were picked from selection plates and 
transferred to 5 ml of LB containing 100 g/ml of ampicillin and 35 g/ml 
chloramphenicol for MoPrP or 100 g/ml ampicillin and 25 g/ml kanamycin for 
SHaPrP. The cultures were incubated at 37C overnight (14–16 hours) with shaking at 
200 rpm. 5 ml overnight cultures were then used to inoculate 1 l flasks of appropriate 
growth media: terrific broth for MoPrP and AP5 medium for SHaPrP expression. One 
litre liquid cultures were incubated overnight at 37C with shaking (150 rpm). MoPrP 
expression was induced when the cells reached optical density at A600 of 0.4–0.6 by the 
addition of 0.4 mM IPTG. Since expression of SHaPrP is auto-induced on phosphate 
depletion, the cultures were simply left to grow overnight for approximately 20–24 
hours. Following overnight incubation, the cells were harvested through centrifugation 
at 3,250 g for 30 minutes at 4C.  Expression was confirmed through SDS-PAGE 
analysis of 500 l aliquots of liquid cultures obtained prior to cell harvesting. 
 
 
2.2.1.10 Isolation and solubilisation of inclusion bodies 
 
The cell pellets isolated from liquid cultures through centrifugation were re-
suspended in buffer A, pooled into two 250 ml centrifuge flasks and re-pelleted through 
centrifugation at 13,000 g for 30 minutes at 4C. The supernatant yielded by 
centrifugation was discarded and the pellet re-suspended again in buffer A. The pellets 
were then sonicated for 20 seconds with 30 second rests between bursts to break open 
the cells. Sonication cycle was repeated three times and resulting cell paste was then 
centrifuged at 13,000 g for 30 minutes at 4C. Obtained supernatant was discarded to 
remove soluble proteins and centrifugation was repeated to wash the inclusion bodies. 
Following second round of centrifugation, the pellets were solubilised in buffer B and 
sonicated by short 5-second bursts with 10 second intervals over a 5 minute period. 
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Sonicated cell extract was then centrifuged at 14,000 g for 30 minutes at 4C and the 
soluble fraction containing PrP was carefully pooled. In order to ensure sterility of the 
inclusion body extract, a 100 l sample was spread on a LB agar plate and only 
removed from the containment laboratory when no colonies could be observed on the 
plate after overnight incubation at 37C. 
 
 
2.1.1.11 Size exclusion chromatography 
 
As a first step of purification, 4 ml aliquots of solubilised inclusion bodies were 
loaded onto a 26/60 sephacryl S-300 high resolution gel filtration column (Amersham 
Biosciences, Buckinghamshire, UK) equilibrated with buffer C over the night before. 
The column was attached to AKTA Prime chromatography system (GE Healthcare, 
Buckinghamshire, UK). During the purification 4 ml fractions were collected across the 
elution profile and 200 l aliquots were removed for analysis through SDS-PAGE. 
Following the analysis, PrP-containing fractions were pooled for subsequent oxidation. 
 
 
2.2.1.12 Oxidation of PrP 
 
In order to maximize the yield of α-helical form of PrP, the disulphide bond 
present in prion protein had to be formed prior to further purification by HPLC. 
Oxidation of cysteine residues necessary for the formation of disulphide bridge was 
achieved using either Cu
2+
 ions or glutathione.. Mouse PrP(91-230) was oxidised using 
30 µM copper sulfate. Syrian Hamster PrP(90–231) was oxidised using oxidised form 
of 0.2 mM glutathione in the presence of 5 mM EGTA. Both oxidation processes were 
accomplished by adding relevant oxidising agent directly to the pooled fractions and 
incubating them overnight at room temperature (20–25C). 
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2.2.1.13 Reverse phase HPLC 
 
Second step of purification protocol involved PrP separation on a 3 ml 
RESOURCE
TM
 RPC column (GE Healthcare). The column was attached to Jasco 
HPLC system consisting of two PU-980 pumps with a HG-980-30 solvent mixer and a 
UV-975 detector unit. During each HPLC run a 20 ml aliquot of the pooled size-
exclusion fractions was injected onto the column, which was then washed with solvent 
A until UV signal returned to zero.  In order to elute PrP bound to the column, an 
acetontirile gradient from 0 % to 100 % was applied over the course of 12 minutes. 
Eluting fractions were collected according to their UV absorbance trace and their PrP 
content verified by SDS-PAGE. 
 
 
2.2.1.14 Refolding of PrP 
 
 Following purification, HPLC fractions containing PrP in acetonitrile and 0.1 % 
TFA were dialysed against 5 litres of 2 mM MES pH 5 at 4C. The dialysis procedure 
was repeated twice to ensure no acetonitrile or TFA content in PrP-containing fractions. 
Dialysed PrP was then concentrated using Centriprep
®
 centrifugal filter devices 
(Millipore, Billerica, MA). Concentration process involved centrifugation at 13,000 g at 
4C in a desktop centrifuge to remove any aggregates. Conformation of concentrated 
PrP was then determined using far-UV circular dichroism. Upon confirmation of α-
helical structure of PrP, protein was aliquoted and flash frozen in liquid nitrogen for -
20C storage.  
Prior to every experiment, PrP samples were thawed and their concentration determined 
spectrophotometrically using a molar extinction coefficient ε280 of 25,700 M
−1
 cm
−1
 for 
MoPrP
Wt 
and MoPrP
Q167R
, 20,100 M
−1
 cm
−1
 for MoPrP
F197W 
and MoPrP
F197W/Q167R 
and 
24420 M
-1
 cm
-1
 for SHaPrP
Wt 
(Gill and von Hippel 1989). 
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2.2.1.15 SDS-PAGE analysis 
 
Following every step of purification, protein-containing fractions were analysed 
through SDS-PAGE (Laemmli 1970) to confirm the presence of PrP at various stages of 
the procedure and determine its purity. Prior to SDS-PAGE analysis, protein samples 
were diluted in sample buffer in 1:1 ratio and heated to 95 C for 5 minutes. Boiled 
samples were then loaded onto 15 % polyacrylamide gels prepared from resolving and 
stacking solutions as stated in Section 2.2.1.5. Following electrophoresis, the gels were 
left in colloidal coomasie staining solution to visualise the proteins.  
Samples of crude extract as well as those collected after size-exclusion chromatography 
but before the HPLC separation required additional processing prior to their analysis by 
SDS-PAGE. High concentrations of GdnHCl present in buffers B and C interfere with 
protein separation through SDS-PAGE due to their high salt concentrations which 
prevent SDS-binding to the protein and consequently disrupt electrophoresis. 
Consequently, these salts had to be removed by precipitating the protein in acetone 
(procedure referred to as acetone-wash). The procedure involved adding 300 l of 
sterile water followed by 1 ml of 100% acetone to each 200 l aliquot and freezing the 
sample on dry ice for 15 minutes. Frozen samples were then centrifuged at 13,000 g for 
30 minutes at 4C in a desk top centrifuge to pellet the precipitated protein. The pellets 
were then re-suspended in adding 500 l of sterile water and 1 ml of 100% acetone, 
frozen on dry ice for 15 minutes and centrifuged at 13,000 g for 30 minutes at 4C. 
Second step of the procedure was repeated two more times, after which precipitated 
samples were re-suspended in sample buffer and analysed through SDS-PAGE. 
 
 
2.2.2 Characterisation of purified PrP 
 
 
2.2.2.1 Mass spectrometry 
 
Molecular weight of purified PrP was verified through positive electrospray 
ionisation mass spectrometry (ESI-MS) performed by Biological Mass Spectrometry 
Facility in the School of Life Sciences, University of Warwick. 
56 
 
2.2.2.2 Circular dichroism spectroscopy 
 
 Structural properties of purified PrP were determined by measuring the far-UV 
(190–260 nm) circular dichroism spectra using JASCO J-815 spectropolarimeter. All 
spectra were measured using 1 mm path length quartz cuvettes, with a scanning rate of 
100 nm / minute, time constant of one second, bandwidth of 1.0 nm, and resolution of 
0.5 nm. Typically 16 scans were averaged per spectrum and corresponding buffer 
backgrounds were subtracted from the final spectra. All measurements were carried out 
at 20 °C. 
For far-UV CD measurements, mean residue ellipticity ([θ]MRW) was calculated using 
Equation 3.1: 
                 (3.1) 
where θ is the observed ellipticity (millidegrees), N is the number of peptide bonds in 
the protein, c is the molar protein concentration, and l the pathlength of the cuvette used 
(cm). 
 
 
 
2.3 Results 
 
 
2.3.1 Expression and purification of PrP  
 
 Relevant strains of E. coli cells were transformed using plasmids containing PrP 
gene. Selection plates containing two antibiotics were used to ensure that only 
transformed cells expressing newly introduced plasmids survived. Upon successful 
transformation, selected colonies were used to inoculate liquid cultures and 
overexpression of PrP-encoding plasmid was ensured either by IPTG induction 
(MoPrP) or phosphate depletion (SHaPrP). Succesfull expression of PrP was confirmed 
using SDS-PAGE (see Figure 2.4). Since overexpressed prion protein aggregated within 
the inclusion bodies, harvested cells were disrupted and solubilised in 8 M GdnHCl 
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solution with 100 mM DTT added. Consequently, solubilised proteins were unfolded 
and had their disulfide bond reduced. 
In order to isolate prion proteins from cell extract, a two-step purification protocol was 
used. 
The first step of purification involved using size-exclusion chromatography (SEC) 
under denaturing conditions to separate PrP from E. coli proteins with higher molecular 
weight. Size-exclusion fractions containing PrP were identified using SDS-PAGE 
analysis (see Figure 2.5) which also allowed for the purity of PrP to be estimated.  
Due to the fact that DTT was separated from protein sample during size exclusion 
chromatography, PrP could oxidise in air following the first purification step. 
Consequently, PrP-containing fractions isolated at the end of SEC protocol consisted of 
a mixture of oxidised and reduced prion proteins. It has been demonstrated that while 
purification of oxidised PrP yields protein with high α-helical content, isolating the 
same protein under reducing conditions generates PrP with elevated β-structure content 
(Mehlhorn et al. 1996, Kazlauskaite et al. 2003). It was therefore vital to ensure that 
PrP in SEC fractions was oxidised prior to second purification step. In order to achieve 
this, PrP-containing fractions were incubated with either copper sulfate (MoPrP) or 
glutathione (SHaPrP). 
During the second step of purification protocol reverse-phase HPLC was used to further 
separate PrP from E. coli proteins with molecular weight too close to that of prion 
protein to be resolved by size-exclusion chromatography. Upon binding to the column, 
PrP can only be eluted using 35-37% acetonitrile which is then removed by dialysis at 
the end of purification protocol. HPLC fractions containing PrP are again identified 
using SDS-PAGE which also allows for the final purity to be determined (see Figure 
2.6).  
 
PrP samples were considered suitable for experimental use when their purity exceeded 
90%. If the estimated final purity of PrP sample was insufficient, additional size-
exclusion chromatography step was performed. The final yield of PrP varied between 
consecutive expressions, usually between 6-9 mg per one litre of liquid culture. 
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Figure 2.4 Picture of SDS-PAGE gel used for analysis of cell extract from E. coli 
cells expressing single tryptophan mutant of MoPrP(Met91-230). Lines 1 and 2 were 
loaded with cell extract while columns 3 and 4 were loaded with aliquots of solubilised 
inclusion bodies. 
The band corresponding to PrP is indicated with black arrow. 
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Figure 2.5 First step of PrP purification: isolation of prion protein from cell extract 
using size-exclusion chromatography.  
Panel A depicts elution profile of MoPrP recorded during size-exclusion 
chromatography. Fractions corresponding to peaks 1 and 2 (indicated with black 
arrows) were suspected to contain PrP and were analysed by SDS-PAGE. 
Panel B shows picture of SDS-PAGE gel used for analysis size-exclusion fractions. 
Lines 1 and 2 correspond to pooled fractions from peaks 1 and 2 in Panel A. The band 
corresponding to PrP is indicated with black arrow. 
The purity of MoPrP isolated through size-exclusion chromatography was estimated to 
be between 75 and 80 %. 
A 
B 
1 
2 
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Figure 2.6 Second step of PrP purification: isolation of prion protein from similarly 
sized proteins present in SEC fractions using HPLC.  
Panel A depicts elution profile of PrP prior to oxidation (black line), MoPrP oxidised 
using copper (red line) and SHaPrP oxidised with glutathione. Acetonitrile gradient 
used to elute PrP is represented by blue line and corresponds to the y-axis on the right 
hand side.   
Panel B shows picture of SDS-PAGE gel used for analysis HPLC fractions. Line 1 
corresponds to pooled fractions from MoPrP peak indicated with red arrow on the 
chromatogram. Line 3 corresponds to SHaPrP fractions indicated with green arrow.  
Lines 2 and 4 show contents of multiple small peaks indicated in chromatogram by 
black bracket. The SDS-PAGE band corresponding to PrP is indicated with black 
arrow. The purity of PrP isolated by HPLC was estimated to be around 95 %. 
A 
B 
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Figure 2.7 Photograph of SDS-PAGE gel showing comparison of MoPrP purity at 
different purification steps. 
Line 1 corresponds to cell extract from E. coli expressing MoPrP, line 2 corresponds to 
size-exclusion fractions containing MoPrP and line 3 shows the final purity of refolded 
MoPrP after HPLC. 
Lines 4 and 5 correspond to aliquots taken before (line 4 – cell extract) and after (line 5 
– post-HPLC) the purification of SHaPrP.   
The SDS-PAGE bands corresponding to PrP are indicated with black arrow.  
The final purity of both MoPrP and SHaPrP was estimated to be over 95 %. 
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2.3.2 Characterisation of purified PrP 
 
 Upon successful purification, molecular weight of isolated prion proteins was 
confirmed using electrospray-ionisation mass spectrometry (ESI-MS). 
Mass of mouse PrP single tryptophan mutant F197W was estimated as 16,104 Da, that 
of disease-related single tryptophan mutant Q167R as 16,132 Da and that of single-
tryptophan Syrian hamster PrP as 16,201 Da. All of the molecular masses are in 
agreement with those determined through ESI-MS (see Figures 2.8 and 2.9).  
Note that actual masses of single-tryptophan mutants F197W and Q167R given by 
deconvoluted ESI-MS spectra are 15,972 Da and 16,001 Da respectively. The 
difference between predicted and estimated mass is due to the cleavage of N-terminal 
methionine residues of both species of mouse PrP. The cleavage occurs during a post-
translational modification catalysed by methionine aminopeptidase which targets 
specific amino acids adjacent to N-terminal methionine. In both prion constructs this 
position is occupied by glycine which is one of the substrates of methionine 
aminopeptidase and is therefore cleaved. Upon taking the post-translational 
modification into account, estimated masses of F197W and Q167R should be 15,972 
Da and 16,001 Da respectively, which agrees with masses determined experimentally 
by mass spectrometry. 
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Figure 2.8 ESI mass spectrometry of single tryptophan mutant SHaPrP(90-231) 
F198W. Molecular mass estimated from the spectrum is 16201.3±1.86 Da which is well 
in agreement with calculated mass.
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Figure 2.9 ESI mass spectrometry of single tryptophan mutant MoPrP(91-230) 
F197W (panel A) and disease-related single tryptophan mutant MoPrP(91-230) Q167R. 
Molecular masses estimated from the spectra are 15972.2±0.65 Da for F197W and 
16001.1±0.7 for Q167R which corresponds to calculated masses. 
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 While mass spectrometry allowed to confirm that molecular mass of purified 
proteins agrees with calculated mass of all three PrP constructs, further characterisation 
of obtained prion proteins was necessary to ensure they were expressed and purified 
correctly. Circular Dichroism was used in order to confirm that purified PrP has been 
successfully refolded to native α-helical form (PrPC) upon its dialysis from HPLC 
buffer into 2 mM pH 5.5 MES buffer used for storage. Since removing native 
tryptophans and introducing fluorescent probe in place of phenylalanine was already 
determined to have no effect on secondary or tertiary structure of neither two MoPrP 
constructs nor SHaPrP one (Jenkins D., 2006, Robinson P., 2009), circular dichroism 
was used exclusively to confirm the structure of prion proteins prior to their 
experimental use. 
The main components of the circular-dichroism spectrum characteristic for α-helical 
proteins are negative bands at 208 and 222 nm and a positive band at 195 nm. All of 
these bands are clearly visible in CD spectra of both mouse constructs (F197 and 
Q167R) as well as that of Syrian hamster (F198W) indicating that all of the proteins 
adopted correct α-helical conformation (see Figures 2.10 and 2.11). 
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Figure 2.10 Far-UV circular dichroism spectra of single tryptophan mutants of 
MoPrP. Panel A shows spectrum of single tryptophan mutant F197W while panel B 
depicts spectrum of disease-related mutant Q167R. Note the presence of two negative 
peaks at 222 and 208 nm and single positive peak at 195 nm characteristic for proteins 
with high α-helical content.  
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Figure 2.11 Far-UV circular dichroism spectra of single tryptophan mutant of 
SHaPrP (panel A) and an overlay of CD spectra of MoPrP F197W, MoPrP Q167R and 
SHaPrP F198W (panel B).While all three proteins have clearly α-helical secondary 
structure, minor differences between mouse PrP and Syrian hamster prions are visible. 
Note that the structure of MoPrP F197W and that of MoPrP Q167R are virtually 
identical, indicating that additional point mutation in disease-related prion strain does 
not affect the structure of the protein. 
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2.4 Summary 
 
Two recombinant prion proteins - mouse PrP(Met91-230) and Syrian hamster  
PrP(90-231) have been successfully expressed and purified according to well-
established two-step protocol combining size-exclusion chromatography and HPLC. 
Purity and identity of all three constructs was confirmed by SDS-PAGE analysis. Final 
purity of 95% for all three constructs and the average yield of 6-9 mg / L were 
satisfactory and proved that purification protocol was effective. 
Electrospray-ionisation mass spectrometry was used to confirm molecular weight of 
purified proteins. Molecular mass of all constructs determined experimentally 
corresponded to theoretical mass calculated from their sequences, however cleavage of 
mouse prions by methionine aminopeptidase had to be accounted for. 
Circular dichroism spectroscopy confirmed that all of the proteins were refolded to 
native, predominantly α-helical conformation and were ready for experimental studies 
detailed in chapters 3 and 4. 
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Chapter 3: Investigation of mechanisms of species barrier and disease-
altering polymorphism by pressure-jump spectroscopy and 
fibrilisation studies. 
 
 
3.1 Introduction 
 
It has been recently reported that the key difference in PrP folding between 
different species known for their vastly different prion susceptibility is the ability of PrP 
to form a β-structured state under slightly destabilizing conditions such as low urea 
concentration or mildly acidic pH (Khan et al., 2010). It has also been proposed that the 
β-state was in fact a folding intermediate which lies between the native and unfolded 
state on the PrP folding pathway (Zhang et al., 1997; Hornemann and Glockshuber, 
1998; Swietnicki et al., 2000). Should the β-state of PrP play a role in the mechanism 
underlying prion diseases, as has been suggested (Collinge and Clarke, 2007), the 
propensity to form the β-state may be a major determinant of prion disease 
susceptibility. 
Consequently, investigating the folding properties of PrP from different species, as well 
as disease-associated mutants should increase our understanding of both the misfolding 
mechanisms associated with the disease‟s occurrence and the phenomenon of the 
species barrier and varied disease susceptibility.  
While certain spectroscopic techniques such as stopped-flow can be used to 
investigate later events in PrP folding pathway (Apetri et al., 2006), the earliest folding 
events occur well within a millisecond, which is beyond the timescale accessible by 
stopped-flow instrument. Consequently, a different spectroscopic method, capable of 
achieving the dead time an order of magnitude shorter than stopped-flow is necessary.  
One of the few instruments capable of investigating the full extent of rapid reactions 
such as PrP folding is continuous-flow. It should be noted that while the author had 
direct access to one such instrument, it was undergoing re-evaluation, reconfiguration 
and upgrading as a separate part of this project (see Chapter 5) and was therefore 
unavailable for kinetic studies. 
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3.1.1 Principles of pressure-jump spectroscopy 
 
Pressure-jump is a spectroscopic technique capable of probing submilisecond 
processes. While the basic principles of method itself are not new (Davis and 
Gutfreund, 1976), it is recent developments in the field of pressure-jump instruments 
that allow very rapid processes to be studied. This method has been successfully used in 
previous studies to investigate folding of Syrian Hamster PrP (Jenkins, 2006), 
demonstrating its capability to follow early events of PrP folding.  
Pressure-jump spectroscopy utilizes rapid changes in hydrostatic pressure in order to 
perturb the equilibrium of the system. Consequently, the method can be used in protein 
folding studies, in research into protein-ligand interactions and many other processes in 
which reversible substrate-product equilibrium exists. In case of folding studies, 
pressure application induces protein unfolding, while pressure release shifts the 
equilibrium of the system back towards the folded state resulting in refolding of the 
protein (Jacob et al., 1999).  
Any changes in protein conformation resulting from shifting the equilibrium upon 
pressure application or release are followed using a relevant spectroscopic technique. 
Fluorescence spectroscopy is commonly employed due to its sensitivity, allowing for a 
number of biochemical processes, such as protein conformational changes and protein-
protein and protein-ligand interactions to be studied (Gross and Jaenike, 1994; Jenkins 
et al., 2009). 
The underlying principle of the pressure-jump is equilibrium perturbation, as mentioned 
before. Application of pressure to a system at dynamic equilibrium will cause the 
equilibrium to shift in order to compensate for the effect of pressure, as predicted by Le 
Chatelier`s principle (Atkins, 1999). This shift in equilibrium is physically manifested 
as a decrease in the volume of investigated system. Such phenomenon can be 
commonly observed in a number of biochemical processes such as protein folding and 
unfolding, protein-ligand interactions and protein isomerisation. 
In case of protein folding, the energetics depend on the relationship between changes in 
conformational entropy of a protein, changes in enthalpy due to side-chain interactions 
and the entropy change in hydrophobic group environments (Fersht, 1999). Changes in 
volume upon pressure application to the system in which an equilibrium between folded 
and unfolded protein exists are largely attributable to solvation effects. When 
sufficiently high pressure is applied, water molecules become compressed around ions 
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in a process known as electrostriction. This process contributes to weakening of 
electrostatic interactions and overall solvation, consequently contributing to unfolding 
of the protein (Mozhaev et al., 1996). 
Changes in Gibbs free energy of given system (ΔG) can be expressed as: 
 
ΔG = – RT lnK        (3.1) 
 
where R is the gas constant (8.314 J K
-1
 mol
-1
), T is the absolute temperature in Kelvins 
and K is the equilibrium constant of the process. 
Alternatively, the same change in free energy can be expressed in terms of change in 
internal energy and entropy as: 
 
ΔG = ΔE + Δ(pV) – (ΔTS)                  (3.2) 
 
where ΔE is the change in internal energy, p is the pressure, ΔV is the change in 
volume, T is the absolute temperature and ΔS is the change in entropy. 
By combining equations 3.1 and 3.2 the following equation can be obtained: 
 
-RT lnK = ΔE + Δ(pV) – Δ(TS)      (3.3) 
 
The relationship between change in pressure (p), volume (V) and equilibrium constant 
(K) indicates that any change in pressure will influence the position of the equilibrium 
of the system as well as the volume. 
This relationship can be used to reveal any changes in volume of the system upon 
pressure application and release and therefore equilibrium perturbation. Changes in 
volume over the course of reactions such as protein folding and unfolding or protein-
ligand interactions may reveal previously unobserved steps in the reaction. Pressure 
dependence of the rate of the reaction can be used to determine the so-called activation 
volume, which is the difference between partial molar volumes of the reactants at the 
same temperature and pressure (Muller, 1994). Hence, activation volume can be 
interpreted as a kinetic barrier that has to be overcome in order for the reaction to 
progress, much like activation energy (Cordeiro et al., 2005b). 
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Figure 3.1 Schematic representation of the basic principles underlying the 
investigation of protein folding and unfolding kinetics by pressure-jump. 
The method utilizes rapid changes in hydrostatic pressure in order to perturb the 
equilibrium of the system. In the system consisting of folded and unfolded proteins at 
dynamic equilibrium application of pressure induces protein unfolding (A), while 
pressure release shifts the equilibrium of the system back towards the folded state 
resulting in refolding of the protein (B).  
Changes in protein conformation upon shifting the equilibrium are followed by 
fluorescence spectroscopy. 
 
 
 
 
 
 
 
 
 
 
 
 
B A 
Dynamic 
equilibrium 
Dynamic 
equilibrium 
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 Unlike stopped-flow or continuous-flow techniques where physical mixing of 
the reactants is one of the key factors determining instrumental dead time, pressure-
jump relies only on the shift in equilibrium to initiate a reaction, be it unfolding, 
refolding on protein-ligand interaction. Thus, the dead time of pressure-jump instrument 
is only limited by the time it takes for the pressure to stabilize following its rapid 
increase or decrease. In many modern instruments, the pressure is fully stabilized within 
a hundred microseconds, allowing for the very earliest events to be observed. Since 
pressure-jump does not rely on mechanical agitation or harsh radiation or heating but 
only on pressure alteration, the entire process of equilibrium perturbation is relatively 
gentle, allowing sensitive reactants to be studied. Moreover, the entire process of 
pressure application and release can be rapidly cycled, allowing for fluorescence 
transients from dozens of equilibrium perturbations to be accumulated within minutes. 
By averaging such high number of individual repeats, a very high signal-to-noise ratio 
can be achieved. 
 While it is possible for the pressure alone to induce shift in equilibrium and thus 
perform folding kinetics studies (Tan et al., 2005, Torrent et al., 2006), it is quite often 
the case that pressure alone is insufficient to denature a protein. In such instances, a 
chemical denaturant such as urea or GdnHCl is included in the reaction mixture. The 
presence of denaturant allows the equilibrium of the system to be poised at suitable 
point on the equilibrium transition curve which favours the presence of partially 
unfolded conformations. When coupled with pressure application, presence of 
denaturant is sufficient to induce equilibrium shift necessary for protein unfolding to 
take place. The combination of denaturant and pressure alteration has been successfully 
used in several studies, such as folding of stabilized mutants of staphylococcal nuclease 
(Vidugiris et al., 1996), fast-folding of cold-shock protein (Jacob et al., 1999) or rapid 
folding of Syrian hamster prion protein (Jenkins et al., 2006). 
Kinetic studies using methods such as pressure-jump spectroscopy can provide 
invaluable insight into earliest kinetic events of protein folding pathway. In prion 
folding, they can be used to identify protein folding intermediates (Hosszu et al., 2005) 
or to determine differences in folding kinetics between prions from different species. 
Investigation of such differences and detection of previously unidentified kinetic 
intermediates may contribute to our understanding of phenomena such as species 
barrier and disease resistance. While pressure-jump experiments can provide kinetic 
data such as whether energy needed to unfold prion variant associated with increased 
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disease susceptibility is lower than wild type, or if there is a large difference in stability 
between species which may account for inability of PrP
Sc
 from certain species to 
convert PrP
C
 from other, it cannot provide details on conformation or propensity to 
form aggregates.  
Recent findings suggest that disease resistance may also be linked to structural features 
of PrP such as stability of a compact loop region encompassing residues 166-175, 
which plays important role in aggregation and formation of the infectious particles in 
several species including bank vole, elk, sheep and mice (Scouras and Daggett, 2012). 
Consequently, investigation of fibrilisation properties of PrP may reveal a link between 
early kinetic behaviour of prions, the presence of folding intermediates and propensity 
to form fibrils. 
Thus, the pressure-jump studies of kinetics of early folding pathway of PrP detailed in 
this chater were supplemented by fibrilization studies of prion proteins, in order to 
identify key processes involved in both species barrier and disease resistance. 
Fibril formation can be investigated in a series of fibrilisation and oligomeristaion 
studies utilizing ThT fluorescence (Gill et al. 2009). Positively charged ThT is known 
to bind to negatively charged nucleic acids as well as fibrils formed by α-synucleins and 
prion proteins. Upon binding, ThT molecules exhibiting low fluorescence in water 
show several-fold enhancement in fluorescence intensity. This increase in emission is 
characteristic only for bound ThT and therefore is often used as a marker of fibril 
formation.  
The aim of this project is to investigate whether the physical folding properties of PrP 
are influenced by the Q167R mutation which is known to confer decreased 
susceptibility, by comparing the unfolding and refolding kinetics of wild type PrP and 
Q167R mutant under native and mildly denaturing conditions using pressure-jump 
spectroscopy. 
Moreover, fibrilisation studies of MoWT, Q167R mutant and SHaPrP are conducted at 
a range of denaturant concentrations and pHs known to induce PrP conversion into β-
state intermediate, in an attempt to answer the question of species variation and disease-
modulating mutations in the folding properties of the prion protein. 
 
All of the pressure-jump experiments conducted during this project were carried out in 
collaboration with Professor Mike Geeves and Dr Dave Pearson from Department of 
Biosciences, University of Kent, Canterbury. 
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3.2  Materials and Methods  
 
 
3.2.1 Materials 
 
All chemicals were purchased from Sigma-Aldrich (Poole, UK) unless stated otherwise. 
 
 
3.2.2 Expression and purification of PrP.  
 
The three piron constructs MoWT (Met91-230), disease-associated mutant 
Q167R (Met91-230) as well as SHaWT (Met91-231) were expressed and purified 
according to protocols described in chapter 2, sections 2.2.1.7 to 2.2.1.14. 
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Figure 3.2  Ribbon representation of the structure of the C-terminal globular domain 
of mouse prion protein (residues 120–230) based on the NMR structure (Gossert et al., 
2005). Main structural features are highlighted in colour with key residues shown using 
stick representation. Three main α-helices A, B and C running from C to N terminus of 
the polypeptide are shown in yellow, with short antiparallel β-sheet S highlighted in 
blue. Residues Q167 and F197 are highlighted in red and green respectively.   
 
The NMR structure was drawn from PDB file 1XYX using UCSF Chimera package 
from the Resource for Biocomputing, Visualization and Informatics at the University of 
Califormia, San Francisco (supported by NIH P41 RR-01081) (Pettersen et al., 2004) 
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3.2.3 Tryptophan fluorescence spectroscopy 
 
Urea unfolding curves of MoWT Q167R and SHaWT were constructed through 
a series of tryptophan fluorescence measurements of each of the proteins in increasing 
urea concentration at two different pH values.  
A stock solution of 10 M urea was prepared and treated with Amberlite deionising resin 
(Merck, Darmstadt, Germany) for several hours. For each experiment a folded and 
unfolded stock solutions of relevant PrP species were constructed. For pH 7, the folded 
stock solution contained 10 μM PrP in 20 mM phosphate buffer and no urea, while 
unfolded stock solution consisted of 10 μM PrP in 20 mM phosphate buffer and 8 M 
urea. 
For pH 4, the folded stock consisted of 10 μM PrP in 20 mM sodium acetate and no 
urea with unfolded stock containing 10 μM PrP in 20 mM sodium acetate and 8 M urea. 
For each unfolding curve a series of measurements was carried out during which an 
aliquot of the folded stock was withdrawn from a 1 cm pathlength quartz cuvette and 
replaced with an aliquot of unfolded stock so that the PrP concentration remained the 
same but urea concentration was increased. 
All fluorescence spectra were recorded using Photon Technology International 
spectrofluorimeter. The tryptophan residues in PrP-containing samples were selectively 
excited using excitation wavelength of 295 nm with the emission spectra collected 
between 305 and 450 nm. The bandwidth of both excitation and emission light was set 
to 2 nm. Four scans were averaged per spectrum and corresponding buffer backgrounds 
were collected and subtracted prior to data analysis. 
 
 
3.2.3.1 Fluorescence data analysis 
 
 Fluorescence unfolding curves were constructed by following the change in 
tryptophan fluorescence intensity and shift in the wavelength of maximum fluorescence 
in increasing urea concentrations. 
The two-state unfolding process of PrP in presence of urea can be represented by the 
following equation: 
KF = [F] / [U]           (3.4) 
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Where [F] is the concentration of the folded protein, [U] is the concentration of 
unfolded protein and KF is the folding constant. Upon reaching equilibrium between the 
two states, the free energy of folding can be expressed by equation 3.1. 
Consequently, the free energy of folding in the absence of denaturant (ΔG0) can be 
calculated using the linear extrapolation method (Santoro and Bolen, 1988). Assuming 
that free energy of the folding observed in the transition region of the folding curve is 
linearly dependent on denaturant concentration, the following formula can be applied: 
 
ΔG = ΔG0 – m [denaturant]         (3.5) 
 
where ΔG is the free energy of folding and m is the constant reflecting the gradient of 
plot of free energy against denaturant concentration. 
Thus, the folding constant at specific denaturant concentration can be calculated from 
combined equations 3.1 and 3.5: 
 
KF = e
-(ΔG
0
 - m [denaturant] / RT)
          (3.6) 
 
where KF is the folding constant, R is the gas constant and T is the absolute 
temperature. 
By calculating the values of the folding constant, the fraction of folded PrP (ƒF) can be 
determined using the following equation: 
 
ƒF = KF / (KF + 1)             (3.7) 
 
and the theoretical blue shift of the tryptophan fluorescence spectrum can be defined as: 
 
S = ƒF (SF – SU) + SU     (3.8) 
 
Where S is the theoretical blue shift of Trp fluorescence spectrum, SF is the blue shift in 
λ max of the completely folded protein and SU is the blue shift in λ max of the 
completely unfolded protein (Greenfield, 2006). 
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It should be noted that the formula 3.8 applies only to the transition region of the 
folding curve, and thus the following correction has to be applied to take into account 
the linear slopes observed in the pre-unfolding baseline: 
 
S = ƒF (SF + [denaturant] × mU - SU) + SU    (3.9) 
 
 Prior to data analysis, recorded fluorescence spectra were normalised. The 
values of the blue shift in maximum fluorescence of tryptophan residues for both fully 
folded and fully unfolded proteins were calculated from plots of raw experimental data 
and used to normalise each individual data set to fraction of folded protein: 
 
ƒF = (S - SU) / (SF - SU)    (3.10) 
 
where S is the value of blue shift in tryptophan fluorescence. 
The fraction of folded PrP was then plotted against urea concentration to construct 
folding transition curves. 
 
 
3.2.4 Circular dichroism spectroscopy 
 
A stock solution of 10 M urea was prepared and treated with Amberlite resin. 
For each CD experiment a folded and unfolded stocks of relevant PrP species were 
constructed. For pH 7, the folded stock contained 10 μM PrP in 20 mM phosphate 
buffer and no urea, while unfolded stock consisted of 10 μM PrP in 20 mM phosphate 
buffer in 8 M urea. 
For pH 4, the folded and unfolded stocks consisted of 10 μM PrP in 20 mM sodium 
acetate with no urea and 10 μM PrP in 20 mM sodium acetate in 8 M urea respectively. 
For each unfolding curve a series of measurements was carried out during which an 
aliquot of the folded stock was withdrawn from a 1 mm pathlength quartz cuvette and 
replaced with an aliquot of unfolded stock so that the PrP concentration remained the 
same but urea concentration was increased. 
The far-UV (190–260 nm) circular dichroism spectra were measured using JASCO J-
815 spectropolarimeter. All spectra were measured using 1 mm path length quartz 
cuvettes, with a scanning rate of 100 nm / minute, response time of one second, 
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bandwidth of 1.0 nm, and resolution of 0.5 nm. Typically 16 scans were averaged per 
spectrum and corresponding buffer backgrounds were subtracted from the final spectra. 
Buffer systems consisting of 20 mM MES and 20 mM sodium acetate were used to 
maintain a constant pH of 7.0 and 4.0 respectively. All measurements were carried out 
at 20 °C. 
For far-UV CD measurements, mean residue ellipticity ([θ]MRW) was calculated using 
Equation 3.11: 
                         (3.11) 
 
where [θ] is the observed ellipticity (millidegrees), N is the number of peptide bonds in 
the protein, c is the molar protein concentration, and l the pathlength of the cuvette used 
(cm). 
The mean residue ellipticity at 222 nm wavelength was then determined for each CD 
spectrum recorded and normalised to fraction unfolded according to equation 3.10, with 
ellipticity values at 8 M urea corresponding to fully unfolded state (SU) and those at 0 
M urea to fully folded state (SF). 
 
 
3.2.5 Pressure-jump instrument 
 
 
3.2.5.1 Components of pressure-jump instrument 
 
All of the pressure-jump experiments were performed using apparatus described 
by Pearson et al. (Pearson et al., 2002; Pearson et al., 2008) with some modifications, 
mentioned below. The heart of the instrument is a sample chamber consisting of small 
sapphire ring closed off at either end by polyimide membranes. At one end, a 
piezoelectric pressure sensor (6158A from Kistler Instrumente AG, Winterthur, 
Switzerland) is used to detect changes in pressure, whilst at the other a piston distorts 
the membrane in order to induce fast pressure changes. The piston is driven by a 
piezoelectric crystal stack (P-245.70, Physik Instrumente GmbH, Waldbronn, Germany) 
capable of delivering pressure changes of up to 45 MPa in as little as 100 µs. 
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Fluorescence transients resulting from both pressure application (up to 45 MPa) and 
release (to 1-2 MPa) are monitored at 90º to the light guide using a R928HA 
Hammamatsu photomultiplier with signal conditioning provided by a modified stopped-
flow instrument with an added transimpedance pre-amp stage, provided by TgK 
Scientific (Bradford-on-Avon, UK). Excitation light was provided by a 75 W Xe/Hg arc 
lamp (Hamamatsu Photonics, Enfeld, UK), delivered to the cell via a liquid light guide 
abutting directly onto the sample chamber. The modified configuration uses a new A/D 
board (DT3010-268, Data Translation Ltd) and specially developed software (D. S. 
Pearson, developed using LabVIEW) to collect pressure and fluorescence data side-by-
side.  The new configuration allows sequential fast repeats followed by a data offload 
phase during which an automated shutter is closed to reduce sample photobleaching.  
This detection and data processing system allows for multiple transients to be averaged 
providing hundreds of averaged spectra per minute, contributing to very low 
signal/noise ratio of the data. 
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Figure 3.3 Schematic diagram illustrating key components of the pressure-jump 
instrument located at the University of Kent.  
Side view (A) highlights both sample delivery and pressure application systems.  The 
sample is introduced into the 50 μl optical chamber (1) via the inlet valve (2). The 
chamber consists of a sapphire ring sealed at the top end by pressure transducer (3) 
coupled to charge amplifier (4), and at the bottom end by elastic polyimide membrane 
(5). The pressure necessary to perturb equilibrium in the sample is provided by a piston 
attached to a piezoelectric actuator (6). Upon application of electric current through 
high-voltage power switch (7), the piston protrudes upwards, deforming the polyimide 
membrane and decreasing the volume of the optical chamber. Upon completion of the 
experiment, the chamber may be emptied through the outlet valve (8). The sample 
chamber is surrounded by a water jacket (not shown), allowing for temperature to be 
thermostatically controlled.  Section view (B) provides details of the detection setup 
used to monitor changes in fluorescence of the sample. The fiber-optic light guide (9) 
supplies monochromatic light used to excite the sample in optical chamber. The 
fluorescence emitted by the sample is passed through appropriate optical filter, focussed 
by a collimating lens and collected by the photomultiplier (10) at 90° to the excitation 
light (adapted from Pearson et al., 2002). 
A B 
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3.2.5.2 Equilibrium perturbation and its effect on protein fold  
 
A change in pressure changes the free energy of a reaction (ΔG°) in which there 
is a difference in volume between the reactants and products (ΔV°) so that the reaction 
must do enthalpic work (given by P ΔV°) against the external pressure to proceed.  The 
pressure perturbation function is given by the differential of the work done with respect 
to pressure:  ΔV° = -RT lnK / P.  Pressure jump using our equipment uses relatively 
little material and is able to access fast reactions because the pressure rise time is ~100 
µs.  Fast reactions can be conveniently measured using repeated averages that are not 
possible over short time periods using temperature jump due to long cooling times 
necessary between temperature jump measurements.  Pressure jump can selectively 
perturb steps on a reaction pathway (Málnási-Csizmadia et al., 2001; Málnási-
Csizmadia et al., 2007; Kintses et al., 2007), can measure the volume change and 
affinity for second order reactions by titrating the total concentration of protein and 
ligand (Pearson et al., 2002; Pearson et al., 2008) and has been used previously in 
protein folding studies (Jacob et al., 1999; Dumont et al., 2009; Jenkins et al., 2009).  
 
 
3.2.6 Pressure-jump experiments 
 
During a typical experiment a 50 µl sample was loaded into the chamber via the 
inlet valve into the bottom of the chamber. Prior to the measurement itself a small pre-
pressure (1–2 MPa) was applied in order to remove elasticity from the system and to 
deform the polyimide membrane into intimate contact with the piston. Once the inlet 
valve was closed measurements were obtained by rapid application and release of 
pressure (up to 35 MPa in ~100 µs). 
A protein concentration of 10 µM was used throughout the experiment, with a 
fluorescence transients obtained during each measurement consisting of at least 1,000 
averages. Protein tryptophan fluorescence was measured using an excitation wavelength 
of 295 nm with a monochromator bandwidth of 1.8 nm. The emitted fluorescence light 
was collected through a WG320 cut-off filter (Schott GmbH, Mainz, Germany), in 
order to block scattered excitation light below 320 nm.  For each denaturant 
concentration used, a corresponding blank measurement was performed and used for 
84 
 
the calculation of relative change in fluorescence.  This was done to account for the 
effect of urea on the refractive index of the solution, which could alter the light path of 
the cell. Buffer systems consisting of 20 mM MES and 20 mM sodium acetate were 
used to maintain a constant pH of 7.0 and 4.0 respectively. 
 
  
3.2.6.1 Data analysis 
 
Raw signal transients resulting from pressure-jump experiments were expressed 
as a percentage change in fluorescence according to the formula:  
 
F(t) = 100((Bt – St) / (B0 – S0) –1)          (3.12)  
 
where F(t) is the fluorescence as a function of time, St and Bt are the signal and blank 
measurements over time, respectively whereas S0 and B0 are the signal and mean blank 
measurements averaged over the pretrigger time before initiation of the jump (Pearson 
et al., 2002). 
Fluorescence transients resulting from pressure-jump experiments were fitted to a single 
exponential decay function with equation:  
 
F(t) = F∞ + A[1 – exp(-t/)]      (3.13) 
 
where F(t) is the fitted fluorescence function, F∞ is the end-point, A is the amplitude 
and  is the time constant (Pearson et al., 2002).  The fluorescence data included an 
early phase too fast to resolve, due to its time course coinciding with the fast pressure 
step. Consequently, the exponential function was only used to fit the slower phase 
beginning at the end of the initial fast pressure step, about 100 µs after the pressure 
application. 
The inverse time constants (1/) resulting from pressure-jump measurements over a 
range of urea concentrations were fitted to a two-state folding model using the 
following formula:  
 
1/ = kf exp(mf [D] / RT) + ku exp(mu [D] / RT)        (3.14)  
85 
 
where mf and mu are the kinetic folding and unfolding fragility parameters respectively, 
kf and ku are the folding and unfolding rate constants in the absence of denaturant, [D] 
is the concentration of denaturant, R is the gas constant, and T is the absolute 
temperature (293 K) (Pearson et al., 2002).   
Fitting was carried out using data transformed to ln(1/) in order to avoid undue bias 
towards large  values. The minima of the chevron plots were determined using the 
following expression:  
 
[D]min = RT / (mf - mu) ln(-mu × ku / mf × kf)        (3.15) 
 
which was obtained by solving the differential (Pearson et al., 2002). The mid-point of 
the corresponding equilibrium ([D]50%) unfolding curve was calculated using to the 
following formula:  
 
[D]50% = RT / (mf - mu) ln (ku / kf)          (3.16) 
 
The amplitudes resulting from pressure jump experiments were fitted by calculating the 
change in fluorescence predicted upon application of pressure (Pearson et al., 2002).  
The denaturant dependent folding equilibrium constant, KD was calculated according to 
the formula: 
 
KD = K0 exp(-m / RT)     (3.17) 
 
where K0 is the equilibrium constant in water and m is the fragility parameter.   
The fraction unfolded given by the formula  
 
( = KD / KD +1)           (3.18) 
 
was used to calculate the equilibrium fluorescence as a function of denaturant (FD) 
according to the following formula:  
 
FD = 1+ (Q-1)         (3.19) 
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where Q is the ratio of fluorescence in the fully folded to the fully unfolded state, with a 
value of 3.2 used in all cases (Gill and Von Hippel, 1989).  The pressure perturbation 
function was used to calculate the change in the equilibrium constant upon application 
of pressure, and thus the change in fluorescence.  The values of K0, m and V° were 
free parameters in this calculation. 
Obtaining realistic confidence limits for the fitted parameters resulting from fits to 
chevron plots is challenging without repeating entire sets of experimental data for the 
purpose of statistical analysis.  We fitted the high and low [urea] data separately as 
linear functions in ln(1/) and propagated the relative error in the slope and intercept 
into an estimate of error in fragility and aqueous rate constants, respectively, in order to 
provide a low threshold estimate of the uncertainties.  Error estimates in the derived 
parameters m and [D]50% come from error propagation.  Uncertainties in the amplitude 
fits were standard errors derived directly from the fitting program (Microcal Origin). 
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Figure 3.4 Example of data yielded by the pressure-jump experiment. Top panels 
show the pressure profile upon pressure application (A) and release (B).  Middle panels 
show examples of three overlaid tryptophan fluorescence transients recorded at 
different urea concentrations, as well as single exponential fits by linear regression to 
said fluorescence transients. upon pressure application and release are shown in left and 
right-hand side panels respectively.  Residuals from fitting fluorescence transient 
coloured in red are shown in the bottom panels. 
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3.2.7 Fibrilization of PrP 
 
Recombinant mouse PrP was fibrillized according to published protocol 
(Breydo et al. 2008). Aliquots of MoWT, Q167R and sHaWT PrP were lyophilized and 
briefly dissolved in 6 M guanidine HCl, pH 6.0, at a concentration of 3 mg/ml. A range 
of fibrillization reactions consisting of 6-5M urea, 10 mM thiourea, 120 μg/ml recPrP, 
50 mM MES, pH 7.0 and pH 4.0, and 10 μM thioflavin T was prepared. 160 µl aliquots 
of reaction mixtures were placed into individual wells of a 96-well plate, and 3 Teflon 
spheres were added to aid mixing (Graham et al., 2010). In some reactions 0.1% (w/w) 
of preformed PrP seed was added to the reaction wells. The 96-well plate was incubated 
in a plate reader at 37 °C with constant shaking (900 rpm, 1-mm diameter). The 
fluorescence from thioflavin T (ThT) was monitored every 30 min by use of a 
fluorescence plate reader (Fluoroskan Ascent, Thermo Scientific) with excitation at 444 
nm and emission at 485 nm. Background fluorescence was calculated from three 
replicate wells containing no PrP and was subtracted from sample readings. Sigmoidal 
curves were fitted to the data where possible by a least squares approach. Fluorescence, 
F, at time, t was calculated from the equation: 
 
F(t) = A+ (B + C) / (1+ e
(k(tm-t))
)        (3.20) 
 
where A is the initial level of ThT fluorescence, B is the peak level of fluorescence, tm 
is the mid point of the transition, and k is the rate of increase of fluorescence. C is an 
empirical parameter describing changes in fluorescence after fibril formation (Graham 
et al., 2010).  
The lag time, t1, is calculated as  
 
t1 = tm – 2 / k        (3.21) 
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3.3 Results and Discussion 
 
 
3.3.1 Equilibrium denaturation of PrP followed by tryptophan fluorescence 
 
Tryptophan fluorescence is the most common spectroscopic technique used to 
monitor protein folding and refolding, relying on changes in fluorescence of reporter 
Trp residues located in the key structural regions of investigated protein.  In this study 
single- tryptophan mutants of MoPrP, Q167R disease-associated mutant and SHaPrP 
were used. Each of the constructs had its two native tryptophan residues at positions 98 
and 144 mutated to phenylalanine residues, with phenylalanine residue at position 197 
(mouse PrP) or 198 (hamster PrP) mutated to tryptophan which acted as a fluorescent 
probe. 
Prior to pressure-jump experiments, the denaturant unfolding transition curves for all 
three species were constructed to determine the range of denaturant concentrations at 
which perturbing the equilibrium would be most effective. Since pressure-jump 
spectroscopy, as an equilibrium perturbation technique, relies on shifting the 
equilibrium between unfolded and folded protein conformations, its effect should be 
most pronounced near the midpoint of the transition curve where populations of 
unfolded and folded states are relatively equal. On the other hand, the further from the 
midpoint, the lower the population of folded/unfolded protein in which conformational 
change can be induced upon pressure application or release and thus lower the 
fluorescence signal. Since pressure values achievable by pressure-jump instrument used 
in this study are insufficient to unfold PrP without denaturant present (Jenkins, 2006), 
determination of behavior of all thee prion proteins along the denaturant unfolding 
curve is of vital importance. 
In order to investigate whether the increased propensity to form β-state intermediate in 
mildly acidic and denaturing conditions can be characterised kinetically, pressure-jump 
experiments with all three PrP species were conducted at two pH values (pH 7.0 and pH 
4.0). Consequently, denaturant folding curves of MoWT, Q167R and SHaWT at both 
pH 7.0 and pH 4.0 were constructed. 
 Comparison of tryptophan fluorescence spectra of three prion species collected 
at increasing urea concentrations (see Figures 3.5, 3.6 and 3.7) reveals key similarities 
shared by investigated proteins. Upon increase in denaturant concentration, the 
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unfolding-sensitive tryptophan residue becomes solvent exposed, resulting in shift in 
wavelength at which maximum fluorescence can be observed (λmax) towards the higher 
energy region of the spectrum – a process referred to as red-shift. For all three proteins, 
the maximum fluorescence under native conditions occurs at 337 nm at pH 7.0 and 339 
nm at pH 4.0, while in presence of 7.5 M urea the λmax is shifted to 351 nm at both pH 
values. The slightly lower total red-shift value of 12 nm at pH 4.0, compared to 14 nm 
at pH 7.0, can be easily attributed to mildly denaturing conditions of low pH, resulting 
in the PrP being slightly destabilized even in absence of urea. This is consistent with the 
total changes in fluorescence intensity in absence of denaturant and in highest 
concentration of urea being lower at pH 4.0 compared to pH 7.0. At neutral pH, the 
fluorescence intensity of fully unfolded protein is approximately 70% lower than that of 
folded protein, while at pH 4.0 fluorescence of unfolded protein is 60% lower.  
It should be noted that this behavior is true for mouse prions MoWT and Q167R, while 
for Syrian hamster PrP (SHaWT) the process is reversed – the fluorescence intensity is 
not decreased upon unfolding but increased, which is consistent with previous folding 
studies of Syrian hamster PrP (Jenkins, 2006). Consistently with the destabilization of 
structure at lower pH, the total increase in fluorescence between fully folded and 
unfolded states is approximately 5% larger at pH 7.0 than at pH 4.0. 
While typically upon unfolding of the protein the fluorescence of tryptophan residues is 
quenched (Lakowicz, 1999), in some cases the local environment of the tryptophan 
residue acts as quencher when protein is folded. In such case, unfolding of the protein 
results in de-quenching of the tryptophan and consequently increased fluorescence. 
Such effect has been observed in single-tryptophan mutant of E.coli aporepressor 
protein (Royer et al., 1993). 
 Both changes in maximum fluorescence intensity and the red-shift can be used 
to monitor protein folding. However, while in case of prion proteins the tryptophan 
fluorescence can be both quenched and increased upon unfolding depending on the 
local environment of the residue, as illustrated above, the red-shift is universally 
unidirectional and associated with unfolding. Thus, for the sake of clarity and uniform 
data processing, the red shift of maximum tryptophan fluorescence was used to 
construct denaturant unfolding transition curves. 
For both mouse prion proteins, MoWT and Q167R (see figure 3.8, panels A and B 
respectively), at neutral pH the major unfolding transition occurs between 5 M urea and 
7 M urea. Such narrow transition range is indicative of the cooperative two-state 
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transition. Moreover, the mid-point of the transition curve of Q167R protein occurs at 
slightly lower urea concentration (see Table 3.1), which is indicative of slight structural 
destabilization conferred by this mutation (Robinson and Pinheiro, 2009). 
The transition region of Syrian hamster PrP is noticeably broader than both mouse 
prions (see Figure 3.9), occurring between 3.5-4 M and 7 M urea. While it can be fitted 
to two-state model by linear regression, the protein which folds via two-state transition 
should exhibit much steeper transition. This suggests that the Syrian hamster PrP does 
not exhibit the cooperativity observed in mouse prions and other proteins that fold via 
essentially two-state mechanism. 
Interestingly, at pH 4.0 all three proteins exhibit extremely broad transition regions 
stretching between 2 M and 6 M urea concentrations. Such broad transitions strongly 
suggest that lowering the pH affects the folding of all three prion species so that they no 
longer clearly follow the two-state mechanism. This in turn might be indicative of the 
presence of a β-state intermediate in low-pH folding pathways of both mouse and 
hamster prions. 
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Figure 3.5 Fluorescence spectra of single-tryptophan mutant of mouse PrP (MoWT) 
at increasing urea concentrations across the folding transition curve at pH 7.0 (A) and 
4.0 (B). 
The fluorescence spectra at 0 M urea (red), 1.0 M urea (green), 2.0 M urea (yellow), 3.0 
M urea (blue), 3.5 M urea (pink), 4.0 M urea (cyan), 4.5 M urea (grey), 5.0 M urea 
(brown), 5.5 M urea (dark green), 6.0 M urea (dark yellow), 6.5 M urea (dark blue), 7.0 
M urea (purple) and 7.5 M urea (teal) are shown. 
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Figure 3.6 Fluorescence spectra of single-tryptophan construct of disease-associated 
mutant of mouse PrP (Q167R) at increasing urea concentrations across the folding 
transition curve at pH 7.0 (A) and 4.0 (B). 
The fluorescence spectra at 0 M urea (red), 1.0 M urea (green), 2.0 M urea (yellow), 3.0 
M urea (blue), 3.5 M urea (pink), 4.0 M urea (cyan), 4.5 M urea (grey), 5.0 M urea 
(brown), 5.5 M urea (dark green), 6.0 M urea (dark yellow), 6.5 M urea (dark blue), 7.0 
M urea (purple) and 7.5 M urea (teal) are shown. 
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Figure 3.7  Fluorescence spectra of single-tryptophan mutant of Syrian hamster PrP 
(SHaWT) at increasing urea concentrations across the folding transition curve at pH 7.0 
(A) and 4.0 (B). 
The fluorescence spectra at 0 M urea (red), 1.0 M urea (green), 2.0 M urea (yellow), 3.0 
M urea (blue), 3.5 M urea (pink), 4.0 M urea (cyan), 4.5 M urea (grey), 5.0 M urea 
(brown), 5.5 M urea (dark green), 6.0 M urea (dark yellow), 6.5 M urea (dark blue), 7.0 
M urea (purple) and 7.5 M urea (teal) are shown. 
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Figure 3.8 Denaturant unfolding transition curves of MoWT (A) and Q167R (B) 
followed by red-shift in tryptophan fluorescence. For each variant of prion protein two 
curves were constructed: at pH 7.0 (blue) and at pH 4.0 (red). Each data point 
represents the value of red-shift in λmax normalized to fraction unfolded as described in 
section 3.2.3.1. Error bars show the standard deviation of two independent experiments. 
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Figure 3.9  Denaturant unfolding transition curve of SHaWT followed by red-shift 
in tryptophan fluorescence. Two transition curves constructed at pH 7.0 and at pH 4.0 
are shown in blue and red respectively. Each data point represents the value of red-shift 
in λmax normalized to fraction unfolded as described in section 3.2.3.1. Error bars show 
the standard deviation of two independent experiments. 
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PrP construct pH ΔG0 kJ mol
-1
 m kJ mol
-1
 M
-1
 [D]50% 
MoWT (F197W) 7.0 30.2 ± 2.7 5.4 ± 0.5 6.0 ± 0.3 
 4.0 25.6 ± 2.3 5.1 ± 0.4 3.7 ± 0.1 
Q167R 7.0 29.4 ± 1.9 4.8 ± 0.4 5.8 ± 0.3 
 4.0 27.3 ± 2.2 4.5 ± 0.3 3.7 ± 0.2 
SHaWT (F198W) 7.0 18.4 ± 1.1 8.8 ± 0.5 5.5 ± 0.2 
 4.0 12.5 ± 0.9 6.5 ± 0.3 3.5 ± 0.1 
 
Table 3.1 Thermodynamic parameters extracted from denaturant unfolding 
transition curves of MoWT, Q167R and SHaWT. 
The free energy of unfolding in the absence of urea (ΔG0) and m values were calculated 
from the two-state analysis of denaturant unfolding transition curves. 
 
 
 
PrP construct ΔG0 kJ mol
-1
 m kJ mol
-1
 M
-1
 [D]50% 
MoWT (F197W) 1.82 0.66 10.29 
Q167R 1.02 0.85 8.24 
SHaWT (F198W) 5.87 5.58 12.56 
 
Table 3.2 T-parameter values obtained via statistical analysis of thermodynamic 
parameters from Table 3.1 using T-test. For each PrP construct the thermodynamic 
parameters at pH 7.0 and pH 4.0 were compared in order to identify any statistically 
significant differences. T-parameter values exceedint 2.920 allow for the null 
hypothesis to be rejected, thus confirming the statistically significant difference 
between thermodynamic parameters. For values below 2.920 the null hypothesis cannot 
be rejected, and consequently no statistically significant difference can be claimed.  
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3.3.2 Equilibrium denaturation of PrP followed by far-UV circular dichroism 
 
 Far-UV circular dichroism was used to construct denaturant unfolding transition  
curves complementary to those obtained by tryptophan fluorescence spectroscopy. 
Moreover, it could potentially determine the presence of elusive β-state intermediate in 
mildly acidic and denaturing conditions, which may not be detectable through 
tryptophan fluorescence. Thus, denaturant folding curves of MoWT, Q167R and 
SHaWT at pH 4.0 were constructed. 
In absence of urea, all three spectra show clear characteristics of predominantly α-
helical structure: two negative bands at 208 and 222 nm. The third band at 195 nm is 
not visible due to spectral properties of the sodium acetate buffer used to maintain low 
pH, which prevent any reliable data to be collected below 200 nm.  
Upon increase in denaturant concentration, the two bands indicative of α-helical 
structure lose their intensity, and a single strongly negative band appears below 205 nm, 
which is characteristic for random coil structure. At urea concentrations exceeding 6 M 
any traces of α-helical structure are absent and entire spectrum corresponds to that of a 
fully unfolded protein. 
The spectra of both mouse prions (MoWT and Q167R) follow the essentially two-state 
transition model, however, in both cases the transition region is unusually broad, 
ranging from 2 M urea to 6 M urea (see Figure 3.10 and 3.11), with midpoints 
occurring at 4.4 and 4.3 M urea respectively. 
All of the transition curves at pH 4.0 exhibit sloping baselines compared to pH 
7.0 (Figures 3.8 and 3.9), which may reflect the lower protein stability at acidic 
conditions and some minimal protein aggregation. The latter seems unlikely, however, 
due to the fact that fluorescence spectra show no significant difference between 
minimal fluorescence at pH 7.0 and pH 4.0 (see Figures 3.5, 3.6 and 3.7), which would 
be visible if some of the protein aggregated, hence decreasing the total fluorescence 
signal. Moreover, possible aggregation at lower pH was accounted for during the 
process of sample preparation. All samples were centrifuged prior to measurements in 
order to eliminate any possible aggregates. No visible pallets were collected and 
supernatants were clear.While there is no clear indication of accumulation of a β-state 
intermediate at urea concentrations between 3 and 5 M, which is characteristic for both 
mouse and hamster prions (Khan et al., 2010), the broadness of the transition itself 
strongly suggests that neither MoWT nor Q167R follow two-state transition model. 
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Consequently, while the presence of β-state intermediate cannot be directly inferred 
from unfolding transition curves, the two-state model characteristic for mouse prions at 
higher pH cannot account for their behaviour at pH 4.0.  
The transition curve of Syrian hamster PrP (see Figure 3.12) differs from two mouse 
spectra, in that while it exhibits similarly wide transition uncharacteristic for two-state 
model, it also contains an unusual feature in form of a plateau region between 3.5 M 
and 4 M urea which is consistent with the presence of β-state intermediate. It should be 
noted that the plateau region observed is narrower than expected – previously reported 
plateau region extends between 2.5 and 4 M urea (Khan et al., 2010). The relatively 
narrow plateau region of hamster PrP, which has by far the highest propensity to form 
the intermediate,may explain why no such feature is visible in mouse PrP spectra, 
which have lower propensity to form β-structured intermediate. All three transition 
curves are visibly shifted towards lower urea concentrations in comparison to transition 
curves collected at pH 7.0 (see Figure 3.13) which is consistent with overall structural 
destabilisation characteristic for lower pH. 
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Figure 3.10 Denaturant unfolding transition curve of single-tryptophan mutant of 
mouse PrP (MoWT) followed by far-UV circular dichroism at pH 4.0. The inset shows 
CD spectra of 10 μM MoWT in 20 mM sodium acetate buffer collected in absence of 
denaturant (red), in presence of 1M urea (green), 2 M urea (blue), 3 M urea (pink), 4 M 
urea (cyan), 5 M urea (grey), 6 M urea (brown) and 7 M urea (dark green). 
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Figure 3.11 Denaturant unfolding transition curve of single-tryptophan construct of 
disease-associated mutant of mouse PrP (Q167R) followed by far-UV circular 
dichroism at pH 4.0. The inset shows CD spectra of 10 μM Q167R in 20 mM sodium 
acetate buffer collected in absence of denaturant (red), in presence of 1M urea (green), 
2 M urea (blue), 3 M urea (pink), 4 M urea (cyan), 5 M urea (grey), 6 M urea (brown) 
and 7 M urea (dark green). 
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Figure 3.12 Denaturant unfolding transition curve of single-tryptophan mutant of 
Syrian hamster PrP (SHaWT) followed by far-UV circular dichroism at pH 4.0. The 
inset shows CD spectra of 10 μM SHaWT in 20 mM sodium acetate buffer collected in 
absence of denaturant (red), in presence of 1M urea (green), 2 M urea (blue), 3 M urea 
(pink), 4 M urea (cyan), 5 M urea (grey), 6 M urea (brown) and 7 M urea (dark green). 
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Figure 3.13 Comparison of CD denaturant unfolding transition curves of of 10 μM 
MoWT (green circles), Q167R (red traingles) and SHaWT (blue squares) collected in 
sodium acetate buffer at pH 4.0 with CD transition curves of MoWT (upward traingles) 
and Q167R (downward triangles) collected in 20 mM phosphate buffer at pH 7.0. 
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3.3.3 Fast folding kinetics investigated by pressure jump 
 
Investigation of folding properties of PrP was performed using the truncated 
form of Syrian hamster and mouse PrP with native tryptophan residues removed and 
extra tryptophan inserted in key structural areas to act as a fluorescent probe sensitive to 
the folding state of PrP.  Previous far-UV circular dichroism studies on Mo-PrP using a 
folding sensitive mutant with the tryptophan residue located at position 197 produced 
transition curves almost identical to those of wild type protein, indicating that folding is 
not affected by the position of tryptophan residue used to monitor the folding pathway 
(Robinson and Pinheiro, 2009). An orthologous mutant protein from Syrian hamster, 
SHaWT F198W, has also been used. It is similar to the protein studied previously 
(Jenkins et al., 2009), with the exception of having its native tryptophan residues 
removed in order to reduce the background fluorescence. All of these measurements 
were conducted at pH 7.0 and pH 4.0, using urea as the denaturant. 
 
 
3.3.3.1 Folding kinetics at varying denaturant concentrations 
 
The PrP folding kinetics were investigated over a broad range of urea 
concentrations, ranging from 3.5 M up to 8.5 M for pH 7.0 and 3.0 M to 7.0 M for pH 
4.0. Lower urea concentrations were required for pH 4.0 due to inherent destabilizing 
effect of decreased pH on the prion protein. In order to ensure that only relevant kinetic 
data will be captured, said concentrations were chosen following a careful investigation 
of published denaturant folding and refolding transition curves for pH 7.0 (Robinson 
and Pinheiro, 2009) as well as folding and refolding curves determined experimentally 
for pH 4.0 by monitoring red shift in Tryptophan fluorescence (Figures 3.8 and 3.9).   
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Figure 3.14 Folding kinetics of 10 µM MoWT monitored by fluorescence during a 
pressure-jump experiment. Unfolding and refolding of MoWT protein at 20
o
 C, pH 7.0 
following pressure application and release.  Top panels show the pressure profile upon 
pressure application (A) and release (B).  Middle panels show three overlaid 
fluorescence transients acquired at different urea concentrations as well as single 
exponential fits by linear regression to saidfluorescence transients.Urea concentrations 
at which particular transients were obtained are shown as numbers next to curves in 
panel C). Data collected upon pressure application and release are shown in panels C 
and D respectively.  Residuals from fitting to 4.7 M urea data are shown in the bottom 
panels (E and F). 
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Pressure application resulted in overall decrease in fluorescence which reverted to 
original state upon pressure release (Figure 3.14). This not only confirmed that pressure 
application shifts equilibrium towards the unfolded state, but also allowed us to 
determine that the process is fully reversible, again in accordance with published 
reports (Zhang et al., 1997).   
Recorded fluorescence transients were fitted to a single exponential function, with rates 
of fluorescence decrease upon pressure application of around 1/ = ~10,000 s-1 at both 
pH 7.0 and pH 4.0 depending on the PrP variant (Table 3.3). Upon pressure release the 
fluorescence transients measured at pH 7.0 follow the reverse pattern, with kinetic 
parameters being only slightly different than parameters derived from unfolding curves 
(1/ = ~13,000 s-1 upon pressure release compared to 1/ = ~10,000 s-1 upon pressure 
application). Interestingly, at pH 4.0 the difference in rates of fluorescence decrease 
upon pressure application and release can only be observed for MoWT, with Q167R 
and SHaWT rates being very similar (Table 3.3). 
 
It should be noted that both folding and unfolding constants (Kf and Ku) can be 
calculated for both pressure application (protein unfolding) and pressure release 
(protein refolding) experiments (see Table 3.3 and 3.4). While obtaining folding 
constant from unfolding experiment seems counter-intuitive, it is a direct consequence 
of perturbation of the equilibrium of the system. 
Upon change in pressure the folding-unfolding equilibrium constant is altered as well, 
allowing for measurement of rate constant (inverse time constant, 1/tau) for the 
exponential relaxation process: 
Y = A exp(-t/τ) 
This 1/τ value depends on the sum of the forward and backward rate constants, under 
the final conditions of the experiment (pressure, denaturant concentration etc.): 
1/τ = ku(D) + kf(D) 
where the unfolding equilibrium constant, K(D) is given by 
K(D) = ku(D)/kf(D) 
Each of these rate constants depend exponentially on the denaturant concentration, a 
fragility parameter and the value of the rate constant in water (no denaturant): 
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ku(D) = ku(0) exp(-mu [D]/RT) 
and 
kf(D) = kf(0) exp(-mf [D]/RT) 
There is thus also an equilibrium constant of unfolding under native conditions, which 
would be expected to be a very small number (as seen in first column of Table 3.3 and 
3.4): 
K(0) = ku(0)/kf(0) 
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Figure 3.15 Effect of urea concentration on amplitudes (A, B, C) and inverse 
relaxation times (D, E, F) resulting from single exponential fits to pressure-jump 
relaxation transients.  Results from MoWT are shown in panels A and D; Q167R are 
shown in panels B and E and SHaWT are shown in panels C and F.  Black lines 
represent data obtained at pH 7.0, while red lines correspond to data yielded by 
experiments at pH 4.0. Upward pointing triangles indicate results of pressure increase 
and downward pointing triangles to pressure decrease.  Smooth curves indicate fits to a 
two-state model – parameters obtained from fits are shown in Table 3.3 (pH 7.0) and 
Table 3.4 (pH 4.0). 
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Amplitudes of the exponential phase plotted against denaturant concentration (Figure 
3.15) follow the bell-shaped curve characteristic for single step reactions for all three 
variants of PrP. The maxima of the amplitude plots occur where the equilibrium 
constant is closest to 1 and correspond to the minima of inverse time constants plotted 
against denaturant concentrations. 
At pH 7.0 the amplitude maxima occur at denaturant concentrations of approximately 
6.0, 5.9 and 5.7 M urea for MoWT, Q167R and SHaWT respectively, close to the 
minima of corresponding chevron plots and midpoints of denaturant unfolding 
transition curves (5.6 and 6.1 M Urea for pressure application and release for MoWT, 
5.5 and 6.4 M urea for Q167R and 5.5 and 6.2 M urea for SHaWT). At lower pH the 
maxima occur at urea concentrations of 5.7, 5.3 and 5.2 M urea for MoWT, Q167R and 
SHaWT respectively, again close to the minima of corresponding chevron plots. This 
shift of parameters towards lower urea concentration is consistent with the destabilizing 
effect of decreased pH on protein stability.  
It should be noted that for both pH 7.0 and pH 4.0 the pressure jump experiments were 
not performed along the entire range of denaturant unfolding transition curves, as at 
both very low and very high denaturant concentrations (below 3.5 and above 8.5M urea 
for pH 7.0 and 3.0 and 7.0M urea for pH 4.0) the amplitudes of the exponential phase 
were below 1% and hence too small to measure reliably. This is clearly visible on the 
amplitude plots, where both arms approach 0% amplitude as the measurements move 
further from the maximum.   
Inverse time constants plotted against denaturant concentrations yielded well-defined 
two-state curves at both pH 7.0 and pH 4.0. As expected, at pH 7.0 the pressure 
increase and resulting shift in equilibrium towards unfolded state moved the midpoint 
of unfolding curves towards lower denaturant concentration, which is reflected by 
pressure application chevron curves being shifted towards lower urea concentration. 
The minima of chevron plots occurred at 5.64 and 6.13 M urea for MoWT for pressure 
application and release respectively, while corresponding values for Q167R were 5.51 
and 6.38 M urea and 5.45 and 6.19 for SHaWT. The large difference between unfolding 
and refolding chevron arms at higher denaturant concentrations compared to lower 
denaturant concentrations hints at ΔVu‡ being negative and larger than -20 mL.mol-1 
which was confirmed by activation volume calculations.                                                                                                    
Similar position of chevron minima of three PrP variants is surprising, taking into 
account the overall different shapes of chevron plots (particularly the MoWT and 
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Q167R curves) as well as the fact that MoPrP reportedly folds via two-state transition 
as opposed to SHaPrP folding via intermediate. 
At pH 4.0 the chevron plots are much more superposable, particularly for Q167R and 
SHaWT, which is reflected in the minima of chevron plots for both pressure application 
and pressure release being much closer. This indicates that the population of folded 
states being shifted towards unfolded states upon pressure application is lower than at 
pH 7.0 due to overall decrease in stability induced by lower pH.  
Independently on pH, the inverse relaxation times resulting from pressure release at low 
denaturant concentrations were faster than those resulting from pressure application, 
with the trend being reversed at higher urea concentrations. The minima of the refolding 
curves obtained during the pressure release are shifted to consistently higher denaturant 
concentrations than the minima of unfolding curves (eg. 5.64 M urea for pressure 
application and 6.13 M urea for pressure release for MoWT). The results of kinetic 
analysis of both amplitude and chevron plots are summarized in Tables 3.3 and 3.4, 
where the equilibrium fragility (m) is the sum of the two values from the two arms of 
the chevron. 
As change in pressure influences the volume of the system, it allows the volume 
changes and pressure dependence of rate constants to be investigated, potentially 
revealing the activation volume of the reaction. This was achieved by plotting rates of 
unfolding and refolding against the net pressure change occurring upon pressure 
application (Figure 3.16). As expected, the relaxation times observed upon pressure 
release are very similar, since they are effectively measured at the same pressure of 1 
bar. For pressure application, however, plots of intrinsic rate constant (kf(D) of ku(D)) 
show strong pressure dependence. While at low pressure (1 bar) the 1/τ is completely 
pressure-independent and depends only on final protein concentration, it does exhibit 
strong pressure dependence at high pressure values. This linear relationship between 
pressure and observed rate constants allows to define ΔV‡ (change in volume between 
start of step and activated complex given by –RTdlnk/dP) for pressure application. 
The ΔV‡ values calculated for different PrP constructs are shown in Table 3.3. 
Interestingly, while activation volumes of both mouse MoWT and hamster SHaWT are 
quite similar (-69 ± 2 and -57 ± 4 mL.mol-1 respectively) the activation volume of Q167R 
is much lower (-39 ± 1 mL.mol-1) hinting at decreased stability of the construct. 
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Figure 3.16 Effect of size of pressure jump on amplitude of change in relative 
fluorescence (A) and rate constant (B). Both fluorescence and rate constants upon 
pressure application (downward black triangles) and pressure release (upward white 
triangles) of 10 μM MoWT were recorded at 5.5 M urea, pH 7.0. Linear regression fits 
for both pressure application and pressure release data are represented in panel B as 
straight solid lines. 
 
A 
B 
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Table 3.3 Kinetic parameters of the folding of MoWT, Q167R and SHaWT at pH 7.0 
 
 MoWT Q167R SHaWT 
 Pressure 
application 
Pressure 
release 
Pressure 
application 
Pressure 
release 
Pressure 
application 
Pressure 
release 
Stopped-Flow 
ku (s
-1
) 6.16 ± 0.03 10.97 ± 0.65 7.0 ± 0.2 7.0 ± 0.2 3.3 ± 0.7 1.5 ± 0.3 0.69 ± 0.04 
kf (s
-1
) 10 000 ± 1100 13 000 ± 560 10 000 ± 2700 13 000 ± 1900 10 000 ± 390 12 400 ± 380 12 000 ± 160 
mu (kJ.mol
-1
.M
-1
) 1.48 ± 0.15 1.11 ± 0.20 1.56 ± 0.22 1.38 ± 0.18 1.79 ± 0.32 1.87 ± 0.44 2.21 ± 0.34 
mf (kJ.mol
-1
.M
-1
) -1.71± 0.19 -1.70± 0.30 -1.65 ± 0.24 -1.59 ± 0.31 -1.80 ± 0.25 -1.69 ± 0.21 -1.67 ± 0.04 
V° (mL.mol-1) -69 ± 2 -39 ± 1 -57 ± 4 N/A 
m (kJ.mol
-1
.M
-1
) 3.19 ± 0.34 2.81 ± 0.50 3.21 ± 0.46 2.97 ± 0.49 3.59 ± 0.57 3.56 ± 0.65 3.88 ± 0.38 
[D](M) 
5.64 ± 0.63 6.13 ± 1.18 5.51 6.38 5.45 ± 1.03 6.19 ± 1.27 6.14 ± 0.65 
 
 
 
 
113 
 
Table 3.4 Kinetic parameters of the folding of MoWT, Q167R and SHaWT at pH 4.0 
 
 MoWT Q167R SHaWT 
 Pressure 
application 
Pressure 
release 
Pressure 
application 
Pressure release Pressure 
application 
Pressure release 
ku (s
-1
) 68 1.26 0.51 8.44 0.26 7.45 
kf (s
-1
) 9988 13056 9977 9737 9997 9766 
mu (kJ.mol
-1
.M
-1
) 1.18 2.30 2.68 1.67 3.11 1.73 
mf (kJ.mol
-1
.M
-1
) -1.68 -1.40 -1.26 -1.38 -1.33 -1.38 
V° (mL.mol-1) -37 -25 -47 
m (kJ.mol
-1
.M
-1
) 2.86 3.71 3.94 3.06 4.44 3.11 
[D](M) 4.24 6.08 6.11 5.62 5.79 5.63 
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A key molecular event in prion diseases is the conversion of cellular PrP to disease-
associated form of the protein called PrP
Sc
. For PrP
C
 to be able to convert to its 
misfolded isoform, it must undergo at least partial unfolding. Consequently, obtaining 
detailed information on the unfolding and folding properties of PrP may provide 
invaluable insight into the mechanism of misfolding.  
Fast pressure-jump fluorimetry was used to investigate early events of the PrP folding 
pathway, as previous folding studies proved it to be an effective and reliable method 
capable of high time resolution, not relying on lowering the temperature to slow down 
the observed reaction (Jenkins et al., 2009). As expected from earlier pressure-jump 
studies, the data collected during experiments on different PrP variants displayed 
similar characteristics, with produced transients compatible with equilibrium 
perturbation of three comparable single tryptophan PrP constructs. 
All pressure-jump traces exhibited a characteristic decrease in fluorescence upon 
pressure application, which reverted to the original state upon pressure release, 
providing strong evidence that the equilibrium perturbation is fully reversible. 
Moreover, since the shape of fluorescence curves shows the relationship between 
pressure application and relaxation and equilibrium perturbation, it can be concluded 
that the equilibrium is perturbed momentarily, its changes depending only on pressure 
application and not other physical factors.  
Independently of denaturant concentration, the PrP unfolding upon pressure application 
can easily be fitted to single exponential function (as shown in Figure 3.14) suggesting 
a single-step transition with little dependence on the denaturant concentration. 
However, very rapid fluorescence change occurring immediately after pressure 
application as well as fast amplitude imply a fast hidden step. The presence of such a 
fast phase may be indicative of the formation of a folding intermediate early in the 
folding pathway.  
Variation in amplitude displayed by fluorescence curves is clearly dependant on the 
denaturant concentration, and hence the positions of the equilibrium along the folding 
curve. The largest amplitude changes occur at denaturant concentrations closest to the 
midpoint of the folding curve, confirming their dependence on the relative size of 
unfolded/folded populations of the protein that can be “recruited” in re-establishing 
equilibrium upon its perturbation by a rapid pressure change. This is confirmed by 
characteristic bell-shaped curves produced by plotting amplitude against urea 
concentration, where the maximum value of those curves corresponds with the midpoint 
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of folding curves. The overall shape, as well as a single, well-defined peak of those 
curves both supports the single-step model of PrP folding. Pressure-dependence of 
amplitude changes is more linear in nature, indicating marginal concentration changes 
upon pressure application. This linear relationship can be explained by larger pressure 
jumps allowing for greater equilibrium perturbation by increasing the population of PrP 
molecules that can change their folded/unfolded state and thus generating larger 
amplitude. Complete lack of any intermolecular interactions (such as dimerization) as 
part of the pathway was confirmed by flat lines obtained upon plotting amplitudes and 
rates against PrP concentration. Folding/unfolding kinetics as well as denaturant 
concentration dependence of rate constants of sHa were confirmed by subsequent 
stopped-flow measurements. 
The amplitude curves obtained from wild-type single-tryptophan mouse and hamster 
proteins (MoWT and SHaWT respectively) show larger amplitudes than for mutated 
mouse variant Q167R, with maximum amplitude changes occurring at 6.1M urea for 
mouse PrP and ~5.8M for hamster PrP. Lower amplitude changes in Q167R mutant 
seem to indicate that the unfolded/folded populations of the protein are smaller with 
respect to MoWT and SHaWT, resulting in lower populations being available for 
folding state transition upon equilibrium perturbation.  
The apparent difference in folding kinetics between MoWT and Q167R mutant is also 
visible in chevron plots. While for all the PrP variants the rate constants calculated from 
recorded transients follow a single-step unfolding model depicting a typical chevron 
shape, the rates themselves differ significantly with Q167R unfolding and refolding 
significantly faster than two other PrP variants (1/min ~ 450 s
-
1 for Q167R compared 
with 1/min ~ 350 s
-1
 for two other constructs). This difference is reflected by kinetic 
parameters calculated for different PrP constructs, with ΔV° of MoWT and SHaWT 
being 69 mL.mol
-1
 and 57 mL.mol
-1
 respectively, compared with only 39 mL.mol
-1
 for 
Q167R, suggesting lower stability of disease-resistant mutant. These findings are 
consistent with structural interpretation of a hydrogen bond existing between R167 and 
Q171 which stabilizes the loop region between strand S2 and helix HB and which is 
missing in Q167R variant where R167 and R171 repel each other (Figure 3.17), 
destabilizing the loop region and consequently decreasing overall protein stability 
(Robinson and Pinheiro, 2009). 
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Figure 3.17 Overlay of the loop region of crystal structures of ovine Q171 (blue) and 
R171 (red) variants with residues 167 and 171 highlighted. 
The NMR structure was drawn from PDB file 1TPX (Q variant) and 1TQC (R variant) 
using UCSF Chimera package as stated in legend of Figure 3.2. 
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3.3.4 Fibrilisation studies of PrP 
 
While kinetic studies using spectroscopic methods such as pressure-jump can 
provide invaluable insight into earliest kinetic events of protein folding pathway, they 
cannot provide details on conformation or propensity to form aggregates. Independently 
of any differences in folding kinetics, the disease resistance and species barrier may not 
be linked directly with the early folding pathway. They may instead be associated with 
propensity of PrP to form neurotoxic oligomers as well as amyloid-like fibrils. Thus, 
the pressure-jump studies of kinetics of early folding pathway of PrP were 
supplemented with fibrilization studies of prion proteins in order to identify key 
processes involved in both species barrier and disease resistance. 
Fibril formation of single-tryptophan constructs of MoWT, Q167R and SHaWT was 
investigated in a series of fibrilisation studies utilizing ThT fluorescence (Gill et al. 
2009).  
 In order to determine whether conditions which promote formation of β-state 
intermediate affect the rate of fibril formation as well as morphology of formed fibrils, 
the fibrilisation experiments for all three PrP constructs (MoWT, Q167R and SHaWT) 
were conducted at pH 4.0 which is known to promote the formation of intermediate, as 
well as at pH 7.0 where the intermediate was not observed. 
Fibrilisation experiments were conducted at 6 M urea concentration for pH 7.0 and 4 M 
urea for pH 4.0 Initial fibrilization experiments were conducted with and without 200 
mM NaCl which mimicked the salt concentrations present in cells. The presence or 
absence of salt was determined to have no quantifiable effect on length of lag phase, 
rate of fibril formation or their morphology. The ThT fluorescence traces obtained 
during fibrilisation experiments are shown in Figures 3.18, 3.19 and 3.20. 
Both species of mouse PrP – MoWT and Q167R – form fibrils after approximately 50-
80 hours from onset of incubation, as indicated by rapid increase in ThT fluorescence 
(see Figures 3.18 and 3.19). In both cases the lag phase observed at neutral pH is 
noticeably shorter than the lag phase at pH 4.0 (see Table 3.5). This is consistent with 
observation that mildly destabilising conditions result in longer lag phase (Birkmann 
and Reisner, 2008). 
At pH 7.0 the observed lag phase of MoWT is slightly shorter than that of Q167R (57.4 
h and 77.2 h respectively); however at pH 4.0 the length of both lag phases is similar 
(see Table 3.5). Interestingly, lag phase of Q167R seems to be affected by change in pH 
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to a lesser extent than that of MoWT. Taking into account that conditions which 
destabilise protein may result in lag phase extension, this seems to be consistent with 
lower overall stability of PrP conferred by Q167R mutation compared to MoWT, 
independently of pH. 
Unlike mouse prions, the formation of fibrils by Syrian hamster PrP could not be 
successfully induced at either pH 7.0 or pH 4.0 (see Figure 3.20). However after 
approximately 80-90 hours the ThT fluorescence exhibits minor increase from 
approximately 1.5 to 3.0-3.5 fluorescence units, which may be indicative of slow 
protofibril formation in the reaction mixture. 
Upon seeding with fibrillous material, both MoWT and Q167R exhibit significant 
reduction in length of average lag phase, from approximately 57 hours to 17 hours for 
MoWT and approximately 77 to 8 hours for Q167R at pH 7.0. At lower pH, the lag 
phases are similarly reduced from 83 hours to 9 hours for MoWT and from 82 hours to 
10 hours for Q167R. 
This is consistent with short PrP oligomers obtained from mature fibrils used in seeding 
providing a template for conversion of PrP
C
 into PrP
Sc
 and its subsequent aggregation 
and fibrilisation (Jones and Surewicz, 2005; Graham et al., 2010). 
In case of Syrian hamster, the minor change in ThT fluorescence attributed to 
protofibril formation also occurs significantly faster upon addition of pre-formed fibrils 
to the reaction mixture. The estimated length of average lag phase is decreased from 
100 hours to just above 30 hours. 
Consecutive seeding of reaction mixture with fibrilous material obtained at the end of 
first seeding experiment did not reduce the lag phase any further, independently of PrP 
construct (see Table 3.5), indicating that the presence of the seeding material itself is a 
key factor in PrP fibrilisation. 
Morphology of fibrils formed during secondary seeding experiment was investigated by 
electron microscopy (see Figure 3.21).  
Both MoWT and Q167R form elongated fibrils characteristic for prion aggregation in 
solution. While pH in general does not seem to have a significant effect on the rate of 
fibril formation and relatively mild effect on the duration of the lag phase, upon 
inspection of EM images it is clear that fibrils formed at pH 4.0 are shorter but much 
more abundant than those formed at pH 7.0 The fibrils of both MoWT and Q167R 
formed at pH 7.0 are longer but less abundant compared to pH 4.0. At lower pH, the 
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sheer number of short fibrils indicates that the total population of PrP molecules 
forming fibrils is higher. 
In case of Syrian hamster, while no fibrillous material seems to be present at pH 7.0, the 
short protofibrils are clearly visible in pH 4.0 sample. 
These findings are of utmost interest if one considers the prevailing opinion that 
formation of fibrils and their aggregation as well as subsequent formation of plaques is 
a protective mechanism evolved to avoid high toxicity of soluble oligomers (Buccianti 
et al., 2002; Kirkitadze et al., 2002; Caughey et al., 2003). Indeed, a growing body of 
evidence indicates that small, soluble oligomers are primary cytotoxic mechanism as 
opposed to fibril formation and deposition on cellular membranes (Chisea et al., 2001; 
Novitskaya et al., 2005). 
Consequently, increased propensity of fibril formation of mouse PrP could explain 
lower susceptibility of mice to prion diseases, compared to Syrian hamster. Since the 
Q167R mutant of mouse PrP exhibits higher propensity to form fibrils and the length of 
its lag phase is less affected by change in pH compared to wild-type construct, the 
structural destabilisation conferred by the point mutation seems to play a key role in 
disease-resistance mechanism. 
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Figure 3.18 Triplicates of ThT fluorescence curves of 120 μg/ml MoWT (see section 
3.2.7 for details on sample preparation) obtained as a result of three independent 
fibrilisation experiments conducted at pH 7.0 (A and C) and pH 4.0 (B and D). Panels 
A and B show fluorescence traces obtained as a result of unseeded fibrilisation.  
Panels C and D depict ThT fluorescence curves collected upon secondary seeding - that 
is seeding with fibrillous material obtained at the end of first seeding experiment. 
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Figure 3.19 Triplicates of ThT fluorescence curves of 120 μg/ml Q167R obtained as 
a result of three independent fibrilisation experiments conducted at pH 7.0 (A and C) 
and pH 4.0 (B and D). Panels A and B show fluorescence traces obtained as a result of 
unseeded fibrilisation.  
Panels C and D depict ThT fluorescence curves collected upon secondary seeding - that 
is seeding with fibrillous material obtained at the end of first seeding experiment. 
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Figure 3.20 Triplicates of ThT fluorescence curves of 120 μg/ml SHaWT obtained as 
a result of three independent fibrilisation experiments conducted at pH 7.0 (A and C) 
and pH 4.0 (B and D). Panels A and B show fluorescence traces obtained as a result of 
unseeded fibrilisation.  
Panels C and D depict ThT fluorescence curves collected upon secondary seeding - that 
is seeding with fibrillous material obtained at the end of first seeding experiment. 
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PrP 
construct 
pH Lag phase 
duration (h) 
Lag phase duration 
primary seeding (h) 
Lag phase duration 
secondary seeding (h) 
MoWT 7.0 57.4 ± 7.6 16.5 ± 2.9 17.2 ± 2.1 
4.0 82.8 ± 4.2 8.5 ± 2.0 7.3 ± 1.3 
Q167R 7.0 77.2 ± 4.7 7.8 ± 2.1 8.6 ± 1.7 
4.0 81.5 ± 2.3 10.2 ± 3.1 9.2 ± 1.1 
SHaWT 7.0 101.5 ± 15.6 36.7 ± 7.1 32.7 ± 9.7 
4.0 104.3 ± 18.0 33.6 ± 6.6 29.6 ± 8.5 
 
Table 3.5 Average lag phase duration observed during fibrilisation experiments of 
MoWT, Q167R and SHaWT at two different pH values. The length of each average lag 
phase was calculated by averaging the duration of lag phases from six independent 
fibrilisation experiments. Errors represent the standard error. 
 
 
PrP construct pH A B 
MoWT 7.0 12.32 0.48 
4.0 39.12 1.23 
Q167R 7.0 33.02 0.73 
4.0 45.25 0.74 
SHaWT 7.0 9.26 0.82 
4.0 9.03 0.91 
 
Table 3.6 T-parameter values obtained via statistical comparison of length of 
unseeded lag time with length of lag time upon primary seeding (column A) and length 
of lag time upon primary seeding with that of secondary seeding (column B) using T-
test. T-parameter values exceedint 1.812 allow for the null hypothesis to be rejected, 
thus confirming the statistically significant difference between thermodynamic 
parameters. For values below 1.812 the null hypothesis cannot be rejected, and 
consequently no statistically significant difference can be claimed.  
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Figure 3.21 Electron microscope images of fibrils formed by secondary seeding of 
MoWT (panels A and D), Q167R (panels B and E) and SHaWT (panels C and F). 
Panels A, B and C depict fibrils formed at pH 7.0, while panels D, E and F show fibrils 
formed at pH 4.0.  
The thin black bar visible in bottom left corner of each image represents a scale bar of 
100 nm. 
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3.4 Summary 
 
 In this study, three single tryptophan mutants of prion proteins from two 
different species – mouse prion constructs MoWT and Q167R and Syrian hamster PrP 
SHaWT - were used to investigate the kinetics early folding pathways as well as 
fibrilisation properties in an attempt to explain the mechanism of species barrier and 
disease resistance. All of the experiments were conducted at neutral pH as well as pH 
4.0 at which both mouse and Syrian hamster prions exhibit increased propensity to form 
a β-state intermediate which has been linked with disease susceptibility (Khan et al., 
2010). 
Equilibrium denaturation studies of PrP by urea showed that while at pH 7.0 both 
mouse constructs exhibit a transition characteristic for two-state mechanism, at pH 4.0 
the same transition is too broad to be explained by a two-state model. This indicates that 
at pH 4.0 mouse PrP may fold via an intermediate state which is not present at higher 
pH. 
The denaturant unfolding transition curve of Syrian hamster shows the propensity to 
form the β-state intermediate at pH 4.0, although at a lower extent than reported (Khan 
et al., 2010). 
 The pressure-jump studies of early folding kinetics of PrP determined that while 
at pH 4.0 the overall stability of all three PrP constructs is lower than at pH 7.0, the 
presence of β-state intermediate at lower pH is not visible in terms of folding kinetics. 
Lower fluorescence amplitudes as well as faster folding and unfolding rates of Q167R 
confirmed that the point mutation negatively affects overall stability of the protein. This 
effect was more pronounced at pH 7.0 than at pH 4.0. 
 Fibrilisation studies demonstrated that both MoWT and Q167R have 
significantly higher propensity to form fibrils compared to Syrian hamster PrP, 
particularly at pH 4.0. The total fibre amount at the end of fibrilisation experiment is 
highest for Q167R, indicating that the disease resistance mechanism conferred by this 
point mutation may be tied to its fibrilisation properties. Since formation of fibrils and 
their aggregation as well as subsequent formation of plaques is considered as a 
protective mechanism evolved to avoid high toxicity of soluble oligomers, highest total 
fibre amount may be indicative of increased propensity to form fibrils, which is a valid 
mechanism of increased disease resistance. 
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Chapter 4: Equilibrium and fibrilisation studies of Elk PrP 
 
 
4.1 Introduction 
 
Chronic wasting disease (CWD) is a prion disease of free-ranging wildlife, 
affecting a number of cervid species such as deer, elk and moose. It is the only prion 
disease identified so far which affect wild animals, which coupled with its high 
transmission rate and the fact that the exact prevalence remains currently unknown is of 
major concern in terms of epidemiology. While the possibility of transmission of CWD 
to other species remains unknown, only a handful of occurrences in human population 
could result in a new disease, much like transmission of bovine prions to humans 
resulted in an emergence of a variant of Creutzfeld-Jakobs disease.  
In transmission experiments, inoculation of squirrel monkeys with CWD prions induced 
the disease, yet transgenic mice expressing human PrP remained unaffected, indicating 
that the species barrier effect between humans and cervids is stronger than between 
cattle and humans (Kong et al., 2005; Sandberg et al., 2010).  
Although these findings reduced the perceived threat of cervid prion disease 
transmission to humans, recent protein misfolding cyclic amplification (PMCA) study 
showed that PrP
Sc 
generated in vitro by PMCA is infectious to wild-type animals and 
maintains the strain properties. PMCA is a technique which mimics prion replication in 
vitro at an accelerated speed, and can be used to generate, adapt, and stabilize new prion 
strains upon crossing species barriers in vitro (Green et al., 2008; Castilla et al., 2008). 
It was determined that serial round of PMCA produce the same adaptation of natural 
CWD prion strain as serial passages in vivo.  
These findings are of great importance in terms of current understanding of emergence 
and adaptation of new prion strains. Based on the available knowledge, two main routes 
of prion strain appearance may be defined: spontaneous route through interspecies 
transmission or by genetic mutations. These “first generation” prions are unstable 
strains that begin a progressive and gradual process of adaptation that may take several 
passages and years or decades to complete (Barria et al., 2011). Consequently, it is 
possible that the CWD prions spreading among the wildlife may at some point adapt to 
other species including humans, as demonstrated by PMCA experiments. 
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It is therefore of vital importance to understand the mechanism underlying CWD, 
particularly the conversion of cervid PrP
C
 into PrP
Sc
 and its transmission between 
individuals, as well as the species barrier existing between humans and cervids. 
Despite differences in primary sequence, the prion proteins from different 
species share almost identical tertiary and secondary structures composed of 
unstructured region and a small globular domain, with three α-helices and two short β-
sheets being the primary features (see Figure 4.1). Cervid prions, however, of which 
Elk PrP is a prime example, possess a unique structural feature which is not 
encountered in other species such as mice, hamsters, cats, dogs, bovine or humans 
(Gossert et al., 2005; Lysek et al., 2005). The loop region located between α-helix 
referred to as α2 and one of the short β-sheet strands known as β2 is very precisely 
defined in Elk PrP, while in other species it exhibits a high structural disorder (Gorfe 
and Caflisch, 2007). 
The source of this highly ordered structure can be traced to two amino acid substitutions 
at positions 170 and 174 with respect to PrP from other species. These findings are 
confirmed by the fact that upon introduction of the sequence of elk loop region into 
mouse PrP, the elk-mouse hybrid S170N/N174T is created, which contains a rigid loop 
region exactly mimicking that of Elk PrP (Gossert et al., 2005). Moreover, the loop 
region of Syrian hamster prion protein containing Asn residue at position 170 is also 
partially stabilised, similarly to S170N variant of human PrP. Unlike mutation at 
position 170, the introduction of Thr residue at position 174 in the loop region of mouse 
PrP if not coupled with second stabilising mutation, does not induce noticeable increase 
in stability. This indicates that it is the presence of serine residue at position 170 which 
is the key factor determining the stability of the entire loop region (Gorfe and Caflisch, 
2007). 
The stabilising effect of point mutations described above is a result of side-chain 
hydrogen bonds formed by residues within the loop region. Interestingly, the residues 
170 and 174 do not interact directly, but instead play key roles in formation of two 
separate groups of hydrogen bonds. The first group of two backbone hydrogen bonds is 
formed between residues 165–169, while the second group forms between side chains 
of residues 171 and 174 (Gossert et al., 2005). 
While the structural effects of both mutations may seem unimportant, a growing body 
of evidence suggests that the stability of the loop region may be important for the 
species barrier effect. The loop, and in particular the residue 170, are thought to play a 
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critical role as a „molecular switch‟ modulating prion transmission (Sigurdson et al., 
2009, 2010). 
Moreover, the higher flexibility of the loop region may be an important factor in the 
species barrier between cervids and other mammals.  
Recent molecular dynamics simulations suggest that a compact loop encompassing 
residues 166-175 is necessary for aggregation and formation of the infectious particles 
in elk, sheep and mouse prion strains. In the protofibril model, the stabilised turn is 
buried between two PrP monomers and makes contact with 35 neighboring residues. In 
absence of S170N and N174T mutations, the loop region is destabilised, and the 
resulting flexible, expanded loop disrupts the packing of the adjacent monomers, 
consequently impairing their incorporation into the protofibril (Scouras and Daggett, 
2012). Another potential disease-resistance mechanism is based on the possibility that if 
the PrP variants carrying loop-destabilising mutations become parts of the infectious 
seeds, the altered stability of their conformation prevents further oligomerisation (Ott et 
al., 2008). 
 Due to the fact that mouse PrP carrying S170N and N174T mutations is 
structurally very similar to elk PrP, it provides a valuable model for further 
investigations into the effects of loop-stabilising mutations. Interestingly, molecular 
dynamics simulations predicted the formation of elk-like rigid loop in MoPrP at pH 7.0, 
but not at pH 5.0 or pH 3.0, suggesting that the pH itself may affect oligomerisation and 
fibrilisation properties of some PrP species.  
Consequently, investigating equilibrium folding and fibrilization properties of a series 
of mouse PrP mutants carrying either or both loop-stabilising point mutations (S170N, 
N174T and double mutant S170N/N174T) and their comparison with wild-type mouse 
PrP should yield to our understanding of both the misfolding mechanisms associated 
with the disease‟s occurrence and the phenomenon of the species barrier and varied 
disease susceptibility.  
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Figure 4.1 Overlay of NMR structures of human PrP (olive), mouse PrP (yellow), 
Syrian hamster PrP (red) and elk PrP (grey) showing remarkable conservation of 
secondary and tertiary structure across different species.  
 
NMR structures were drawn from PDB files 1B10, 1QM0, 1XYW and 1XYX using 
UCSF Chimera package from the Resource for Biocomputing, Visualization and 
Informatics at the University of Califormia, San Francisco (supported by NIH P41 RR-
01081) (Pettersen et al., 2004). 
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Figure 4.2 Ribbon representation of NMR structure of globular domain of murine 
prion protein (residues 91-230). Main structural features are highlighted in colour with 
locations of two elk mutations highlighted using stick representation. Three main α-
helices are shown in red, with short antiparallel β-sheet highlighted in blue. 
 Residues N174 and S170 are highlighted in green.   
 
The NMR structure was drawn from PDB file 1XYX using UCSF Chimera package 
from the Resource for Biocomputing, Visualization and Informatics at the University of 
Califormia, San Francisco (supported by NIH P41 RR-01081) (Pettersen et al., 2004). 
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4.2  Materials and Methods  
 
 
4.2.1 Materials 
All chemicals were purchased from Sigma-Aldrich (Poole, UK) unless stated 
otherwise. 
 During the study, four full length mouse constructs carrying point mutations 
characteristic for elk PrP were used. The full length wild type mouse PrP is referred to 
as MoPrP in this chapter to avoid confusion with MoWT designation given to single 
tryptophan truncated construct Mo(91-230)F197W used in other chapters. Two 
constructs carrying single point mutations at positions 170 and 174 are named S170N 
and N174T respectively. Double mutant with both substitution mutations is referred to 
as S170N/N174T. 
Note that all of the mutations are described using elk numbering rather than mouse 
numbering, as commonly used in literature.  
All of the full-length prion protein constructs described above were supplied by 
Dr Andrew Gill (Roslin Institute, University of Edinburgh). 
 
 
4.2.2 Circular dichroism spectroscopy 
 Urea unfolding curves of MoPrP, N174T, S170N and S170N/N174T were 
constructed through a series of circular dichroism measurements similar to those 
described in section 3.2.3, with the following differences: 
Stock solutions of unfolded prion proteins were prepared in 9 M urea instead of 8 M 
urea used in section 3.2.3; other stock solutions, buffers, measurement procedures and 
data processing methods were identical.  
 
 
4.2.3 Fibrilization of PrP 
 Fibrilization studies of MoPrP, N174T, S170N and S170N/N174T were carried 
out according to the protocol stated in section 3.2.7. All buffers, measurement 
procedures and data processing methods were identical. 
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4.3 Results and Discussion 
 
 
4.3.1 Equilibrium denaturation of elk PrP followed by far-UV circular dichroism 
 
 Far-UV circular dichroism was used to construct denaturant unfolding transition 
curves of MoPrP, N174T, S170N and S170N/N174T at pH 7.0 and pH 4.0 in order to 
determine the range of denaturant concentrations best suited for fibrilisation 
experiments. 
Since fibril formation of PrP occurs in mildly denaturing conditions (Breydo et al., 
2008), urea concentrations corresponding to mid points of transition curves were 
selected.  
Two different pH values were used throughout the experiment in order to determine the 
effect of formation of rigid elk-like loop observed in mouse PrP at pH 7.0, but absent at 
lower pH (Scouras and Daggett, 2012). 
In absence of urea, all CD spectra show clear characteristics of predominantly α-
helical structure: two negative bands at 208 and 222 nm and a positive band at 195 nm 
(see Figures 4.3, 4.4, 4.5 and 4.6, panels B and C).  
Upon increase in denaturant concentration, the two bands indicative of α-helical 
structure lose their intensity, and a single strongly negative band appears around 205 
nm, which is characteristic for random coil structure. Changes in the third band at 195 
nm are not visible due to spectral properties of urea present in solutions at increasing 
concentrations, which prevented any reliable data to be collected below 200 nm.  At 
urea concentrations exceeding 6 M at pH 4.0 and 7 M at pH 7.0 any traces of α-helical 
structure are absent and entire spectrum corresponds to that of fully unfolded protein. 
The spectrum of wild type mouse PrP collected at pH 7.0 follows a typical the 
two-state transition model, characteristic for proteins which fold without any 
intermediates. The transition region visible in spectrum collected at pH 4.0 is much 
broader, stretching between 2.0 M and 6.5 M urea compared to 4.5 M and 7.0 M urea at 
pH 7.0 (see Figure 4.3). Such dramatic increase in the width of transition suggests that 
at lower pH the MoPrP can no longer be described by a two-state model. Moreover, a 
small plateau region visible at pH 4.0 between 4.5 M and 5.5 M urea concentrations 
indicates a presence of intermediate which is absent at higher pH. While unexpected, 
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these findings are consistent with the presence of β-state intermediate characteristic for 
truncated mouse and hamster PrP at low pH conditions (Khan et al., 2010). 
The folding curve collected at pH 4.0 is visibly shifted towards the lower urea 
concentration - at pH 7.0 the midpoint of the transition curve occurs at 5.9 M urea while 
at pH 4.0 it is shifted to 4.4 M urea. This difference can be easily explained by partial 
structural destabilisation of PrP in low pH conditions. 
 The behaviour of N174T construct at both pH values (Figure 4.4) is similar to 
that of MoPrP. The transition region of N174T at pH 7.0 is only marginally broader 
than that of MoPrP (between 4.0 M and 7.0 M for the latter compared to 4.5 M and 7.0 
M urea for the former), suggesting that both variants follow a two-state transition. 
Similarities between MoPrP and N174T extend to pH 4.0, at which the transition region 
of single mutant extends from 2.0 M urea to 6.5 M urea, much like in wild type mouse 
PrP. The presence of plateau region between 4.5 M and 5.5 M urea closely follows 
similar feature exhibited by MoPrP, and the midpoints of both transition curves (5.9M 
urea at pH 7.0 and 4.3 M urea at pH 4.0) occur at similar urea concentrations indicating 
almost identical structural destabilisation resulting from decrease in pH. All of these 
findings demonstrate that N174T substitution mutation has hardly any effect on stability 
and overall behaviour of mouse PrP, which is consistent with molecular dynamics 
simulations (Scouras and Daggett, 2012). 
 The equilibrium folding transition curves of S170N construct (Figure 4.5) fit 
well into a pattern set by MoPrP and N174T. The transition region of S170N at pH 7.0 
is slightly broader than N174T (3.5 M to 7.0 M for S170N and 4.0 M to 7.0 M urea for 
N174T), with the transition region at pH 4.0 remaining the same (2.0 M to 6.5 M urea). 
Interestingly, the plateau region occurs at slightly lower denaturant concentration 
(between 4.0 M and 5.0 M urea), but is quite well defined much like in two previous 
constructs. 
The decrease in stability conferred by the S170N mutation is much more visible, with 
midpoints of transition curves occurring at 5.5M urea at pH 7.0 and 3.8 M urea at pH 
4.0 
 As expected, the mutant S170N/N174T exhibits broadest transition at pH 7.0 
(3.0 M to 7.0 M urea), with pH 4.0 transition very similar to that of wild type and single 
mutants (see Figure 4.6). The broadness of transition region at both pH 7.0 and pH 4.0 
suggests that unlike MoPrP and N174T, the double mutant does not follow a typical 
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two-step transition, instead behaving much like Syrian hamster PrP which is known to 
fold via intermediate. 
The plateau region of pH 4.0 folding curve occurs between 4.5 M and 5.5 M urea, much 
like in N174T and MoPrP, again hinting at the presence of intermediate unique to low 
pH conditions. It should be noted that the plateau region observed in all constructs at 
pH 4.0 is narrower than expected - previously reported plateau region extends between 
2.5 and 4 M urea (Khan et al., 2010). 
All of the above findings are of particular interest in terms of the effect of loop-
stabilizing mutations on overall stability of the protein. Upon comparison of transition 
curves of MoPrP, N174T, S170N and S170N/N174T it becomes apparent that the 
mutations which stabilize the loop region result in expansion of the transition region of 
the folding curves constructed at pH 7.0. This in turn suggests that stabilisation of the 
loop region increases the overall propensity of given protein to from an intermediate, as 
implied by the increase in width of the transition region of folding curves. 
From recent studies of truncated constructs of PrP from different species including 
mouse and Syrian hamster, it is known that the increased propensity to form β-state 
intermediate correlates with increased disease susceptibility (Khan et al., 2010). 
Consequently, it is possible that increased loop stability results in higher propensity to 
form such intermediate, which leads to increased disease susceptibility. Such 
mechanism corresponds to the differences in susceptibilities between mouse and Syrian 
hamster. Since wild type mouse PrP lacks any stabilising mutations in the loop region, 
it exhibits lower propensity to form β-state intermediate and lower disease susceptibility 
compared to Syrian hamster PrP in which Asn residue at position 170 increases loop 
stability. Alternatively, the propensity to form intermediate could be an observable side 
effect rather than a direct cause of loop stabilisation, which correlates with 
susceptibility to prion disease  
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Figure 4.3 Denaturant unfolding transition curves of MoPrP (A) followed by far-
UV circular dichroism at pH 7.0 (blue) and at pH 4.0 (red). Each data point represents 
the value of [θ]MRW at 222 nm normalized to fraction unfolded as described in section 
3.2.3. Error bars show the standard error of two independent experiments 
Panels B shows CD spectra collected at pH 7.0 in absence of denaturant (red), in 
presence of 1M urea (green), 2 M urea (yellow), 3 M urea (blue), 4 M urea (pink), 5 M 
urea (cyan), 6 M urea (brown), 7 M urea (dark green), 8 M urea (dark yellow) and 9 M 
urea (dark blue). 
Panels C shows CD spectra collected at pH 4.0 in absence of denaturant (red), in 
presence of 1M urea (green), 2 M urea (yellow), 3 M urea (blue), 3.5 M urea (pink), 4 
M urea (cyan), 4.5 M urea (brown), 5.0 M urea (dark green), 5.5 M urea (dark yellow) 6 
M urea (dark blue) and 7 M urea (purple). 
B 
A 
C 
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Figure 4.4 Denaturant unfolding transition curves of N174T (A) followed by far-
UV circular dichroism at pH 7.0 (blue) and at pH 4.0 (red). Each data point represents 
the value of [θ]MRW at 222 nm normalized to fraction unfolded as described in section 
3.2.3. Error bars show the standard error of two independent experiments 
Panels B shows CD spectra collected at pH 7.0 in absence of denaturant (red), in 
presence of 1M urea (green), 2 M urea (yellow), 3 M urea (blue), 4 M urea (pink), 5 M 
urea (cyan), 6 M urea (brown), 7 M urea (dark green), 8 M urea (dark yellow) and 9 M 
urea (dark blue). 
Panels C shows CD spectra collected at pH 4.0 in absence of denaturant (red), in 
presence of 1M urea (green), 2 M urea (yellow), 3 M urea (blue), 3.5 M urea (pink), 4 
M urea (cyan), 4.5 M urea (brown), 5.0 M urea (dark green), 5.5 M urea (dark yellow) 6 
M urea (dark blue) and 7 M urea (purple). 
A 
B C 
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Figure 4.5 Denaturant unfolding transition curves of S170N (A) followed by far-
UV circular dichroism at pH 7.0 (blue) and at pH 4.0 (red). Each data point represents 
the value of [θ]MRW at 222 nm normalized to fraction unfolded as described in section 
3.2.3. Error bars show the standard error of two independent experiments 
Panels B shows CD spectra collected at pH 7.0 in absence of denaturant (red), in 
presence of 1M urea (green), 2 M urea (yellow), 3 M urea (blue), 4 M urea (pink), 5 M 
urea (cyan), 6 M urea (brown), 7 M urea (dark green), 8 M urea (dark yellow) and 9 M 
urea (dark blue). 
Panels C shows CD spectra collected at pH 4.0 in absence of denaturant (red), in 
presence of 1M urea (green), 2 M urea (yellow), 3 M urea (blue), 3.5 M urea (pink), 4 
M urea (cyan), 4.5 M urea (brown), 5.0 M urea (dark green), 5.5 M urea (dark yellow) 6 
M urea (dark blue) and 7 M urea (purple). 
A 
B C 
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Figure 4.6 Denaturant unfolding transition curves of S170N/N174T (A) followed 
by far-UV circular dichroism at pH 7.0 (blue) and at pH 4.0 (red). Each data point 
represents the value of [θ]MRW at 222 nm normalized to fraction unfolded as described 
in section 3.2.3. Error bars show the standard error of two independent experiments 
Panels B shows CD spectra collected at pH 7.0 in absence of denaturant (red), in 
presence of 1M urea (green), 2 M urea (yellow), 3 M urea (blue), 4 M urea (pink), 5 M 
urea (cyan), 6 M urea (brown), 7 M urea (dark green), 8 M urea (dark yellow) and 9 M 
urea (dark blue). 
Panels C shows CD spectra collected at pH 4.0 in absence of denaturant (red), in 
presence of 1M urea (green), 2 M urea (yellow), 3 M urea (blue), 3.5 M urea (pink), 4 
M urea (cyan), 4.5 M urea (brown), 5.0 M urea (dark green), 5.5 M urea (dark yellow) 6 
M urea (dark blue) and 7 M urea (purple). 
A 
B C 
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PrP construct pH ΔG0 kJ mol
-1
 [D]50% 
MoPrP 7.0 27.8 ±2.2 5.9 ± 0.2 
 4.0 22.1 ±1.8 4.4 ± 0.2 
N174T 7.0 26.4 ± 1.9 5.9 ± 0.3 
 4.0 20.5 ± 2.0 4.3 ± 0.2 
S170N 7.0 23.9 ± 2.1 5.5 ± 0.2 
 4.0 15.2 ± 1.4 4.0 ± 0.1 
S170N/N174T 7.0 17.1 ± 0.9 5.3 ± 0.3 
 4.0 13.3 ± 0.8 4.0 ± 0.1 
 
Table 4.1 Thermodynamic parameters extracted from denaturant unfolding 
transition curves of MoPrP, N174T, S170N and S170N/N174T. 
The free energy of unfolding in the absence of urea (ΔG0) was calculated from the two-
state analysis of denaturant unfolding transition curves. 
 
 
 
PrP construct ΔG0 kJ mol
-1
 [D]50% 
MoPrP 2.94 7.5 
N174T 3.02 6.28 
S170N 4.87 9.49 
S170N/N174T 4.46 5.81 
 
Table 4.2 T-parameter values obtained via statistical analysis of thermodynamic 
parameters from Table 4.1 using T-test. For each PrP construct the thermodynamic 
parameters at pH 7.0 and pH 4.0 were compared in order to identify any statistically 
significant differences. T-parameter values exceedint 2.920 allow for the null 
hypothesis to be rejected, thus confirming the statistically significant difference 
between thermodynamic parameters. For values below 2.920 the null hypothesis cannot 
be rejected, and consequently no statistically significant difference can be claimed.  
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4.3.2 Fibrilisation studies of PrP 
 
 In this study, a series of fibrilisation experiments was conducted in an attempt to 
correlate the effects of mutations which alter the stability of the unstructured loop 
connecting helix α2 with β-strand β2 of prion protein with propensity to form fibrils. 
Fibrilisation experiments involving MoPrP, N174T, S170N and S170N/N174T were 
carried out at pH 7.0 at which the elk-like stabilised loop is known to form in mouse 
PrP, as well as at pH 4.0 which destabilizes the loop.  
Formation of fibrils was monitored by ThT fluorescence assays (Gill et al. 2009).  
A series of urea concentrations were used throughout the experiment in order to 
determine the optimal conditions for fibril formation at given pH (see Figure 4.7). As 
expected, denaturant concentrations corresponding to the midpoint of denaturant 
transition curves were determined to be most effective in terms of promoting 
fibrilisation.The length of the lag phase was not affected in any significant manner, 
however the lag phases were slightly shorter for 6M urea at pH 7.0 and 4 M urea at pH 
4.0 (data not shown). This was most likely due to the fact that at urea concentration 
close to midpoint of unfolding curve, the equilibrium between folded and unfolded 
conformations of proteins in solution would be poised in such a way that population of 
partially unfolded PrP molecules which could be recruited into fibril formation was 
highest. Consequently, subsequent experiments were conducted at 6 M urea 
concentration for pH 7.0 and 4 M urea for pH 4.0. Initial fibrilization experiments were 
conducted with and without 200 mm NaCl which mimicked the salt concentrations 
present in cells, however presence or absence of salt was determined to have no 
quantifiable effect on length of lag phase, rate of fibril formation or their morphology. 
The ThT fluorescence traces obtained during fibrilisation experiments are shown in 
Figures 4.8, 4.9, 4.10 and 4.11. 
In unseeded experiments, both MoPrP and N174T  failed to form fibrils within 200 
hours of incubation, at any of investigated urea concentrations and pH values.  S170N 
exhibited limited fibrilisation capacity, with slow fibril formation after approximately 
20 hours at pH 7.0 and 40-60 hours at pH 4.0. The double mutant of S170N/N174T 
showed by far the highest propensity to form fibrils, with ThT fluorescence indicating 
fibril formation after 40-60 hours at pH 4.0 and 90+ hours at pH 7.0. These data 
correlate well with structural effects of each mutation, with mutations conferring 
highest loop rigidity also exhibiting highest propensity to form fibrils. 
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As mentioned before, if the loop region is flexible, the packaging of monomers and 
their oligomerisation and incorporation into protofibrils is impaired (Ott et al., 2008; 
Scouras and Daggett, 2012). The lower the loop rigidity, the higher the negative effect 
on fibril formation, as demonstrated by MoPrP and N174T. In both of these constructs, 
the loop is not stabilised at all and consequently the formation of oligomers and 
protofibrils occurs very slowly. The S170N construct, with partially rigid loop exhibits 
limited fibril formation and the double mutant in which the loop is fully stabilised 
forming elk-like turn fibrilizes well.  
Consequently, subsequent experiments involved seeding of all of the constructs with 
fibrillous material obtained at the end of S170N/N174T fibrilisation in order to test 
whether loop rigidity affects formation of fibrils even in presence of pre-formed 
protofibrils. 
Both MoPrP and N174T formed fibrils upon seeding, although the ThT fluorescence 
traces suggest that the process was somewhat irregular, particularly at low pH. 
The S170N construct responded well to addition S170N/N174T seeds, with fibrils 
forming within 20 hours at pH 7.0 and 30-40 hours at pH 4.0.  
Adding seeds to reaction mixture of double mutant decreased the lag phase 
significantly, particularly at pH 4.0 (see Table 4.3) which is consistent with short PrP 
oligomers obtained from mature fibrils providing a template for conversion of PrP
C
 into 
PrP
Sc
 and subsequent aggregation and fibrilisation (Jones and Surewicz, 2005; Graham 
et al., 2010). 
Morphology of fibrils formed during seeding experiment was investigated by electron 
microscopy (see Figure 4.12).  
As suggested by ThT fluorescence traces, no fibrils were observed in unseeded samples 
of MoPrP and N174T, independently of pH. Upon addition of S170N/N174T seeds, 
MoPrP formed several relatively sparse clusters of straight fibrils, indicating that 
increased flexibility of loop region impairs fibril formation to limited extent, even if 
pre-formed protofibrils are present. The fibrils formed by N174T during seeding 
experiments were slightly longer than those formed by MoPrP, while also forming 
denser network.  
The S170N mutant was the first construct (in order of increasing loop stability) 
observed to form fibrils at both pH 7.0 and pH 4.0 even without seeding.  Although 
scarce and very short, the fibrils nonetheless demonstrated that increasing the stability 
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of the loop region is necessary for oligomerisation and formation of protofibrils. 
Addition of S170N/N174T seeds resulted in formation of much greater number of 
longer and more pronounced fibrils. 
The double mutant S170N/N174T was the only construct which demonstrated high 
fibrilisation propensity in absence of seeding material. Fibrils formed in unseeded 
experiments are very similar in appearance to those formed after addition of pre-formed 
fibrillous material. This indicates that except for providing additional templates for 
PrP
Sc
 recruitment and incorporation therefore decreasing lag phase, seeds have little 
impact on the quality of fibrils themselves. Interestingly, some of the EM images of 
S170N/N174T samples seem to reveal the presence of small oligomeric particles (see 
Figure 4.13), consistently with high fibrilisation propensity exhibited by the construct. 
All of the above findings, while unexpected, provide a fascinating insight into 
structural features of PrP which may be key factors determining disease susceptibility. 
Molecular dynamics simulations strongly suggest that a compact loop between helix α2 
and β-sheet β2 is necessary for aggregation and formation of the infectious 
protofibrillar species in several different species, particularly elk and sheep. Nearly all 
of the point mutations which confer increased disease resistance perturb the structure of 
the loop, preventing the initial formation of infectious oligomers (Scouras and Daggett, 
2012). 
Thus, it is possible that while flexibility of loop region affects nucleation and 
oligomerisation, consequently preventing fibril formation from “free” PrP molecules, 
its effect may be limited if the pre-formed protofibrils are already present in the reaction 
mixture. In such case loop stability would affect spontaneous generation of prions in the 
organism, as well as disease transmission via small oligomers. While flexible loop 
region would be likely to prevent spontaneous nucleation and/or oligomerisation and 
thus protofibril formation due to impaired packaging of PrP monomers, it would not 
affect pre-formed protofibrils originating from external source. 
Consequently, the disease-resistant, mutations which decrease loop rigidity would have 
significant effect on fibril formation in unseeded fibrilisation, but their impact on fibril 
formation in presence of seeds would be much more limited. The difference would be 
due to the fact that already pre-formed seeds may recruit PrP
C
 from environment and 
incorporate it into growing fibril without the need for nuclei and oligomers to form first 
from free PrP
C
 molecules. Such model correlates well with the experimental data 
obtained in this study. 
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These findings seem to be counterintuitive, if one considers the prevailing opinion that 
formation of fibrils and their aggregation as well as subsequent formation of plaques is 
a protective mechanism evolved to avoid high toxicity of soluble oligomers (Buccianti 
et al., 2002; Kirkitadze et al., 2002; Caughey et al., 2003). Loop destabilisation, being a 
potential protective mechanism, should not affect fibrilisation and decrease its potential 
to trap neurotoxic particles. It is these soluble oligomers, however, that are thought to 
be the primary cytotoxic mechanism as opposed to fibril formation and deposition on 
cellular membranes (Chisea et al., 2001; Novitskaya et al., 2005). Consequently, while 
the protective mechanism based around loop-destabilizing mutations could potentially 
lead to increased susceptibility to the disease due to the fact that the neurotoxic species 
are not trapped in fibrils, it is the oligomer formation that is primarily affected. 
Thus, proposed source of disease resistance conferred by loop-destabilising mutations is 
the decreased formation of neurotoxic particles in the organism as well as diminished 
ability of infectious oligomers from both inside and outside to propagate 
oligomerisation of PrP.  
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Figure 4.7 Total fibre load of S170N at pH 7.0 (blue) and pH 4.0 (red) across a 
range of denaturant concentrations. Bars represent the final ThT fluorescence observed 
in each sample which corresponds to total fibre load after 190 hours of incubation. 
All bars show the average ThT fluorescence values from three independent fibrilisation 
experiments. 
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Figure 4.8 Triplicates of ThT fluorescence curves of MoPrP obtained as a result of 
three independent fibrilisation experiments conducted at pH 7.0 (A and C) and pH 4.0 
(B and D). Panels A and B show fluorescence traces obtained as a result of unseeded 
fibrilisation.  
Panels C and D depict ThT fluorescence curves collected upon seeding with 
S170N/N174T fibrillous material. 
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Figure 4.9 Triplicates of ThT fluorescence curves of N174T obtained as a result of 
three independent fibrilisation experiments conducted at pH 7.0 (A and C) and pH 4.0 
(B and D). Panels A and B show fluorescence traces obtained as a result of unseeded 
fibrilisation.  
Panels C and D depict ThT fluorescence curves collected upon seeding with 
S170N/N174T fibrillous material. 
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Figure 4.10 Triplicates of ThT fluorescence curves of S170N obtained as a result of 
three independent fibrilisation experiments conducted at pH 7.0 (A and C) and pH 4.0 
(B and D). Panels A and B show fluorescence traces obtained as a result of unseeded 
fibrilisation.  
Panels C and D depict ThT fluorescence curves collected upon seeding with 
S170N/N174T fibrillous material. 
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Figure 4.11 Triplicates of ThT fluorescence curves of S170N/N174T obtained as a 
result of three independent fibrilisation experiments conducted at pH 7.0 (A and C) and 
pH 4.0 (B and D). Panels A and B show fluorescence traces obtained as a result of 
unseeded fibrilisation.  
Panels C and D depict ThT fluorescence curves collected upon seeding with 
S170N/N174T fibrillous material. 
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PrP construct pH Lag phase duration (h) Lag phase duration of 
seeded fibrilisation (h) 
MoPrP 7.0 N/A 47.6 ± 4.2 
4.0 N/A 52.3 ± 5.1 
N174T 7.0 N/A 36.7 ± 4.7 
4.0 N/A 95.3 ± 17.5 
S170N 7.0 38.8 ± 7.6 18.1 ± 3.8 
4.0 51.3 ± 9.4 24.2 ± 8.7 
S170N/N174T 7.0  53.2 ± 10.8 20.5 ± 2.7 
4.0 97.5 ± 7.9  24.6 ± 3.1 
 
Table 4.3 Average lag phase duration observed during fibrilisation experiments of 
MoPrP, N174T, S170N and S170N/N174T at two different pH values. The length of 
each average lag phase was calculated by averaging the duration of lag phases from 
three independent fibrilisation experiments. Errors represent the standard error. 
 
 
 
PrP construct pH A 
MoPrP 7.0 N/A 
4.0 N/A 
N174T 7.0 N/A 
4.0 N/A 
S170N 7.0 4.22 
4.0 3.66 
S170N/N174T 7.0 5.09 
4.0 14.88 
 
Table 4.4 T-parameter values obtained via statistical analysis of thermodynamic 
parameters from Table 4.1 using T-test. T-parameter values exceedint 1.812 allow for 
the null hypothesis to be rejected, thus confirming the statistically significant difference 
between thermodynamic parameters. For values below 1.812 the null hypothesis cannot 
be rejected, and consequently no statistically significant difference can be claimed.  
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Figure 4.12 Electron microscope images of fibrils formed upon seeding of MoPrP 
(A), N174T (B), S170N (D) and S170N/N174T (F). Fibrils formed by S170N and 
S170N/N174Tduring unseeded experiments are shown in panels C and E respectively.  
All panels depict fibrils formed at pH 7.0. The thin black bar visible in bottom left 
corner of each image represents a scale bar of 100 nm. 
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Figure 4.13 Electron microscope images of possible small oligomeric particles 
present in S170N/N174T sample. 
Panel A depict particles present at pH 7.0, panel B at pH 4.0. 
The thin black bar visible in bottom left corner of each image represents a scale bar of 
50 nm (A) and 100 nm (B). 
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4.4 Summary 
 
 In this study, three mutants and wild type mouse prion proteins were used to 
investigate the effects of several loop-stabilising mutations on equilibrium folding and 
fibrilization properties or PrP. 
Equilibrium denaturation studies of the four constructs showed that mutations 
which confer increased loop rigidity (S170N and S170N/N174T) result in expansion of 
the transition region of the folding curves constructed at pH 7.0. This in turn suggests 
that higher rigidity of the loop region increases the overall propensity of given protein 
to from an intermediate, while at the same having a net negative effect on overall 
protein stability, as implied by the increase in width of the transition region of folding 
curves and decrease in [D]50%. From recent studies of truncated constructs of PrP from 
different species including mouse and Syrian hamster, it is known that the increased 
propensity to form β-state intermediate correlates with increased disease susceptibility 
(Khan et al., 2010). Consequently, it is possible that increased loop rigidity results in 
higher propensity to form such intermediate, which leads to increased disease 
susceptibility. Such mechanism corresponds to the differences in susceptibilities 
between mouse PrP in which the loop region is fully flexible and Syrian hamster which 
carries loop stabilizing Asn residue at position 170. 
Fibrilisation studies demonstrated that increasing loop rigidity correlates 
negatively with propensity to form fibrils, irrespective of pH, but only in the absence of 
seeding material. Upon addition of seeds, all of the constructs demonstrated good 
fibrilisation capacity only slightly dependent on flexibility of the loop region. 
These findings are consistent with molecular dynamics simulations which suggest that a 
compact loop between helix α2 and β-sheet β2 is necessary for aggregation and 
formation of infectious protofibrils. Point mutations which confer increased disease 
resistance perturb the structure of the loop, preventing the initial formation of infectious 
oligomers (Scouras and Daggett, 2012). Thus, proposed source of disease resistance 
conferred by loop-destabilising mutations is the decreased formation of neurotoxic 
particles in the organism as well as diminished ability of infectious oligomers from both 
inside and outside to propagate oligomerisation of PrP.  
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Chapter 5: Development and Testing of a Continuous-Flow 
Instrument for Investigation of Sub-millisecond Reactions 
 
5.1  Introduction 
 
From the simplest enzymatic reactions to complex folding processes associated with 
formation of multimeric protein complexes, important information can be gained about 
the pathways of chemical and biological reactions by studying the rates at which they 
occur. 
Vast majority of biological and chemical reactions are studied in aqueous environment 
or other relevant solution as this not only offers a convenient working medium, but also 
reflects the conditions in which those processes take place in vivo. 
A great number of biochemical processes occurs in sub-second timescale, therefore 
requiring a specialised instrumentation for efficient and effective study. 
Stopped-flow is one of the most common and effective methods of investigating 
rapid reactions in aqueous environment thanks to its flexibility, sample economy 
(usually requiring only few millilitres of sample to yield reliable data) and adaptability. 
It relies on physical mixing of two or more reagents to initiate a reaction which can then 
be followed using a number of spectroscopic techniques such as tryptophan 
fluorescence and Raman spectroscopy (Sergiu et al., 2006). 
An important aspect of stopped-flow systems is the long observation window they 
provide, allowing them to monitor the progress of the reaction from one millisecond up 
to a few minutes. The earliest time at which scientifically reliable data can be collected 
following the onset of the reaction (referred to as “dead time” of the instrument) 
depends primarily on how quickly and effectively the two or more reagents can be 
mixed, making efficient and thorough mixing one of the most important aspects of the 
method.  
Even with most recent developments in the field, SF instruments cannot reliably 
investigate processes shorter than 1 millisecond such as the earliest events of protein 
folding pathways. This is due to the fact that factors associated with flow of the 
reagents such as mixing and dissipation of mixing artefacts after the solution is stopped. 
Although one millisecond dead time is sufficient for most applications, a number of 
biologically important reactions such as the earliest processes of protein folding 
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pathways take place within the dead time of stopped-flow instruments. Thus, 
considerable efforts were made to create instruments capable of accessing the sub-
millisecond timescale and shed light some light on those elusive events. 
Currently there are only three methods capable of following sub-millisecond reactions: 
temperature-jump, pressure-jump and continuous-flow, all of which have successfully 
been used to investigate very rapid protein folding (Jacob et al., 1999; Nolting et al., 
1997). 
A continuous-flow instrument relies on the same principle as stopped-flow – 
that is mixing of two or more reagents to initiate a reaction and utilizing a number of 
spectroscopic methods to follow its progress. While in case of a stopped-flow 
instrument the data collection can only begin after the flow of mixing reactants has 
stopped and any mixing artefacts thus created have cleared, in continuous-flow the data 
are collected by imaging a whole flow-channel through which the reagents travel. This 
allows both the onset and progress of the reaction to be observed at once, as the 
distance the mixed solution has travelled through the flow channel correspond to the 
progress of the reaction. As the reagents are continuously pumped through the flow 
channel, no mixing artefacts are created as a result of rapidly stopping the flow, 
allowing for the data collection to begin as soon as the reagents are fully mixed. This 
allows considerably faster reactions to be monitored, at the expense of increased sample 
consumption, as the reagents have to be continuously delivered throughout the course 
of the measurement.  
Another potential disadvantage is the reduced timeframe at which the reaction can be 
monitored, as the observation window is limited by the length of the flow channel and 
flow rate of the solutions. Continuous-flow instruments are thus not suitable for 
investigating reactions longer than few seconds, as longer observation time would 
require unsuitably long flow channels. 
In order to access the sub-millisecond timescale and observe reactions 
inaccessible to stopped-flow, mixing in continuous flow must be as rapid and thorough 
as possible, making an efficient and effective mixer the most important part of the 
instrument and at the same time a main limiting factor as far as performance is 
concerned.  
A continuous-flow instrument requires a delivery system for reagents, a mixer coupled 
to an observation channel, as well as an appropriate light source and a detection system 
(Figure 2). Solutions are delivered to the mixer from at least two separate reservoirs 
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(usually syringes) driven preferably by a stepper-motor device (this offers more stable 
flow velocities than those generated by pressure-driven devices). Upon reaching the 
mixer, solutions are mixed as rapidly and as efficiently as possible starting the reaction, 
and enter the observation channel where reaction progresses as it travels down the 
channel. The reaction is then measured through an appropriate spectroscopic method. 
The most common observation methods widely used in biological and chemical 
applications rely on absorbance or fluorescence changes during the reaction. 
A typical layout of a continuous-flow instrument assembled for reactions detected 
through fluorescence changes is shown in Figure 5.1. In this configuration a light 
source, typically a strong mercury or mercury-xenon arc lamp, is used and specific 
wavelengths selected with a monochromator. Fluorescence from the sample is collected 
through a set of lenses and optical filters on the sensor of a CCD camera. The output of 
a continuous-flow instrument is an image of the reaction progressing along the 
observation channel. 
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Figure 5.1.  Schematic diagram of a continuous-flow instrument which uses 
fluorescence measurements to follow the reaction. The stepper motor (A) drives two 
syringes (B) which supply reactant solutions to the mixer (C). The mixed solution flows 
up the flow-channel (D) where it is illuminated by monochromatic light provided by 
mercury-xenon lamp (E) coupled to the monochromator (F). Excitation light is focussed 
by the cylindrical lens (G). Fluorescence is collected at right-angles to the incident 
light, passes through filters (H), is focussed by a lens and collected by the CCD (I). 
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Protein folding involves a number of submillisecond processes, such as secondary 
structure formation and intrachain diffusion (Bieri and Kiefhaber, 1999) which are too 
rapid to be reliably investigated using stopped-flow instruments, but can be easily 
followed by continuous-flow. Studies such as investigation of early folding pathways of 
β-lactoglobulin (Kuwata et al., 2001), acyl-CoA binding protein (Teilum et al., 2002), 
and cytochrome c (Takahashi et al., 1997) have all benefited greatly from application of 
continuous flow method. Another protein, kinetics of which could be reliably 
investigated using continuous-flow instrument, is the prion protein. 
It is known that at 20 °C prion proteins fold within 1-2 miliseconds, which is well 
within the dead time of most commercial stopped-flow instruments (Wildegger et al., 
1999). Thus, characterisation of kinetics of early folding pathways of PrP requires 
application of techniques capable of accessing the sub-milisecond timescale, such as 
pressure jump or continuous-flow. 
Therefore, in collaboration with Warwick School of Engineering and the company TgK 
Scientific (Salisbury, UK), the aim of this study was to further develop a CF instrument 
assembled in-house (Pinheiro et al., 2001). Previous studies (Pinheiro et al., 2001, 
Jenkins, 2006) have highlighted the requirement of thorough understanding of mixing 
process itself in order to decrease the dead time of continuous-flow apparatus well 
below a milisecond. Thus, in collaboration with Warwick School of Engineering a 
simultnaneous study into turbulent mixing in micromixers was conducted, and its 
findings utilized in designing and manufacturing new continuous-flow apparatus. 
This new apparatus would be capable of accessing the microsecond timeframe 
necessary to characterise the kinetic folding pathway of PrP. The instrument would also 
have wider applications for any sub-millisecond process detectable by fluorescence.  
 
This chapter describes the process of designing, microfabricating and testing of the 
efficiency of different new mixers developed jointly with TgK Scientific, as well as 
proving the effectiveness and reliability of its hardware components and custom-written 
computer software, with the view of developing a commercially applicable CF 
instrument.  
Tests described in this chapter make use of a fluorescence quenching reaction of a 
soluble, monomeric derivative of the amino acid tryptophan N-acetyl-L-
tryptophanamide (NATA) with N-bromosuccinimide (NBS) which is widely considered 
a standard fluorescence decay reaction (Peterman, 1979). 
158 
 
5.2 Materials and Methods 
 
5.2.1 Materials 
 
All solutions used in the continuous-flow instrument were made using distilled 
water passed through a cellulose acetate filter with 0.2 μM pore size (Whatman, Clifton, 
NJ, USA). Prepared solutions were filtered again directly prior to their introduction into 
the continuous-flow apparatus in order to prevent the entry of any particulate matter 
into the system which could potentially obstruct the narrow tubing used to carry 
solutions. Both NATA and NBS were purchased from Sigma in powdered form. 
Solutions of NBS were made fresh on the day of the experiment by first dissolving the 
necessary quantity of NBS powder into a small amount (roughly 0.5 - 1 ml) of 
dimethylformamide (DMF) (BDH, Poole, UK). The NBS solution was then diluted with 
filtered distilled water to the desired concentration and stored in the dark and cool. 
 
 
5.2.2 Components and assembly of the continuous-flow instrument 
 
The continuous-flow instrument assembled in this group (Pinheiro et al., 2001) 
which served as the basis for new, upgraded apparatus (Figure 1) was originally based 
on that of a collaborator‟s (Shastry et al., 1998). 
 
 
5.2.2.1 Instrument layout 
 
The instrument described in this chapter follows a typical layout of continuous-
flow apparatus assembled for investigating reactions which can be followed by 
monitoring detected fluorescence changes in reaction mixture.  
Excitation light used to induce fluorescence in the sample is provided by a 103 Watt 
mercury-xenon (Hg-Xe) arc lamp (Osram, Germany) and gathered by a half-spherical 
reflector and directed towards the water filter which blocks the infrared part of the light 
spectrum. The light beam is then passed through monochromator (Photon Technology 
International, Birmingham, NJ, USA) which is used to select the relevant wavelength 
for fluorescence excitation.  
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A cylindrical lens (Oriel, Stratford, CT, USA) positioned between the monochromator 
and the flow-cell is used to focus the incident beam exiting the monochromator into the 
“heart” of the machine which is a single-piece unit which combines the mixer 
(microfabricated by Warwick School of Engineering) coupled to a quartz flow-cell 
(Hellma Cells, Inc.) using a stainless steel holder. 
A stepper-motor drive unit (TgK Scientific) is used to deliver reactants from solution 
reservoirs (usually two 5 ml and one 0.5 ml syringes) to the mixer and flow-cell. The 
mixer is oriented so that the mixed solutions flow upwards against gravity and under the 
force of the drive, allowing to minimise any cavitation or gravity effects on the flow of 
the reagents. The stepper-motor drive is capable of delivering a precisely controlled and 
consistent flow over the course of experiment, and its gearing provides access to a 
range of flow velocities varying from 4 ms
-1
 up to 14 ms
-1
.  
Reactants are carried to the mixer through a PEEK tubing (Upchurch Scientific, WA, 
USA) from three syringes driven by the stepper-motor drive unit. 
Mixing of the solution takes place in the microfabricated mixer, with the flow forcing 
the reaction mixture down the channel in the quartz flow-cell (also referred to as 
observation channel) where progress of the reaction can be monitored. 
Fluorescence from the sample passes through a selective filter which blocks light with 
wavelengths shorter than 320 nm (WG320 filter, Schott GmbH, Mainz, Germany). 
Filtered fluorescent light is then focussed by another lens (Oriel), and collected at 90° to 
the incident excitation light by a digital camera (Retiga-2000R, QImaging Scientific, 
Surrey, Canada). The camera is equipped with a charge coupled device (CCD) sensitive 
to ultra-violet light (model Kodak Sensors KAI-2020), with an array of 1600 × 1200 
pixels. The camera system was electrically cooled to 25 °C below ambient temperature 
to prevent thermally-induced noise. 
The entire instrument is assembled on an optical bench for stability (Melles Griot, 
Irvine, CA, USA). 
Evaluations of the mixing efficiency and dead time of the instrument were 
carried out using the so-called asymmetric mixing mode typical of protein folding 
experiments. In such an experiment an aqueous solution containing unfolded protein in 
denaturant would be loaded at a relatively high concentration into the small 0.5 ml 
syringe and then rapidly diluted by an excess of buffer, supplied from the two larger 
syringes (2.5 ml each).  
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Due to the fact that the output of two larger syringes containing buffer is combined at a 
PEEK tubing junction before reaching the mixer, only two input lines into the mixer are 
required (consequently simplifying its design).  
Such configuration gives a final mixing ratio of buffer to denaturant of 10:1 (a dilution 
factor of 11-fold), which is usually adequate for protein folding experiments. 
Alternative dilution factors can be achieved by filling only a single syringe with buffer 
or by replacing small 0.5 ml syringe used to store protein solutions with larger one. 
All of the syringes are contained within a sealed compartment on the top of the stepper-
motor drive unit where water from a thermostatically controlled water bath is circulated 
around the syringes. The local temperature is monitored by a platinum resistance 
thermometer (Digitron 2024T, SIFAM instruments, Devon UK). The same water is 
circulated through a copper pipe in order to control the temperature of the solution in 
the PEEK tubing leading to the mixer. It was deemed unnecessary to apply thermostatic 
control to the flow-cell itself due to the very brief contact time the mixed solution has 
with it. The camera, focusing lenses and cell holder are all contained within a darkened 
light-proof box. 
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Figure 5.2 Photograph of an early configuration of continuous-flow instrument on 
the optical bench showing the main components: lamp housing (1) with ignition and 
power control (2), water filter compartment (3), monochromator (4), stepper motor 
drive (5) with syringe compartment (6) and old model CCD camera (7) replaced since 
with Retiga-2000R. Note the presence of two large external units (8 and 9) required to 
synchronise the old camera with a stepper-motor drive (8) and process the output of the 
CCD chip into a format recognisable by the computer (9). 
The flow cell is not visible as it was removed for maintenance.  
Note the unusual position of the camera which is facing the monochromator rather than 
being positioned at 90°. This is due to the fact that at the time of taking the photograph 
a number of different optical configurations were considered, one of which was 
positioning the camera to face the excitation light and use several filters to block any 
incident light other than fluorescence (see section 5.2.3.1). 
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Figure 5.3 Schematic diagram of a 90° detection configuration of continuous-flow 
instrument developed over the course of this study. 
A stepper motor drive (A) delivers reagents from solution reservoirs (B) into the 
microfabricated mixer (C) where reaction is initiated. A light source (D) provides 
illumination selected by a monochromator (E). Focusing lenses (F) focus the light 
exiting the monochromator into a narrow band aligned with the observation channel 
inside the flow cell coupled to the mixer (G). As the reaction progresses, fluorescence 
emitted from the flow cell is gathered by focusing lenses and filters (H) before reaching 
the CCD camera (I). 
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5.2.2.2 Current and potential light sources 
 
An important aspect of this study, in addition to designing a novel, highly 
efficient micromixer, was to enhance the detection capabilities of the instrument in 
order to improve the quality of collected data and increase sample economy.  
This was achieved by replacing the old CCD camera with a newer, more user-friendly 
model boasting enhanced sensitivity and durability. This aspect was accomplished by 
purchasing Retiga-2000R CCD camera equipped with high sensitivity chip (see section 
5.3.1.1 for comparison with the old Micromax camera).  
A second method of improving data quality and enhancing detection is to increase the 
strength of fluorescence in the flow cell. This could be achieved by either increasing the 
fluorophore concentration and thus sample consumption (a method both undesirable 
and counter-productive) or by increasing the intensity of excitation light reaching the 
sample by replacing the light source. The latter option was deemed attractive and 
consequently pursued. 
Before a new light source could be considered, potential areas for improvement 
had to be identified. Current light source, a 103 Watt mercury-xenon arc lamp, provides 
intense light which can be focused into the flow cell by a system of cylindrical and 
convex lenses. However, the lamp itself emits a broad spectrum of light of different 
wavelengths which have to be filtered by a monochromator and a set of filters. While 
such system allows one to narrow down the wavelengths present in the excitation beam 
to just a few nanometres (e.g. 500 nm ± 1 nm), it also reduces the intensity of the 
excitation light. Moreover, if the arc lamp is to be used for Tryptophan fluorescence 
detection, it requires particular care while selecting wavelength with a monochromator. 
This is due to the fact that the output of the arc lamp is uneven across different 
wavelengths (see Figure 5.4) and its application to Tryptophan fluorescence relies on 
selecting particular mercury spike at 281 nm. If care is not taken, this particular spike 
can be missed – setting monochromator to 282 nm could easily result in decreasing the 
light intensity of the excitation beam by half. Any excitation light exiting the 
monochromator would be dispersed into a cone, much like a flashlight light. This 
necessitates the use of focusing lenses which gather the excitation light and focus it into 
the flow cell. As single focusing lens could never provide homogenous illumination 
along the entire flow-channel, complex multi-lens systems are often required to ensure 
even light distribution increasing both cost of instrument and its complexity. 
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Figure 5.4 Radiant intensity profile of a mercury-xenon arc lamps of different 
power across a range of wavelengths. Numerous peaks across the spectrum correspond 
to spectrum lines of xenon (peaks above 800 nm) and mercury (peaks between 230-800 
nm). Note logarithmic scale on vertical axis illustrating the intensity of the lines and 
importance of careful calibration of monochromator used with the lamp. 
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An ideal light source should have none of those limitations. It should be tunable 
to a single wavelength, should emit tightly focussed beam which could be easily 
focused along the channel using single cylindrical lens and should provide higher light 
intensity than Hg-Xe lamp resulting in stronger excitation and therefore increased 
fluorescence of the sample. 
All of the above features are characteristic for laser-based light sources and 
consequently lasers were the first alternative to be considered. Two possible setups 
were considered: a deep UV laser tuned to 280 nm (such as DUV manufactured by 
Laser 2000, Stockholm, Sweden) or tunable visible light laser coupled to frequency 
doubler (e.g. MBR family by Coherent, Santa Clara, USA).  
While both setups offered similar advantages over a mercury-xenon arc lamp, they also 
shared a common disadvantage: their price. Deep UV lasers are much more expensive 
than visible light lasers, however the latter is only applicable for fluorescence studies 
when coupled to a frequency doubler which decreases the wavelength of emitted light 
into the deep-UV region. In both cases financial costs associated with purchasing the 
laser, installing it in a dedicated workroom in accordance to health and safety 
regulations and finally personnel training required to operate them safely proved to be 
well beyond the financial scope of the grant. 
It should be noted, however, that laser light sources remain a very attractive and viable 
option as far as future developments and instrument improvements are concerned. 
Following rejection of lasers as prospective light source for the new instrument, 
attention was shifted to ultraviolet diodes. Recent developments in LED technology 
allowed for construction of deep UV diodes with wavelengths varying from near-UV 
down to 240 nm.  
For this study, a 280 nm UVTOP diodes manufactured by Sensor Electronic 
Technology, Inc. (Columbia, SC, USA) were considered. Among numerous advantages 
offered by this particular light source are adaptability (diodes are offered in a variety of 
wavelengths ranging from 400 nm to 240 nm in 5 nm increments), very long life span 
(between 40-50,000 hours compared to 500 hours for Hg-Xe arc lamp) and low price. 
They can be manufactured in different shapes, providing either dispersed illumination 
or very focussed, narrow cone of light. Moreover, since individual diodes are small, 
having diameter of 3-4 mm, several diodes can be arranged into an array and positioned 
along the flow channel in order to provide homogenous illumination without the need 
for focusing lenses.  
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The only disadvantage of diodes is the intensity of light they provide, which is an order 
of magnitude lower than that of mercury-xenon arc lamp, particularly at 280 nm where 
a mercury spike in an arc lamp spectrum is often used for biological and biochemical 
applications such as Trp fluorescence. 
Lower output of diode array would result in decreased fluorescence intensity, 
negatively affecting the quality of the data gathered. Due to this reason, the concept of 
using diode array as a source of excitation light was discarded and decision was made 
to continue the use of mercury-xenon lamps, despite their many shortcomings. 
 
 
5.2.2.3 Computer software and data analysis 
 
An important advance in reliability and consistency of operation of the 
continuous-flow instrument used in this study was the introduction of the custom-
written software „μHi Flow‟ (TgK Scientific) by previous PhD student Dr David 
Jenkins (Jenkins, 2006). This software was used to control the stepper motor drive unit 
via drive unit controller custom-built by our industrial collaborator (TgK Scientific). 
The controller interfaced with the computer by a PCI-bus card.  
The μHi Flow software allowed for a specification of most important parameters such 
as the linear flow velocity of the solution pushed through the flow-channel (from 4 to 
16 ms
-1
 in increments of 2 ms
-1
), the time delay between the start of the flow (i.e. 
activation of stepper motor drive) and the onset of data collection by CCD camera, and 
finally the total volume of reactants to be displaced in particular experiment.  
The volume of solutions displaced during each run also specified the duration of 
measurement, with higher flow velocities resulting in shorter time span and increased 
sample consumption. 
While the Micromax CCD camera was installed, the μHi Flow software could interact 
directly with camera control and data collection software WinView/32 (Roper 
Scientific) allowing for data collection to be automatically triggered each time stepper-
motor drive was activated, greatly adding to ease of use of the instrument. 
With a replacement of CCD camera came the necessity to re-wire the drive unit 
controller so that it could interface with new hardware. Fortunately, the QImaging Suite 
software provided with Retiga-2000R proved to be flexible and was easily adapted for 
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μHi Flow, allowing data collection to be synchronised with stepper motor drive 
activation. 
The QImaging Suite software was used to both interface the camera with drive unit 
controller and to process raw data acquired during continuous-flow experiments. 
Fluorescence intensity profiles made from flow-channel images (see Section 5.2.3) 
were imported into QImaging Suite and converted into relative fluorescence traces.  
The final kinetic trace could be exported from the QImaging Suite software as an XLS 
file and easily loaded into Excel (Microsoft, Redmond, WA, USA), SigmaPlot (Systat 
Software, Richmond, CA, USA) or Kinetasyst 3 (Hi-Tech Scientific) for curve-fitting 
by non-linear regression. 
 
 
5.2.3 Continuous-flow mixer 
 
 Continuous-flow relies greatly on rapid and complete mixing of reactants in 
order to initiate the reaction as quickly as possible and thus decrease the dead time after 
which viable data can be collected. It is therefore not surprising that efficient and robust 
mixer is a key element of every continuous-flow instrument, being the limiting factor in 
terms of performance. 
Since there are currently no continuous-flow instruments available commercially, every 
single apparatus assembled to date was custom made by respective research group. 
Consequently, every mixer was also assembled in-house, leading to very poor 
reproducibility of the results between groups making use of different instruments. 
Careful handling and very regular maintenance were required, as spare mixers were 
unavailable. 
Thus, a specific market niche was formed, which could be filled by a simple, cheap and 
easy to handle mixer that could be discarded in case of critical failure and replaced with 
identical one.  
By far the easiest way of manufacturing large quantities of simple, non-mechanical 
components such as mixers is microfabrication, which was therefore incorporated into 
the study. Mass produced microfabricated mixers made from chemically inert, durable 
materials would be a very attractive alternative to hand-crafted devices.  However, due 
to technological limitations microfabrication is essentially limited to production of two-
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dimensional objects, rendering most common mixer designs difficult to manufacture. 
Thus a completely new design suitable for mass production was required. 
Extensive literature review yielded particularly interesting design of single-plane mixer 
which followed the T-mixer geometry widely used in stopped-flow instruments, where 
two delivery channels and an observation channel machined in a thin sheet of 
chemically inert polymer were sandwiched between two layers of glass (Billsel et al., 
2005).  
This particular designed served as a basis for the development of very first prototype of 
planar continuous flow mixer manufactured by collaborators from Warwick School of 
Engineering (see Section 5.2.3.1). 
 
 
5.2.3.1 Initial prototypes of planar continuous-flow mixers 
 
 A first prototype of continuous-flow mixer served as a technology demonstrator 
to test the feasibility of manufacturing device based on selected design (see Figure 5.5). 
The central part of the prototype was a planar PEEK sheet in a form of a square with 
side length of 25.4 mm and thickness of 100 μm. Two 100 μm wide delivery channels 
were cut along the sides, intersecting at one of the corners, their meeting point serving 
as a mixing chamber. A single 100 μm wide observation channel was cut along the 
diagonal of the sheet, stretching from the mixing chamber to the opposite corner.  
Such configuration was a result of careful analysis of fluid flow dynamics in 
microscopic channels performed by a collaborator Ching-Hsien Cheng from Warwick 
School of Engineering. It was discovered that placing two delivery channels at 90° to 
each other and the flow channel along the diagonal results in increased turbulent flow in 
the mixing chamber itself, as well as in the initial section of flow channel. This in turn 
should increase mixing efficiency and therefore decrease instrumental dead time. 
The PEEK layer was then sandwiched between two 5 mm thick, 25.4 x 25.4 mm quartz 
windows placed above and below the PEEK sheet, thus forming a flow channel with 
square cross-section and side length of100 μm. Upper quartz window had three holes 
drilled in it which coincided with the ends of delivery channels and observation channel 
and thus served as reagent inlets and reaction mixture outlet.  
Two 1.6 mm thick 25.4 mm x 25.4 mm Teflon gaskets located at the top and bottom of 
glass-PEEK sandwich served as a seal between the mixer and a stainless steel holder. 
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The holder consisted of two 5 mm thick plates each 40 mm long and wide held together 
by 4 screws. The plates also had a simple alignment system manufactured into them: 
eight 1 mm thick pillars protruding from the surface of the bottom plate would fit 
tightly into eight holes drilled through the upper plate guaranteeing perfect alignment of 
all elements of the mixer. 
Delivery lines were connected to the upper plate of the steel holder via standard 10-32 
HPLC fittings. 
 
 
 
 
 
 
Figure 5.5  First prototype of continuous flow mixer manufactured at Warwick 
School of Engineering. Schematic diagram (A) demonstrates details of the design, 
while photographs of upper plate (B) and bottom plate (C) show outer features of the 
mixer. Black arrows on the PEEK layer in panel A indicate the direction of the flow of 
reagents. 
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Having successfully demonstrated the feasibility of microfabrication for the 
manufacture of continuous-flow mixer, the design was modified to facilitate its 
incorporation into the instrument.  
While PEEK-quartz glass sandwich forming the core of the mixer was unchanged, the 
steel holder was significantly strengthened in order to withstand high pressure exerted 
by solutions pumped through narrow channels of the mixer at high flow rates. The 
bottom plate of the holder was enlarged to 60 mm x 60 mm and its thickness increased 
to 10 mm to withstand greater pressure. The shape of the upper plate was modified to 
accommodate horizontal bar used to position the mixer in the instrument (see Figure 
5.6). Four screws holding upper and bottom plates together were replaced with eight 
bolts with hex nuts to increase durability of the holder. 
Following its assembly, second prototype underwent a series of pressure and leakage 
tests in order to verify its suitability for integration into the continuous-flow apparatus. 
Prior to live testing with fluorophores, the entire optical setup of continuous-flow 
apparatus had to be revised. This was due to the fact that new mixer prototype relied on 
180° detection as opposed to 90° detection characteristic for mixers previously installed 
in the instrument. 
In 180° detection the CCD camera is facing the light source, with the mixer positioned 
between the light source and the camera. Such method is not commonly used as any 
excitation light exiting the monochromator is focussed into the flow channel and upon 
passing through the channel may reach the camera. Since the intensity of excitation 
light is several orders of magnitude higher than fluorescence emitted by the sample, the 
excitation light can easily blind the CCD sensor rendering collection of data impossible. 
Thus a set of two 320 mm cut-off filters was installed between the camera lens and the 
mixer in order to eliminate any incident light passing through the flow channel (see 
Figure 5.6). Since both NATA and Tryptophan fluoresce at higher wavelengths, the 
CCD camera can detect their emissions unhindered. 
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Figure 5.6 Optical setup of continuous flow instrument revised in order to 
accommodate new microfabricated mixer requiring 180° detection. Excitation light 
focussed by cylindrical lens passes through the flow channel of PEEK mixer exciting 
fluorophore mixture. Upon exiting the flow cell fuorescent light emitted by the sample 
is mixed with much stronger excitation light which has to be blocked by a selection of 
cut-off or bandpass filters. Fluorescent light passing through the filters freely is then 
focussed into the CCD camera by focusing lenses to facilitate detection. 
 
 
 
 
Figure 5.7 Second prototype of a continuous-flow mixer demonstrating enlarged 
steel casing and horizontal bar used to integrate the mixer into the instrument. Front 
plate (A) was modified in order to accommodate the horizontal bar while the layout of 
the back plate (B) remained largely unchanged. The side view of the mixer (C) 
demonstrates the thickness of steel holder necessary to withstand high pressure 
generated during instrument operation. 
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With newly installed mixer prototype and revised optical setup, experimental evaluation 
of effectiveness of the instrument carried out. It was immediately revealed that 
fluorescence emitted by the sample at working concentration was too weak compared to 
excitation light. Optical filters designed to block intense excitation light were also 
blocking fluorescence. This was due to the fact that no optical filter is 100% transparent 
to light of any wavelength, and even light of wavelength which can pass through the 
filter would lose some of its intensity. Reducing a number of optical filters from two to 
one did not reduce the intensity of excitation light sufficiently enough to prevent 
saturation of CCD chip thus preventing the camera from gathering any useful data. 
Removing this shortcoming required re-designing the mixer and was accomplished in 
the third prototype. 
 
 
5.2.3.2 Microfabricated planar T-mixer 
 
With 180° observation proved impossible, alternate solution was quickly 
implemented. The observation slit of the mixer was widened in order to facilitate a 150° 
observation. Such angle allowed the camera to be moved outside the excitation light 
beam while simultaneously allowing for unhindered observation of flow channel (see 
Figures 5.8 and 5.9). Thus a third and final prototype of the mixer was manufactured. 
 
Figure 5.8 Photographs of the back plate of third prototype of continuous flow 
mixer demonstrating widened observation slit to facilitate wide-angle detection. Front 
plate remained unchanged and is not shown. Note black coating of the entire steel 
holder designed to minimise internal light scattering from metallic surfaces and 
glass/metal interfaces. 
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Figure 5.9 Schematic representation of modifications introduced in third mixer 
prototype in order to facilitate 150° detection. Panel A shows how widening the 
observation slit on the back plate of the mixer allowed the detection angle to be altered, 
compared to unmodified mixer. Panels B illustrates the basic principle of 90° detection 
which relies on positioning the camera (grey shape) at 90° angle to excitation light 
(orange lines) allowing for fluorescence (black lines) emitted by the sample flowing 
through the flow channel (green square) to be easily detected. Panel C represents the 
camera positioned at 180° being blinded by excess excitation light reaching CCD sensor 
despite the use of filters. Panel D demonstrates how decreasing the detection angle to 
150° allows for the camera to be moved beyond the beam of excitation light and thus 
collect reliable data. 
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 Initial stages of third prototype evaluation involved leakage and pressure 
resistance tests which proved that the mixer can operate without problems at flow 
velocities of up to 12 ms
-1
, much like the second prototype. At 14 ms
-1
 minor leaking 
occurred, but this was not considered an issue since flow dynamics simulations showed 
that for this particular mixer configuration most efficient mixing occurred at flow 
velocities of 6-8 ms
-1
. Below 6 ms
-1
 the flow of reactants changed from turbulent to 
laminar and thus mixing efficiency was severely decreased. Similarly, at flow velocities 
exceeding 10 ms
-1
 simulated mixing efficiency decreased. 
Live tests of third prototype aimed at both verifying the conclusions drawn from flow 
dynamics simulations and evaluating mixing efficiency of the mixer itself quickly 
revealed that although no excitation light was reaching the camera positioned at 150° to 
the light source, no fluorescence decay could be observed during NATA/NBS 
quenching experiments. 
Thorough investigation of the phenomenon led to a conclusion that light scattering 
occurring at interfaces between quartz windows and metal surfaces of the steel holder, 
as well as additional scattering at the edges of the flow channel produced enough 
refracted light to swamp NATA fluorescence (see Figure 5.10). 
Any modifications to the third prototype aimed at eliminating light scattering such as 
coating the entire steel holder with black paint proved unsuccessful. Similarly, altering 
the detection angle between 130° (smallest angle which positioned the camera beyond 
the excitation light beam) and 160° (largest observation angle achievable with widened 
observation slit of the third prototype) yielded no positive results. 
Due to the fact that the wavelengths of scattered light and those of NATA or tryptophan 
fluorescence overlapped greatly (see Figure 5.10, panel B) introduction of additional 
optical filters to block scattered light was deemed impossible. 
In such circumstances, a decision was made to abandon the planar geometry of 
microfabricated mixers and adopt a completely new design which included a three-
dimensional geometry and 90° fluorescence detection. 
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Figure 5.10 Diagram illustrating light scattering occurring during continuous-flow 
experiment. Panel A demonstrates how scattered light interferes with fluorescence 
measurements in 150° detection. Although excitation light (orange lines) can pass freely 
through the mixer and does not reach the CCD sensor (grey shape), light scattered (red 
lines) at glass/metal interfaces and flow channel edges can easily reach the camera and 
interfere with detection of fluorescence (green lines). Panel B shows a graph created by 
quantifying both fluorescence (blue line) and scattered light (green line) using handheld 
fibre-optic spectrometer. Red line in panel B represents fluorescence intensity in 
previous generation of ball-mixer and T-mixers used in previous study by Dr David 
Jenkins (Jenkins, 2006). Flow channels in those devices were significantly wider - 250 
μm by 250 μm allowing for larger volume of fluorophore to be visible to the camera 
and therefore stronger signal to be detected. 
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5.2.3.3 Hybrid T-mixer with vertical flow cell 
 
 Three prototypes of planar mixers, while successfully demonstrated suitability 
of microfabrication for production of continuous flow mixers and mechanical 
robustness of the design, were also unsuitable for fluorescence data collection. While 
solving the problem of light scattering was achievable in the long term, it would require 
dramatic re-designing of the entire prototype, and was therefore deemed to time and 
resource-consuming. Thus a decision was made to design a completely new prototype 
using knowledge gained from previous prototypes as well as flow dynamics 
simulations. 
New mixer design combined elements of microfabricated planar mixers such as steel 
holder, and PEEK layer with delivery channels arranged in planar geometry, with a 
three-dimensional layout and 90° detection offered by more typical continuous-flow 
mixers. 
Much like in previous prototypes, the central part of the prototype was a planar PEEK 
sheet 25.4 mm long and 25.4 mm wide. While thickness of the layer remained 
unchanged, the width of both delivery channels was increased from 100 μm to 250 μm. 
Geometry of delivery channels, each 100 μm high and 250 μm wide, was also altered. 
They no longer ran along the sides of the layer to meet at 90° in one of the corners, but 
rather stretched from opposite corners of the layer along the diagonal and met head-on 
in the middle of the sheet (see Figure 5.11). 
Unlike previous prototypes, flow-channel was not machined in the layer along with 
delivery channels, but was formed by placing PEEK sheet on top of 20 mm long quartz 
cuvette (see Figures 5.11 and 5.12). The cuvette made from fused silica contained a 250 
μm x 250 μm flow-channel positioned so that one of its ends would coincide with the 
meeting point of two delivery channels. Increasing the diameter of flow channel 
allowed for larger volume of the sample to be viewed by the camera, increasing 
fluorescence intensity.  
Quartz cuvette was encased in the bottom part of stainless steel holder with four 
observation windows machined in each of its sides to facilitate 90° detection. Steel 
holder was held together by four screw-in bolts, allowing for precise regulation of 
mechanical pressure applied to all of the components. 
In order to increase durability of the mixer the PEEK layer was not placed directly on 
top of the quartz cuvette, but sandwiched between upper plate of the steel holder and 
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100 μm-thick tungsten plate. While this generated a gap between the mixing chamber 
and visible part of the flow channel (see Figures 5.11 and 5.12), it also offered 
necessary rigidity and pressure resistance vital for instrument operation at high flow 
velocities. 
The seal between PEEK, tungsten plate and upper plate of the holder was provided by 
PEEK itself upon pressing all of the elements together by four bolts in the steel holder. 
Entire configuration was again subjected to simulations of flow dynamics which 
suggested virtually no loss in turbulence of the flow mainly due to head-on collision of 
two reactants flowing through delivery channel, and thus no noticeable change in 
mixing efficiency of the design. 
Upon assembly, the mixer was subjected to standard leakage and pressure tests which 
verified its pressure and flow velocity operation range. At flow velocities of up to 12 
ms
-1
, no leaking was detected, while at 14 ms
-1
 only minor leaking occurred. Much like 
with previous mixer prototypes, this was deemed satisfactory. 
Live tests with fluorophore revealed no unexpected problems such as light scattering, 
which was expected given 90° detection utilised in this design. 
Thus a fully functional mixer was created, mixing efficiency and dead time of which 
could be experimentally verified. 
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Figure 5.11 General layout of the hybrid T-mixer with vertical flow cell.  
Ferrules and tubing (A) are used to deliver reagents to the mixer. The reagents flow 
through the 250 μm wide channel cut in the 100 μm thick PEEK layer. The PEEK layer 
sits atop the 100 μm thick tungsten plate which provides necessary durability. The 
entire PEEK-tungsten sandwich is placed atop the quartz flow cell (D) with 250 x 250 
μm wide channel running through its centre (E). The PEEK layer, tungsten plate and the 
flow cell are pressed together by a two-part stainless steel holder consisting of upper 
plate which houses the delivery system (F) and bottom plate which encases the flow cell 
(G). 
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Figure 5.12 Detailed structure of a hybrid T-mixer with vertical flow cell. Panel A 
illustrates the details of the design and its assembly. The PEEK mixer is squeezed 
between upper plate of the steel holder and thin tungsten plate. This sandwich is in turn 
placed on top of the quartz flow cell encased in steel holder with observation slits cut in 
its sides. Panel B highlights a small dead volume created by tungsten plate located 
between the PEEK mixer and quartz flow cell. Panel C shows an actual image of the 
channel filled with 20 μM NATA. 
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5.2.4 Mixing efficiency 
 
5.2.4.1 Data collection and analysis 
 
During a typical continuous-flow experiment fluorescence emitted by the 
sample passing through the flow-channel of the mixer is monitored by the CCD camera. 
The chip of the camera is sensitized in the deep-UV region allowing for detection of 
NATA and tryptophan fluorescence. Fluorescence data are collected in a form of digital 
images of the flow channel and stored on PC hard drive for further analysis. All of the 
experimental variables (excluding reactant concentrations) were controlled by μHi Flow 
software together with QImagin Suite facilitating easy and efficient collection of the 
data. 
The exposure time during each of the experiments detailed in this chapter was set to 5 
seconds, allowing clear images of the flow-cell with high signal to noise ratio to be 
obtained. A time interval of 0.5 second was set between activation of stepper-motor 
drive and thus flow initiation and the onset of data collection. This time delay was 
necessary to ensure that the flow channel was filled with reaction mixture prior to data 
collection as well as to provide enough time for any residual solution leftover from 
previous runs to be flushed from the observation channel by fresh reactants. 
While QImaging Suite software was capable of manipulating variables such as gain and 
contrast of acquired images, it was deemed unnecessary to manipulate any of those 
settings and hence throughout all of the experiments they remained set to default values.  
The linear flow velocity controlled by μHi Flow software could be set to a number of 
values ranging from 4 to 14 ms
-1
 in 2 ms
-1
 increments. Similarly, the total reactant 
volume displaced during each individual experiment could be set to a value which 
allowed for a run time of at least 5.5 s. The run time itself was calculated by the μHi 
Flow software from the flow velocity and the volume displaced, based on the 
knowledge of the dimensions of the flow-channel provided prior to the experiment. 
Following the run, data acquired over the entire five-second runtime were immediately 
displayed by QImaging Suite in a form of an image showing the fluorescence intensity 
of the mixed solution travelling up the flow-channel (see Figure 5.13, panel A). Since 
fluorescence intensity of individual pixels in the entire image was recorded 
automatically by the software, the only processing needed to obtain average 
fluorescence profile of the flow-cell was to select the outline of the channel visible in 
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the image. Upon selection of channel outline, average fluorescence values in every row 
or every column of pixels could be calculated by the software (this corresponds to 
averaging fluorescence along or across the channel respectively) and exported in form 
of XLS or ASCII file. For continuous-flow experiments detailed in this chapter, 
averaging columns of pixels allowed for construction of fluorescence profile along the 
channel (see Figure 5.13, panel B). Between 18 and 20 pixels in each column were 
typically used in the calculation of average fluorescence. 
Once calculated, mean fluorescence intensity was plotted against pixel number to give a 
fluorescence intensity profile for each flow-cell image. Using fluorescence values from 
these profiles together with Equation 5.1 allowed for calculation of normalised 
fluorescence decay relative to initial (unquenched) NATA fluorescence: 
 
           (5.1) 
 
where F(reaction) is the fluorescence profile of NATA quenched by NBS, F(background) is the 
profile of distilled water alone, and F(initial) is the profile of unquenched NATA. The 
profile of distilled water was used to account for any background signal reported by the 
CCD not attributable to NATA fluorescence (such as scattered or reflected excitation 
light, background levels of the CCD or “dead” pixels).  
Prior to mixing efficiency or dead time estimation, the x-axis scale of relative 
fluorescence graphs had to be converted from pixel number to kinetic time-base. This 
was achieved by implementing Equation 5.2 
            (5.2) 
 
where Δt is the change in time in seconds over the distance of flow-channel viewed by 
the CCD camera, A is the area of the cross-section of the flow-cell measured in mm
2
, L 
is the length in mm of the channel observed by the CCD, and γ is the flow-rate in mls-1, 
calculated by μHi Flow software on the basis of the linear flow-velocity set for 
particular run and dimensions of the flow-cell specified prior to the experiment.  
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Figure 5.13 Illustration of the method of data processing from image to relative 
fluorescence profile. Panel A shows an image of the flow-cell acquired during 
experiment which involved quenching 20 μM NATA fluorescence with 0.5 mM NBS. 
Red lines and arrows indicate the boundaries of the flow-channel between which 
columns of pixels were averaged to construct fluorescence intensity profile by 
QImaging Suite software as shown in panel B. Panel C represents relative fluorescence 
profile calculated from fluorescence intensity profile in panel B using Equation 5.1. 
Note that fluorescence profile in panel B shows uneven fluorescence intensity along the 
flow-channel resulting from non-uniform illumination. 
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5.2.4.2 Mixing efficiency tests 
 
 In order to confirm suitability of new mixer for investigation of very rapid 
reactions such as folding of PrP, both mixing efficiency and instrumental dead time had 
to be evaluated. Estimation of mixing efficiency was performed by comparison of 
fluorescence profiles of NATA recorded in two separate experiments. 
During the first experiment 220 μM solution of NATA was diluted with distilled water 
to a final concentration of 20 μM. Diluted fluorophore was then loaded into all three 
syringes serving as reactant reservoirs and pushed through the mixer at flow velocities 
of 4, 6, 8 and 10 ms
-1
. This was done in order to evaluate whether mixing efficiency 
varies depending on the flow velocity and if so, which flow velocity provides optimal 
mixing. Recorded fluorescence profile of pre-mixed NATA served as a reference of 
“ideal mixing”.  
Intensity profile of distilled water alone was also recorded and processed to account for 
any background noise. 
Second experiment involved loading 220 μM solution of NATA into the smallest 0.5 ml 
syringe with distilled water being loaded into two 2.5 ml syringes. Over the course of 
the experiment NATA was diluted by distilled water in 1:10 ratio, resulting in final 
concentration of 20 μM. Flow-cell image obtained during the experiment was then 
processed into fluorescence intensity profile using Equation 5.1 and compared with the 
profile recorded during the first experiment. The more similar the fluorescence profile 
from second experiment was to the profile from first experiment, the greater the mixing 
efficiency. If the mixer was 100% efficient, the two profiles would be identical, 
indicating no difference between fluorescence profile of pre-mixed fluorophore with the 
profile recorded in vivo during the mixing experiment.  
 
 
5.2.4.3 Determination of instrumental dead time 
 
Dead time of the instrument equipped with newly developed mixer was 
determined using a well-established procedure of following the kinetics of the first-
order reaction of NATA fluorescence quenching by NBS (Peterman, 1979; Shastry et 
al., 1998) upon their mixing within the instrument under evaluation.  
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The experiment itself involved mixing of 20 μM NATA with a range of NBS 
concentrations varying from 0.25 mM to 5.0 mM. In order to achieve desired 
fluorophore concentration, 220 μM NATA was loaded into the smallest syringe 
(fluorophore reservoir), with NBS loaded into Larger syringes (quencher reservoirs). 
Upon mixing initiation NATA was diluted by NBS in 1:10 ratio, resulting in final 
concentration of 20 μM. In order to account for minor dilution of NBS with NATA, 
concentrations of solutions loaded into the reservoirs were 10% higher than desired 
final concentration (e.g. in order to achieve 5.0 mM final concentration, 5.5 mM NBS 
was loaded into quencher reservoirs). 
Progress of the reaction was monitored by CCD camera and recorded in form of flow-
cell images. The images obtained during the experiment were then processed into 
fluorescence intensity profiles using QImaging Suite and Equation 5.1, with Equation 
5.2 later used to calculate the time-base of the reaction. Resulting kinetic profiles were 
imported as XLS files into statistical analysis software (SigmaPlot 9.0) for curve-fitting, 
and plotted as a graph for visual inspection. In order to account for any turbulences or 
mixing artefacts present in the earliest stages of fluorescence profile, the earliest time-
base coordinate at which the data deviated from an exponential decay was determined 
and only the data further down the x-axis were used to determine key kinetic parameters 
of the reaction. One of such artefacts can be seen in Figure 5.13, panel A as circular-
shaped are of intense fluorescence between pixels 0 and 100, as well as in resulting 
fluorescence profiles (Figure 5.13, panels B and C). 
In order to determine the key kinetic parameters, the data were fitted by a single 
exponential decay function, of the form 
       (5.3) 
where Ft is the fitted fluorescence function, F0 is the end-point, a is the amplitude, k is 
the rate constant and t is time.  
Following the fitting, relative fluorescence curves obtained during given experiment 
were re-plotted on a single semi-logarithmic plot, and the fit lines extrapolated back to a 
common intersection with a y-axis value close to 1, which corresponds to the value of 
relative fluorescence of NATA in the absence of NBS. The x-axis difference between 
the common intersection and the first data point of fitted curves provided an estimation 
length of the dead time of the instrument at given flow velocity.  
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5.3 Results and discussion 
 
 
5.3.1 Fluorescence signal intensity enhancement 
 
5.3.1.1 Increased sensitivity CCD camera 
 
 Over the course of the project multiple methods of improving the overall 
sensitivity of the instrument were considered. The issue of low sensitivity of Micromax 
camera became particularly important following the evaluation of third prototype of 
microfabricated mixer, when relatively low levels of excitation light scattered into the 
camera produced as strong a signal as NATA fluorescence in the channel.  Thus, prior 
to mixing efficiency and dead time evaluation of the final prototype of the mixer, a 
decision was made to replace ageing Micromax camera with a newer, more sensitive 
and efficient model. Several commercially available models were evaluated and a 
Retiga-2000R model boasting enhanced deep-UV sensitivity was purchased (for 
comparison between Micromax camera and Retiga-2000R see Figure 5.14). As a side-
effect of changing the camera from 15-year old model to a 2-year old one, a bulky 
signal processing unit (see #9, Figure 5.2) could be discarded, as the new camera could 
be connected to the computer via USB cable. This significantly increased the reliability 
of the system, as the old camera had to be connected to the signal processing unit with a 
specialised connector cable custom made by Micromax, which in case of failure would 
be both expensive and time-consuming to replace as it is only manufactured in the 
USA. 
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Figure 5.14 Comparison of sensitivites of Micromax CCD camera with SenSys: 
1401E chip (A) and Retiga-2000R camera equipped with Kodak Sensors KAI-2020 
chip (B). The channel inside the flow-cell is visible as a bright horizontal band roughly 
in the centre of each image. Both images were acquired over the course of one second 
with 220 μM NATA filling the channel.  
Panels C and D show numerical values of fluorescence intensity distribution across the 
fragment of each image indicated by red lines. Although fluorophore concentration was 
identical, Retiga-2000R detected much stronger signal of 260-280 Grays as opposed to 
Micromax, which registered only 80-90 Grays. 
Note that this particular test was conducted with a flow channel blocked at both ends 
and filled with stationary fluorophore solution. This allowed for exactly the same 
channel to be viewed by both cameras to facilitate sensitivity comparison. 
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5.3.1.2 Fluorescence enhancement by light reflection 
 
 An important aspect of any instrument used for biological studies is sample 
economy. 
Protein solutions used in experiments often take weeks to prepare, particularly if 
expression of given protein in prokaryotic system and subsequent purification are 
required. Therefore, it is of great importance for the instrument to offer greatest 
possible sensitivity, thus limiting sample consumption. 
While replacing the camera with a more robust model increased detection capabilities 
of the instrument, a second method of improving data quality and enhancing detection 
was available, which involved increasing the strength of fluorescence in the flow cell. 
As mentioned in Section 5.2.2.2, this could be achieved by either increasing 
fluorophore concentration in the sample or by increasing the intensity of excitation light 
reaching the sample. The latter could be achieved not only by replacing the light source, 
but also by reflecting any incident light transmitted through the sample and the walls of 
the flow-cell back into the quartz cuvette. This could be achieved by installing mirrors 
in the flow-cell holder to reflect transmitted light back towards the flow-channel. Upon 
closer inspection of the holder housing both the mixer and the flow cell, it became 
apparent that installation of mirrors would require re-designing the entire steel frame. 
Thus, another solution was implemented: two walls of the quartz cuvette were mirror-
coated by depositing silver on cuvette surfaces, one opposite to the face exposed to 
incident light, and the other opposite the face observed by the CCD (see Figure 5.15). 
In order to assess the extent of fluorescence intensity increase upon coating two sides of 
the cuvette with silver, a typical continuous-flow experiment was set up in which 220 
μM NATA was diluted in 1:10 ratio by distilled water at linear flow velocity of 6 ms-1. 
Several channel images for both non-coated and coated cuvettes were recorded and 
fluorescence intensity profiles constructed using QImaging Suite software (see Figure 
5.16). 
 
 
 
 
 
 
188 
 
 
 
Figure 5.15 Comparison of excitation light transduction through non-coated and 
mirror-coated quartz cuvette. In non-coated cuvette (A) any incident light not focussed 
into the fluorophore-filled flow-channel may pass freely through the cuvette and is 
therefore lost into the environment. Upon coating two sides of the cuvette with silver, 
any excitation light missing the channel and passing through the flow-cell is now 
reflected back into the cell with high probability of passing through the flow-channel 
again, therefore increasing the overall intensity of excitation light reaching the sample. 
 
 
 
 
 
 
 
 
 
 
A B 
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Figure 5.16 Flow cell images and fluorescence intensity profiles collected during the 
experiment aimed to compare fluorescence intensity in non-coated and mirror-coated 
cuvettes. Panel A shows image of the flow-channel acquired by CCD camera (top) as 
well as fluorescence intensity profile along the channel (bottom) of the non-coated 
cuvette. In comparison, fluorescent light visible in the photograph of the flow-channel 
of coated cuvette (panel B, top) is much more intense. This is confirmed by the 
fluorescence profile constructed for that image (panel B, bottom). 
Note that in both flow cell images recorded during the test, fluorescence intensity is 
significantly higher towards the centre of the flow-channel (between pixels 600 and 
800) than at the entrance and exit of the channel (pixels 0 and 1200 respectively). 
This effect again highlights the uneven intensity profile of the excitation light beam 
which has to be corrected for by subtraction of background profiles, as described in 
section 5.2.4.1. 
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Upon comparison of the fluorescence intensity profile of NATA flowing 
through non-coated cuvette with corresponding profile for mirror-coated cuvette, 
significant signal enhancement achieved by silver coating two sides of a quartz flow-
cell becomes apparent. 
While in non-coated cuvette a 20 μM NATA solution yielded observed fluorescence 
intensity of approximately 150 Grays, the very same fluorophre concentration flowing 
through mirror-coated cuvette provided signal of 300-350 Grays, demonstrating an 
enhancement of approximately 250 % of the total fluorescence intensity. 
These data clearly indicate that by silver-coating two sides of the quartz flow-cell 
significant increase in fluorescence signal can be achieved, consequently improving 
both sample economy during CF experiments and detection capabilities of the 
apparatus. 
 
 
5.3.2 Dimensions of the flow channel visible to the CCD camera 
 
 Precise evaluation of key parameters, such as instrumental dead time as well as 
analysis of kinetics of monitored reaction requires an accurate measurement of the time-
base. 
In continuous-flow the time-base of the experiment is determined by the length of the 
flow-channel visible to the CCD camera. Thus, an accurate determination of the time-
base (Δt) as calculated by Equation 5.2 requires the exact length of the flow-channel 
viewed by the camera (L) to be known. 
In this study, the field of view of the camera itself was used to determine how many 
pixels in the image of the mixer are occupied by the flow channel. Estimating what part 
of the channel is visible to the camera was not necessary, since observation windows 
cut in the frame of steel holder allowed for entire 20 mm flow channel to be visible. 
Thus by correlating the length of the channel with the number of pixel it stretches 
across the image, length of the channel in pixels can be estimated. 
With the pixel resolution of the screen being 1600 x 1200 pixels, the flow channel was 
positioned to occupy exactly 1300 pixels. Approximately 100 pixels at the very end of 
the channel usually had to be cut due to large light scattering artefact occurring at the 
interface between the quartz glass cuvette and the steel holder (see Figure 5.14, panels 
A and B) this however had minimal effect on the time base since any reactions 
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observed by the camera were usually finished by the time the reaction mixture reached 
far end of the flow cell. 
Thus, a total of 1300 pixels were visible for 20 mm long channel, resulting in a 
calculated conversion factor of 65 pixels per millimetre of the channel. This was 
slightly less than 86 pixels mm-1 obtained in previous study (Jenkins, 2006). Unlike 
previous study, however, the entire flow channel was visible to the CCD camera, 
allowing for longer time-base to be observable. 
 
 
5.3.3 Determination of dead time and efficiency of a hybrid T-mixer  
 
 By far the most important parameter of continuous-flow instrument is the “dead 
time”, which is a time between the initiation of investigated reaction and collection of 
first reliable data. Shortest possible dead time may determine whether important early 
events of the reaction pathway are observed or not, greatly influencing the outcome of 
the research. 
Key factors determining the length of the dead time of continuous-flow instrument are 
undoubtedly the mixing efficiency and robustness of its mixer. Thus, dead time 
evaluation was of great significance to the project, defining its success upon achieving 
dead times comparable to published mixer designs, or failure should the dead time be 
unacceptably long. 
The hybrid T-mixer developed jointly with TgK Scientific and Warwick School of 
Engineering was tested using two standard methods of mixer efficacy evaluation 
(Shastry et al., 1998). The first of these tests assessed mixing efficiency of the design 
by comparing fluorescence intensity profiles of premixed solutions of NATA with 
fluorescence profiles of fluorophore mixed in vivo in the mixer. The second test 
provided estimates of the dead time of the instrument by monitoring the first order 
reaction of NATA fluorescence quenching with NBS (Peterman, 1979). Both of these 
tests were carried out at linear flow velocities of 4, 6, 8, and 10 ms
-1
 to assess the effects 
of flow velocity alteration on mixer performance, as well as to determine the optimal 
flow rate for mixer operation. 
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5.3.3.1 Mixing efficiency test 
 
 In order to evaluate mixing efficiency of continuous-flow mixer design, 
fluorescence intensity profiles of 220 μM NATA diluted by distilled water in 1:10 ratio 
and mixed both prior to injection into the apparatus and during the instrument run were 
constructed. Ratio of fluorescence intensities observed for pre-mixed solutions to those 
recorded during the mixing in-vivo allowed to determine the overall mixing efficiency 
for particular flow velocities. 
Should the mixer perform with 100% efficiency, the ratio of fluorescence intensities 
would form a straight line with value of 1 across the length of the channel (see Figure 
5.17). 
Upon inspection of mixing efficiency estimates presented in the figure, it becomes 
apparent that mixing is by far more efficient at flow velocities of 6 and 8 ms
-1
 with 
much lower efficiency at both 4 and 10 ms
-1
. Those estimates confirm the conclusions 
drawn from flow dynamics simulations conducted during the process of designing 
hybrid T-mixer prototype with vertical flow cell, that at 4 ms
-1
 flow of reactants is not 
turbulent enough to facilitate efficient mixing, while at 10 ms
-1
 it is the velocity of the 
fluids themselves that reduces mixing efficiency by forcing two streams of reactants to 
spiral around each other rather than mix turbulently through head-on collision. While 
mixing efficiencies at both 6 and 8 ms
-1
 flow velocities are close to unity, it should be 
noted that at 6 ms
-1
 the mixer efficacy is slightly higher across the entire channel. 
At each of the flow-rates a considerable noise in the relative fluorescence profile can be 
seen between pixels 0 and 200. Such behaviour can be attributed to turbulences 
generated in the mixing chamber extending into the entrance of the flow-channel which 
is visualised in this region. 
It should be noted that no attempt was made to determine the efficiency of the mixer at 
a linear flow velocity of 12 ms
-1
. This was due to the fact that according to flow 
dynamics simulations mixing efficiency at 12 ms
-1
 would be even lower than at 10 ms
-1
. 
Since simulations proved very reliable in the 4 ms
-1
 – 10 ms-1 region, it was decided not 
to expose the only working prototype of the new mixer to mechanical stress involved in 
pumping reactants through the mixer at 12 ms
-1
 flow velocity and thus risk any 
mechanical damage. 
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Figure 5.17 Ratios of fluorescence intensity profiles of reactants mixed in vivo to 
pre-mixed solutions of 20 μM NATA at 4, 6, 8 and 10 ms-1 flow velocities. Two 
separate repeats of mixing efficiency estimation  are represented on panels A and B to 
verify validity of conclusions drawn from the experiment. Solid black line represents a 
constant at 1 and thus ideal mixing.  
It is apparent that at both very low flow velocity of 4 ms
-1 
(green line) and very high 
velocity of 10 ms
-1
 (purple line) the mixing is far from optimum. In contrast, medium 
flow velocities of 6 ms
-1
 and 8 ms
-1
 (blue and red lines respectively) provide much 
better performance along the entire flow-cell. 
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5.3.3.2 Dead time determination 
 
 Instrumental dead time was estimated by monitoring the quenching of NATA 
fluorescence upon its mixing with NBS. A solution of 220 μM NATA was mixed in 
1:10 ratio with solutions of NBS with concentration increasing from 0.25 mM to 5 mM. 
Four sets of dead time measurements were carried out in total at the same range of flow 
velocities as those used for mixing efficiency tests (4 ms
-1
, 6 ms
-1
, 8 ms
-1
, and 10 ms
-1
). 
All measurements were made at 20 °C. 
Flow cell images recorded during the experiment were processed according to methods 
described in Sections 5.2.4.1 and 5.2.4.3 and plotted in form of relative fluorescence 
kinetic traces (see Figures 5.18 to 5.21, upper panels). Fitted single exponential 
functions determined by nonlinear regression are shown as black lines. The absolute 
value of time difference between the point of intersection of the fitted lines and the first 
recorded data point (represented by 0 on the time axis in figures 5.18 to 5.21)  gives a 
dead time estimate. At each of the four flow-rates the fit lines extrapolate back to a 
common relative fluorescence close to 1, which is the expected initial fluorescence of 
NATA in the absence of quenching by NBS. 
For every set of data, obtained graphs were re-plotted on a logarithmic fluorescence 
scale, in order to allow more precise estimation of the point of intersection. 
The estimated dead times for different flow velocities are summarised in Table 1.  
At 4 ms
-1
 flow velocity the fit lines cross over a relatively broad time range, making a 
precise estimate of the dead time difficult, which is reflected in high reported error. 
Similarly at 10 ms
-1
 the fit lines do not form a clear crossover point, indicating less 
thorough and reliable mixing in comparison to intermediate flow-velocities of 6 ms
-
1
and 8 ms
-1
. This confirms the mixing efficiency estimates which clearly indicate less 
efficient mixing at either extremely low or extremely high flow-velocities. 
The smallest dead time estimated by the quenching of NATA fluorescence by NBS was 
130 ± 35 μs achieved at 8 ms-1, with 170 ± 25 μs achieved at 6 ms-1 falling close 
behind. 
Although this is well within the desired time frame of less than a millisecond, it is 
greater than was anticipated, compared for instance to the dead time of 100 μs reported 
for another CF instrument equipped with a T-mixer, working at a flow-rate of 2 ms
-1 
(Takahashi et al., 1997). 
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Linear flow velocity  
[ms
-1
] 
Volumetric flow rate  
[mls
-1
] 
Dead time  
[μs] 
4 0.18 460 ± 110 
6 0.27 170 ± 25 
8 0.36 130 ± 35 
10 0.45 270 ± 160 
 
Table 5.1 Estimated dead times of continuous-flow instrument equipped with 
hybrid T-mixer with vertical flow-cell. 
Dead time for each of four linear flow velocities was estimated by following the 
kinetics of fluorescence quenching of 20 μM NATA upon its mixing with varying 
concentrations of NBS. 
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Figure 5.18 Dead time determination of continuous-flow instrument at a linear flow 
velocity of 4 ms
-1
.  
Fluorescence traces illustrate kinetics of quenching of 20 μM NATA with a range of 
final concentrations of NBS: 0.5 mM (green line), 0.75 mM (yellow), 1.0 mM (dark 
blue), 1.5 mM (pink), 2.5 mM (light blue) and 5 mM (grey). Kinetic trace obtained at 
NBS concentration of 0.25 mM not shown, as concentration of regent was insufficient 
to induce quenching and thus produce reliable kinetic data. 
Single exponential decays fitted to the data are represented by solid black lines. Initial 
fits were plotted on a linear relative fluorescence scale (panel A) and re-plotted on a 
semi-logarithmic chart (panel B), for more precise dead time estimation.  
Estimated dead time at 4 ms
-1
 linear flow velocity: 460 ± 110 μs. 
A 
B 
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Figure 5.19 Dead time determination of continuous-flow instrument at a linear flow 
velocity of 6 ms
-1
.  
Fluorescence traces illustrate kinetics of quenching of 20 μM NATA with a range of 
final concentrations of NBS: 0.5 mM (green line), 1.0 mM (yellow), 1.5 mM (dark 
blue), 2.0 mM (pink), 3.5 mM (light blue) and 5 mM (grey). Kinetic trace obtained at 
NBS concentration of 0.25 mM not shown, as concentration of regent was insufficient 
to induce quenching and thus produce reliable kinetic data. 
Single exponential decays fitted to the data are represented by solid black lines. Initial 
fits were plotted on a linear relative fluorescence scale (panel A) and re-plotted on a 
semi-logarithmic chart (panel B), for more precise dead time estimation.  
Estimated dead time at 4 ms
-1
 linear flow velocity: 170 ± 25μs. 
A 
B 
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Figure 5.20 Dead time determination of continuous-flow instrument at a linear flow 
velocity of 8 ms
-1
.  
Fluorescence traces illustrate kinetics of quenching of 20 μM NATA with a range of 
final concentrations of NBS: 0.5 mM (green line), 0.75 mM (yellow), 1.5 mM (dark 
blue), 2.0 mM (pink), 3.5 mM (light blue) and 5 mM (grey). Kinetic trace obtained at 
NBS concentration of 0.25 mM not shown, as concentration of regent was insufficient 
to induce quenching and thus produce reliable kinetic data. 
Single exponential decays fitted to the data are represented by solid black lines. Initial 
fits were plotted on a linear relative fluorescence scale (panel A) and re-plotted on a 
semi-logarithmic chart (panel B), for more precise dead time estimation.  
Estimated dead time at 4 ms
-1
 linear flow velocity: 130 ± 35μs. 
A 
B 
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Figure 5.21 Dead time determination of continuous-flow instrument at a linear flow 
velocity of 10 ms
-1
.  
Fluorescence traces illustrate kinetics of quenching of 20 μM NATA with a range of 
final concentrations of NBS: 0.75 mM (yellow), 1.0 mM (dark blue), 1.5 mM (green), 
2.5 mM (red), 3.5 mM (pink) and 5 mM (grey). Kinetic trace obtained at NBS 
concentration of 0.5 mM not shown, as concentration of regent was insufficient to 
induce quenching and thus produce reliable kinetic data. 
Single exponential decays fitted to the data are represented by solid black lines. Initial 
fits were plotted on a linear relative fluorescence scale (panel A) and re-plotted on a 
semi-logarithmic chart (panel B), for more precise dead time estimation.  
Estimated dead time at 4 ms
-1
 linear flow velocity: 270 ± 160μs. 
A 
B 
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5.4 Summary 
 
 
5.4.1 Summary of instrument development 
 
 Development of continuous-flow mixer detailed in this chapter provided a 
wealth of new information on the subject of microfluidic mixers. 
Three consecutive prototypes of mixers developed in the initial stages of the study 
proved that microfabrication can be successfully utilized as a method of cheap mass 
production of durable, identical devices such as simple mixers or mixer components. 
Since one of the key aspects of any commercially available instrument second only to 
performance is its price, optimizing mass-production technology was of significant 
benefit. Moreover, by adapting the entire instrument for the use of cheap and widely 
available light source such as mercury-xenon lamps while simultaneously keeping an 
option of introducing more specialised light sources such as deep UV lasers, the range 
of potential users can be expanded.  
Important lessons learned from development, testing and improving the first three 
prototypes were used during development of a new hybrid T-mixer which proved to be 
effective and robust design. Shortest dead time of only 130 μs achieved by the mixer 
puts the design in line with other published continuous-flow mixers (Shastry et al., 
1998, Pinheiro et al., 2001). 
Moreover, this study was the very first project which attempted to combine the design 
and fabrication of continuous-flow mixer with flow dynamics simulations in order to 
gain thorough understanding of physical the processes within the mixer and maximise 
efficiency of the design. As expected, flow dynamics simulations allowed for accurate 
predictions of the fluid behaviour within the mixer and thus not only optimise the 
design, but also specify optimum operation parameters such as flow velocity 
Further developments in the design of continuous-flow mixer coupled with detailed 
knowledge of flow mechanics gained through simulations should yield even more 
reliable and effective mixers. 
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5.4.2 Future developments 
 
 While both robustness and efficiency of the mixer created in this study were 
proven experimentally, there is still a great potential for improvement. 
Flow dynamics simulations conducted in the design phase suggested that mixing 
efficiency of the mixer can be further refined by the introduction of obstacles in mixing 
chamber. Physical obstacles such as pillars or narrowings can greatly increase 
turbulence in the flow of reagents and thus enhance mixing. 
Further testing of the mixer with reactants more relevant to biochemical studies should 
be carried out, such as GdnHCl or urea solutions commonly used in protein folding 
experiments. 
Since such solutions are much more viscous than NATA and NBS solutions in distilled 
water, their behaviour within the narrow delivery and observation channels of the mixer 
could be very different. It would be of great importance to test whether any detrimental 
sheer forces exist within the mixer which may physically damage a protein sample. 
While flow dynamics simulations could provide theoretical data on the issue, only live 
tests such as Cytochrome C refolding can provide definite answer to those questions. 
Upon completion of further tests detailed above, investigation of the fast folding 
kinetics of prion proteins using continuous-flow instrument could be carried out. With a 
recent study (Apetri et al., 2006) proving that continuous-flow can reveal important 
details of protein folding taking place on the timescale not accessible to stopped-flow 
instruments, using a rapid mixing technique would provide an excellent comparison to 
pressure-jump or temperature-jump studies of prion folding kinetics. 
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Chapter 6: General Discussion 
 
 
Prion diseases, also known as transmissible spongiform encephalopathies 
(TSEs), are a group of fatal neurodegenerative disorders affecting numerous species, 
including humans. Despite their species-dependent differences, all TSEs are 
inadvertently associated with a conversion of native, cellular form of the prion protein 
(PrP
C
) to an altered, pathological conformation known as scrapie isoform (PrP
Sc
).   
The key, species-independent aspect of prion diseases is the self-perpetuating nature of 
PrP aggregates and their deposition in brain tissues in a form of amyloid fibrils. The 
template-assisted mechanism of PrP
C
 to PrP
Sc
 transformation involves refolding of PrP 
from its cellular form to an altered disease-associated conformation, although the details 
of the conversion process itself are yet to be fully understood. 
In this thesis two properties of PrP which may influence the prion disease mechanism 
have been investigated: the kinetics of folding mechanism of PrP and the propensity to 
form amyloid fibrils in different conditions.  
 
 
6.1 Kinetic and equilibrium folding of PrP 
 
An interesting phenomenon associated with TSE‟s transmission is the apparent 
inability of prions to induce a disease in certain species, while retaining full infectivity 
upon transferring to others. The species barrier, as it is known, results in a longer 
incubation time and lower incidence of disease upon transfer of the infection between 
individuals from different species (Beringue et al., 2008). Through compelling 
experimental evidence, it has become apparent that the mechanism of the species 
barrier is directly controlled by the primary sequence of prion proteins (Moore et al., 
2005). As the structure of PrP is highly conserved, it is unlikely that structural 
differences between PrP from different species are directly responsible; however, the 
very fact that both primary sequence and structure are conserved does not mean that the 
folding mechanism itself is conserved (Robinson and Pinheiro, 2009).  
Consequently, investigating the folding properties of PrP from different species, as well 
as their disease-associated mutants should yield to our understanding of both the 
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misfolding mechanisms associated with the disease‟s occurrence and the phenomenon 
of the species barrier and varied disease susceptibility. 
Detailed investigations of the folding pathway of PrP
C
 have been impaired by its 
rapid folding (Wildegger et al., 1999). Although several successful studies of the 
folding pathways and intermediates have been conducted at low temperatures (Apetri 
and Surewicz, 2002; Apetri et al., 2004; Apetri et al., 2006), instruments capable of 
characterising the folding kinetics at more physiological temperatures have only 
appeared recently. One such technique which employs a pressure-jump instrument 
capable of perturbing the equilibrium between folded and unfolded PrP molecules 
within microseconds has been successfully used in this study (see Chapter 3). 
The instrument originally intended to carry out these fast-folding measurements was a 
continuous-flow instrument developed by Dr David Jenkins in collaboration with the 
company Hi-Tech Scientific (Jenkins, 2006), however the original instrument was 
determined to be insufficiently robust to be reliably used in protein folding kinetics 
measurements. Consequently, a part of this study was aimed at revising the design of 
original instrument and improving its detection capabilities (see Chapter 5). Necessary 
improvements and revisions were implemented in collaboration with members of 
Warwick School of Engineering and the company TgK Scientific (formerly Hi-Tech 
Scientific). Dead time and mixing efficiency measurements proved that the instrument 
is both effective and reliable and can be applied to protein folding kinetics 
measurements. 
Pressure-jump measurements of PrP folding kinetics were preceded by equilibrium 
folding studies of truncated single tryptophan constructs of mouse PrP (MoWT and 
Q167R) and Syrian hamster prion protein (SHaWT) using tryptophan fluorescence and 
circular dichroism. Folding studies at pH 7.0 confirmed the two-state nature of MoWT 
and Q167R transitions and were consistent with the presence of folding intermediate in 
the folding pathway of Syrian hamster PrP. Interestingly, at pH 4.0 which is known to 
induce the formation of a β-state intermediate (Khan et al., 2010) all three proteins 
exhibited extremely broad transition regions stretching between 2 M and 6 M urea 
concentrations. Such broad transitions strongly suggest that lowering the pH affects the 
folding of all three prion species so that they no longer clearly follow the two-state 
mechanism. This in turn might be indicative of the presence of a β-state intermediate in 
low-pH folding pathways of both mouse and hamster prions. 
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The propensity to form such an intermediate has been strongly correlated with disease 
susceptibility exhibited by wide variety of species (Khan et al., 2010). Its presence in 
both mouse and hamster folding pathways at low pH seems to confirm that structural 
destabilisation plays a role in the mechanism of disease-associated misfolding. 
Pressure-jump measurements of PrP folding kinetics highlighted decreased 
stability of Q167R in comparison to the wild type mouse construct. This decrease in 
stability has been previously observed through equilibrium folding studies (Robinson 
and Pinheiro, 2009). The fact that a disease-resistant mutation has a destabilising effect 
on the protein is surprising, particularly in case of prion proteins. Since prion 
propagation relies on cellular PrP being partially unfolded and subsequently recruited 
by PrP
Sc
, decreased stability of the native fold should make misfolding more 
energetically favourable and consequently enhance the disease progression. This 
suggests, however, that the stability of PrP not always reflects its misfolding propensity, 
which is supported by the fact that not all disease-inducing mutations destabilize PrP 
(Horiuchi and Caughey, 1999).  This interpretation is further supported by fibrilization 
studies of mouse PrP and Q167R variant, which indicate that both constructs form 
fibrils at very similar rate, as indicated by very similar durations of their lag phases (see 
Chapter 3, Figures 3.17 and 3.18). 
Interestingly, the destabilisation of Q167Rwith respect to MoWT is not reflected in 
folding rates upon extrapolation to 0M denaturant concentration, with kf of MoWT, 
Q167R and SHaWT being approximately 12–13000 s-1 at 1 bar and 10000 s-1 at 320 bar 
and calculated ΔVf‡ in water being +14–20 mL.mol-1 apparently independent of 
construct, hinting at common transition state on folding pathway. This observation 
contrasts strongly with significantly lower ku values calculated for all constructs (6.16 s
-
1
 at 320 bar and 10.97 s
-1
 at 1 bar for MoWT, 7.0 s
-1
 for Q167R and 3.3 s
-1
 at 320 bar to 
1.5 s
-1
 at 1 bar for SHaWT) indicating that transition state for folding is different than 
transition state for unfolding, suggesting an on-pathway folding/unfolding intermediate 
present in all three proteins. 
The existence of such an elusive intermediate is consistent with recent studies (Khan et 
al., 2010) which identified β-structured monomeric states in folding pathways of prion 
proteins from 6 different species including both mouse and Syrian hamster. In all cases, 
the β-state intermediates were very elusive, visible only in moderately destabilizing 
conditions such as ~5M urea and low pH, which might explain why they were not 
detected in earlier studies performed at pH 7.0 (Jenkins et al., 2008). Since in both 
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mouse and hamster PrP the β-state propensity is by far the highest, the mildly 
destabilizing conditions in which pressure-jump experiments were performed, coupled 
with equilibrium shift upon pressure application might have allowed to observe those 
intermediates indirectly through folding/unfolding rates. 
Recent molecular dynamics simulations suggest that a compact loop 
encompassing residues 166–175 is necessary for aggregation and formation of the 
infectious particles in several species including bank vole, elk, sheep and mouse. 
Moreover, the stability of the loop region is decreased in a number of point mutations 
associated with increased disease resistance (Scouras and Daggett, 2012).  
According to the modelling studies of infectious protofibrils, the stabilised turn is 
buried between two interacting PrP monomers, allowing for progression of 
oligomerisation. In the absence of stabilising mutations, the loop region is destabilised, 
and the resulting flexible, expanded loop disrupts the packing of the adjacent 
monomers, consequently impairing their incorporation into the protofibril (Scouras and 
Daggett, 2012). Another potential disease-resistance mechanism is based on the 
possibility that if the PrP variants carrying loop-destabilising mutations are incorporated 
into infectious seeds, the altered stability of their conformation prevents further 
oligomerisation (Ott et al., 2008). 
Due to the fact that mouse PrP carrying S170N and N174T mutations is structurally 
very similar to elk PrP, it provides a valuable model for further investigations into the 
effects of loop-stabilising mutations. Interestingly, molecular dynamics simulations 
predicted the formation of elk-like rigid loop in MoPrP at pH 7.0, but not at lower pH, 
suggesting that the pH itself may affect oligomerisation and fibrilisation properties of 
some PrP species.  
In order to investigate the structural effect of loop-stabilising mutations, a series of 
equilibrium folding studies of mouse PrP mutants carrying elk point mutations known 
to stabilise the loop region (S170N, N174T and double mutant S170N/N174T) were 
carried out, and their results compared with wild-type mouse PrP (see Chapter 4). 
Upon comparison of transition curves of MoPrP, N174T, S170N and S170N/N174T it 
becomes apparent that the mutations which stabilize the loop region result in expansion 
of the transition region of the folding curves constructed at pH 7.0. This in turn suggests 
that stabilisation of the loop region increases the overall propensity to from an 
intermediate. Recent studies of truncated constructs of PrP from different species 
including mouse and Syrian hamster, revealed the increased propensity to form β-state 
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intermediate which correlates with increased disease susceptibility (Khan et al., 2010). 
Consequently, it is possible that increased loop stability results in higher propensity to 
form such intermediate, which in turn leads to increased disease susceptibility. This 
corresponds to the differences in susceptibilities between mouse and Syrian hamster. 
Since mouse PrP lacks any stabilising mutations in the loop region, it exhibits lower 
propensity to form β-state intermediate and lower disease susceptibility compared to 
Syrian hamster PrP in which Asn residue at position 170 is known to stabilise the loop 
region.  
 
 
6.2 Fibrilisation and oligomerisation of PrP 
 
Fibrilisation studies of mouse and Syrian hamster constructs were carried out 
throughout the course of this study to complement relevant kinetic and equilibrium 
folding experiments, in an attempt to correlate the kinetic behaviour of PrP with 
formation of amyloid fibrils. 
Following the pressure-jump studies of MoWT, Q167R and SHaWT folding 
kinetics, fibrilisation experiments were conducted to investigate the effects of structural 
destabilisation conferred by Q167R on fibrilisation, and whether propensity to form β-
state intermediates at low pH exhibited by both mouse and hamster PrP affects the 
formation of fibrils. 
Both MoWT and Q167R formed elongated fibrils characteristic for prion 
aggregation in solution. While pH did not seem to have a significant effect on the rate 
of fibril formation and only a mild effect on the duration of the lag phase, inspection of 
EM images obtained at the end of fibrilisation experiments revealed surprising 
differences in morphology of fibrils formed at different conditions. Fibrils formed at pH 
4.0 were found to be shorter but much more abundant than those formed at pH 7.0 
Fibrils of both MoWT and Q167R formed at higher pH were longer but less abundant 
compared to pH 4.0, indicating that at lower pH, that the total population of PrP 
molecules which aggregated into fibrils was higher. In case of Syrian hamster, while no 
fibrillous material was detected at pH 7.0, the distincive short protofibrils were formed 
at pH 4.0. 
These findings are interesting in the light ofprevailing opinion that formation of fibrils 
and their aggregation is a protective mechanism evolved to avoid high toxicity of 
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soluble oligomers (Buccianti et al., 2002; Kirkitadze et al., 2002; Caughey et al., 2003). 
Indeed, soluble oligomers are thought to be the primary cytotoxic species as opposed to 
fibril formation and deposition on cellular membranes (Chisea et al., 2001; Novitskaya 
et al., 2005). Consequently, increased fibrilisation propensity of mouse PrP is 
concurrent with lower susceptibility of mice to prion diseases, compared to Syrian 
hamster. Since the Q167R mutant of mouse PrP exhibits higher propensity to form 
fibrils and the length of its lag phase is less affected by change in pH compared to wild-
type construct, the structural destabilisation conferred by the point mutation seems to 
play a key role in disease-resistance mechanism. 
Fibrilisation studies of mouse PrP constructs carrying elk point mutations 
revealed a surprising link between the stability of the loop region and formation of 
fibrils. Fibrilisation propensity was found to be proportional to the stability of the loop 
region, with the double mutant S170N/N174T which carried two loop stabilising 
mutations and therefore contained rigid, elk-like loop region showing by far highest 
propensity to form fibrils. The S170N mutation which conferred partial stability of the 
loop region exhibited second-highest fibrilisation propensity, and both MoPrP and 
N174T mutant in which the loop stability does not differ significantly from the wild 
type mouse PrP did not form fibrils unless seeded with S170N/N174T material. These 
findings were consistent with molecular dynamics simulations, which suggest that a 
compact loop between helix α2 and β-sheet β2 is necessary for aggregation and 
formation of the infectious protofibrillar species in several different species, particularly 
elk and sheep. Nearly all of the point mutations which confer increased disease 
resistance perturb the structure of the loop, preventing the initial formation of infectious 
oligomers (Scouras and Daggett, 2012). 
Thus, it is possible that while the destabilisation of loop region affects oligomerisation, 
consequently preventing fibril formation from “free” PrP molecules, its effect may be 
limited if the pre-formed protofibrils are already present in the reaction mixture.  
Loop stability would affect spontaneous generation of prions in the organism, as well as 
disease transmission via small oligomers. While destabilised loop region would be 
likely to prevent spontaneous oligomerisation and protofibril formation, it would not 
affect pre-formed protofibrils originating from external source. 
Consequently, the disease-resistant, loop-destabilizing mutations would have significant 
effect on fibril formation in unseeded fibrilisation, but their impact on fibril formation 
in presence of seeds would be much more limited. The difference would be due to the 
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fact that already pre-formed seeds may recruit PrP
C
 from environment and incorporate 
it into growing fibril without the need for oligomers to form “from scratch”. Such 
model correlates well with the experimental data obtained in this study. 
These findings seem to be counterintuitive, if one considers the prevailing opinion that 
formation of fibrils and their aggregation as well as subsequent formation of plaques is 
a protective mechanism evolved to avoid high toxicity of soluble oligomers (Buccianti 
et al., 2002; Kirkitadze et al., 2002; Caughey et al., 2003). Loop destabilisation, being a 
potential protective mechanism, should not affect fibrilisation and decrease its potential 
to trap neurotoxic particles. It is these soluble oligomers, however, that are thought to 
be the primary cytotoxic mechanism as opposed to fibril formation and deposition on 
cellular membranes (Chisea et al., 2001; Novitskaya et al., 2005). Consequently, while 
the protective mechanism based around loop-destabilizing mutations could potentially 
lead to increased susceptibility to the disease due to the fact that the neurotoxic species 
are not trapped in fibrils, it is the oligomer formation that is primarily affected. 
Thus, proposed source of disease resistance conferred by loop-destabilising mutations is 
the decreased formation of neurotoxic particles in the organism as well as diminished 
ability of infectious oligomers from both inside and outside to propagate 
oligomerisation of PrP.  
 
 
6.3 Summary 
 
This study represents a substantial step in the study of mechanisms of folding of 
PrP and their connection with disease-related properties such as formation of amyloid 
fibrils. 
The use of pressure-jump instrument allowed to confirm experimental observations 
made previously by the members authors research group (Robinson and Pinheiro, 
2009). The destabilising effect of Q167R mutation previously observed via equilibrium 
folding studies was confirmed through direct kinetic observations. 
Subsequent fibrilisation experiments performed by the author suggested a possible link 
between the stability of mouse prion protein and its propensity to form fibrils at neutral 
and mildly destabilising conditions, elucidating a potential mechanism of increased 
disease resistance conferred by Q167R mutation. 
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Equilibrium folding studies of full length mouse constructs carrying point mutations 
characteristic for elk which confer increased stability of the loop region encompassing 
residues 166-175 characteristic for cervids revealed a surprising correlation between the 
degree of stability of the loop and propensity to form fibrils. These finding are 
consistent with the recent molecular dynamics simulations, which suggest that a 
compact loop encompassing residues 166-175 is necessary for aggregation and 
formation of the infectious particles in elk, sheep and mouse prion strains. 
Due to the fact that destabilisation of the region resulting in flexible, expanded loop 
disrupts the packing of the adjacent monomers of PrP, consequently impairing 
oligomerisation and formation of protofibrils (Scouras and Daggett, 2012), a disease 
resistance mechanism based on decreased formation of neurotoxic particles in the 
organism as well as diminished ability of infectious oligomers from both inside and 
outside to propagate oligomerisation of PrP has been proposed.  
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